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ABSTRACT 
This thesis describes the feasibility of implementing a near real-time vaccine safety 
surveillance system (NRTVSS) using data from the Clinical Practice Research Datalink (CPRD), 
a United Kingdom (UK) research-level primary care database. 
NRTVSS is one method in the vaccine safety post-licensure toolkit, used since 2005. To 
understand how NRTVSS has been applied I conducted a systematic review of studies using 
NRTVSS. I identified 31 systems, mainly in the USA. Several sequential tests were in use, most 
commonly the Poisson-based maximized sequential probability ratio test (PMaxSPRT, 44%) 
and its binomial version (BMaxSPRT, 24%). Only 75% of studies addressed confounding, 
mainly by adjusting the expected rate. Delays in data availability may hinder the feasibility 
of implementing a system; some studies delayed the analysis, whilst others adjusted for 
delays and partially accrued periods.  
In CPRD, delays in recording outcomes are particularly relevant. Hence, I assessed those 
delays for selected outcomes of interest for vaccine safety (Bell’s palsy, Guillain-Barré 
syndrome (GBS), optic neuritis, and febrile seizures (FS)) by comparing the deemed date of 
diagnosis to the date the event was recorded in the system. Three-quarters of the records 
accrued during the first month, considered as sufficient to implement NRTVSS.  
I thus trialled the implementation of a system using previously collected CPRD data, for 
seasonal influenza/GBS and measles-mumps-rubella/FS. This included power calculations for 
detecting a signal. I used PMaxSPRT for both vaccine/outcome pairs and BMaxSPRT for 
measles-mumps-rubella/FS. Both tests were adjusted for delays in recording outcomes, 
based on the previous analysis. It was possible to implement a system, but power was <80% 
to detect less than a four-fold increase in the risk of GBS following influenza vaccine. For this 
pair, I re-evaluated power after removing delays in data availability, with no significant 
improvement.  
This work establishes the foundation of a NRTVSS using CPRD for potential application in the 
UK. Future research could assess further vaccine/outcome pairs and explore the use of other 
statistical tests. Overall, this project contributes to UK vaccine pharmacovigilance.  
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1 INTRODUCTION 
Vaccination is one of the most effective public health interventions.1-3 However, the success 
of vaccination itself poses challenges. As vaccine-preventable diseases have been 
dramatically reduced, the possibility of adverse reactions has gained relevance. The concerns 
regarding the safety of vaccines led some to decide against vaccination, which has 
contributed to the resurgence of some of these diseases.4,5 
Vaccine safety is studied throughout the vaccine lifecycle. This starts with the assessment of 
a vaccine candidate, during clinical trials. If the vaccine candidate meets the requirements 
and is approved the safety continues to be studied using post-licensure studies. At this stage, 
the main focus is to detect rare adverse events which might have been missed by pre-
licensure studies. Several methods are available, including passive and active surveillance.2 
Passive surveillance is mainly represented by spontaneous reports, used worldwide. Active 
surveillance includes a variety of methods and has benefitted from the advent of electronic 
health records. Such records allow the study of large volumes of data, which are essential to 
detect rare adverse events.6 Given that vaccines are administered to a large number of 
individuals, it is important to identify these events as soon as feasibly possible. Most available 
studies do not incorporate a timeliness dimension; to address this issue in 2005 a new 
method to assess vaccine safety was introduced in the United States of America (USA).7 This 
method, initially known as rapid cycle analysis (RCA), and then as near real-time vaccine 
safety surveillance (NRTVSS) uses electronic health records and sequential tests to identify 
safety signals in a timely manner. NRTVSS is started very soon after vaccine delivery and data 
are examined at regular points in time.8 It is now used routinely in the USA, where it has 
allowed the identification of several safety signals.9   
In the United Kingdom (UK), vaccine pharmacovigilance has relied largely on spontaneous 
reports and on epidemiologic studies aimed at testing hypotheses generated by a variety of 
sources. NRVTSS has been implemented using spontaneous reports to obtain the number of 
observed events.10 However, spontaneous reports suffer from under-reporting and are 
subject to biases, while hypothesis-testing studies are generally designed in response to 
suspicions raised some time after the vaccine’s introduction. Electronic health records are 
required for a new UK NRTVSS that relies fully on routinely collected data; such research-
level data are available, such as the Clinical Practice Research Datalink (CPRD),11 The Health 
Improvement Network (THIN),12 The Royal College of General Practitioners Research and 
Surveillance Centre (RCGP RSC) network,13 and ResearchOne.14 Given the availability of data 
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that are potentially suitable to implement NRTVSS, it is then necessary to determine which 
methods are available, their characteristics, and whether available electronic health records 
are adequate to perform this kind of surveillance.  
This thesis reviews the methods available for NRTVSS and explores the feasibility of using 
CPRD, as an example of a general practice dataset, to perform NRTVSS. In Chapter 2, the 
main concepts in the field of vaccine safety are summarised, with a particular focus on 
methods available to assess vaccine safety. The use of near-real time vaccine safety 
surveillance is introduced. The Chapter finishes with the objectives of the thesis. Chapter 3 
provides information on the methods used in this thesis. It starts with information on the 
data sources used and further explanation of the tests available to perform near real-time 
vaccine safety surveillance. The remaining Chapters provide an explanation of the work 
conducted to address the objectives of the thesis. Chapter 4 presents a systematic review 
undertaken to assess the worldwide use of near real-time vaccine safety surveillance. This 
work was published as a paper in Pharmacoepidemiology and Drug Safety, which is 
reproduced in Chapter 4 (Paper 1). Chapters 5 and 6 establish the foundation of the 
feasibility assessment. This assessment includes a trial implementation of near real-time 
methods using CPRD data (Chapter 7). Chapter 5 details the framework used to establish the 
feasibility of using CPRD to implement a near-real time system. It starts with information on 
the process used to select the outcomes and the vaccines to include in the trial 
implementation, followed by aspects of the data which were considered as essential to 
implement a near real-time system. One of the key aspects was delays in recording data, and 
an in-depth analysis of these delays is presented. This analysis was also published as a paper 
in Pharmacoepidemiology and Drug Safety, reproduced in Chapter 5 (Paper 2). The Chapter 
ends with the explanation of the decision about which vaccine/outcome pairs were 
considered for the feasibility study. Chapter 6 focuses on how the format and availability of 
CPRD data limited the design of the trial implementation study, and how these issues were 
addressed. This is followed by the implementation study itself, which is presented in Chapter 
7. This work has been written as a paper published in Vaccine (Paper 3). One of the issues 
identified during this work was lack of power to identify a signal for rare outcomes. Knowing 
that delays in recording and receiving data for analysis can influence power, this issue was 
further explored and is reported in a fourth paper, accepted for publication in 
Pharmacoepidemiology and Drug Safety. Finally, Chapter 8 summarises and provides an 
overall discussion of the findings, and presents the implications of the work.  
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2 BACKGROUND 
2.1 Vaccine safety overview 
Vaccines are considered one of the most cost-effective public health interventions.1-3 The 
exact number of cases of disease prevented since their introduction is unknown, but 
estimates for the USA indicate that 103.1 million cases of polio, measles, rubella, mumps, 
hepatitis A, diphtheria and pertussis might have been prevented from 1924 to 2011.15 The 
value of vaccines seems certain. 
Vaccine are administered to healthy individuals, often children, and thus the standard for 
vaccine safety is particularly high. However, not all events following administration of a 
vaccine will be due to the vaccine itself. The Council for International Organization of Medical 
Sciences (CIOMS) defines adverse events following immunisation (AEFI) as “any untoward 
medical occurrence which follows immunisation and which does not necessarily have a 
causal relationship with the usage of the vaccine”.16 p39-40 AEFI can be: (i) vaccine product-
related (related to vaccine components); (ii) vaccine quality-related (due to defects in the 
product); (iii) immunisation error-related (owing to errors in the handling, prescribing, and 
administration process); (iv) immunisation anxiety-related (including reactions such as 
vasovagal syncope); and (v) coincidental events (unrelated to the vaccination process and 
that would have occurred regardless of the vaccine administration). It is important to make 
a clear distinction between these different causes of AEFI whenever possible, to avoid undue 
concerns. Adverse events (AE) and Adverse Reactions (AR) are related concepts: AE is similar 
to AEFI but are applied more broadly to drugs in general.17 On the other hand, AR does 
require a causal association. It is defined as “a response to a drug which is noxious and 
unintended, and which occurs at doses normally used in man”.17 Vaccine pharmacovigilance 
activities try to detect AR quickly in order to minimise their impact.16 
Public concerns with the safety of vaccines started with their introduction, due initially to 
events arising from production methods and subsequently due to other safety concerns.18 
These concerns can undermine the success of immunisation programmes as suggested by 
Chen and colleagues,4 who have described the evolution of these programmes (Figure 2.1). 
They emphasise how vaccine coverage, disease incidence, and the perception/incidence of 
AE are interlinked. As more people are vaccinated and the disease is controlled (stage 1) 
disease consequences are less evident and the perception of AE increases (stage 2). This can 
lead to loss of confidence and decreasing coverage resulting in outbreaks (stage 3). Public 
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health authorities might be able to restore confidence, with resumption of high coverage 
and low incidence of the vaccine-preventable disease (stage 4). In special cases, eradication 
might be achievable and the vaccine can be stopped, as well as its related AE (stage 5).  
One example of this evolution started in 1998 with a suggested association between 
measles-mumps-rubella (MMR) vaccine and gastrointestinal disease and autism.19 In the UK, 
MMR coverage by two years of age dropped from 92.5% (1995) to 78.9% (2003) with 
increasing incidence of measles by 2006-07.5 Several measles outbreaks have occurred 
subsequently in Europe and USA.20 
 
 
Figure 2.1. Potential stages in the evolution of an immunisation programme.4,21 
 
Vaccines can cause AR but, overall, benefits are considered to outweigh the risks. For 
example, measles-related serious complications/death risk can be up to 1/20 while vaccine-
related encephalitis risk is around 1/1,000,000.22,23 Vaccine safety is assessed at several 
stages, broadly divided into pre-licensure studies (before vaccine approval) and post-
licensure (after approval), as outlined in Sections 2.2 and 2.3. 
2.2 Pre-licensure studies 
Vaccines are studied extensively in-vitro and in animals before the human tests start. At that 
stage, clinical trials are the first step in demonstrating a vaccine candidate is safe and 
efficacious. These trials are conducted in three phases with progressively bigger samples. In 
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phase I clinical trials the vaccine candidate is tested in a small sample of healthy individuals. 
For phase II trials a larger sample size is evaluated, allowing identification of common AE and 
providing important information on the best dosage and schedule. Finally, during Phase III 
trials a bigger sample is assessed, to ensure precise estimation of vaccine efficacy and 
enabling detection of less common events.2,21,24 As mentioned above vaccine safety 
standards are particularly high and thus phase III vaccine trials tend to enrol more subjects 
than other drugs trials. At this stage, the sample usually includes between 5,000 to 10,000 
individuals but this number can be larger if rare adverse events are anticipated, as in the case 
of rotavirus vaccine.24 Following withdrawal of a rotavirus vaccine after approval due to an 
increased risk of intussusception (estimated to be 1 excess case/10,000 vaccinated children), 
a new vaccine was required to demonstrate safety regarding intussusception and thus phase 
III trials included 70,000 children.2,25 Nevertheless, sample size considerations tend to focus 
on vaccine efficacy rather than vaccine safety.  
If a vaccine candidate meets the efficacy and safety requirements it can be approved. 
Nevertheless, clinical trials follow strict enrolment criteria (resulting in highly selected 
populations), do not give information on long-term AE, and they can miss rare AE.2,26 It is 
thus important to continue surveillance after vaccine approval. In the European Union, 
companies are required to submit a risk management plan when applying for approval.27 This 
should include information on (i) safety profile; (ii) plans to gain further insight into the safety 
and efficacy profile; and (ii) risk minimisation activities if required. Risk management plans 
ensure that any potential safety concerns arising from but not confirmed during clinical trials 
are followed during the post-licensure stage.  
2.3 Post-licensure safety surveillance 
Post-licensure safety surveillance aims to identify safety signals. CIOMS defines a signal as 
“information that arises from one or multiple sources (…), which suggests a new potentially 
causal association, or a new aspect of a known association, between an intervention and an 
event (…), that is judged to be of sufficient likelihood to justify verificatory action”.28 In the 
context of vaccine pharmacovigilance, the intervention is the vaccine and the event the 
suspected AR. Throughout this work, these will be referred to as the vaccine/outcome pair 
or pair of interest.  
Identifying a safety signal is not the end of surveillance but rather an initial step in a multi-
stage process. Several authors have described the process, but concepts have been applied 
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loosely, with no clear definition.1,26,29 It is generally agreed that an initial step is to find a 
signal – the signal identification or detection phase. Nelson et al. defines this phase as the 
stage to detect unknown AE.26 Traditionally, this has relied on the use of spontaneous reports 
(passive surveillance) and employment of a set of techniques known as data mining. Active 
surveillance approaches have complemented the use of spontaneous reports and include 
hospital-based surveillance, cohort recruitment, large population-based datasets and 
internet-related data.1 Signal strengthening or refinement is an intermediate stage which 
addresses previously suspected events but does not provides a final confirmation of a 
potential signal. Ecological studies, observed-to-expected calculations and near real-time 
surveillance using electronic health records are included in this stage. Signals emerging from 
both the signal detection and signal strengthening stages need to be confirmed, generally 
using traditional epidemiological designs, which provide a more rigorous assessment than 
the methods previously mentioned. Results from confirmatory studies should be interpreted 
in light of additional considerations such as biological plausibility. Figure 2.2 summarises the 
approaches used at each stage.1  
 
Figure 2.2. Stages in the post-licensure safety surveillance. Adapted from Bonhoeffer et al.1 
 
These stages should not be regarded in a linear way: for a given vaccine/outcome pair the 
assessment might start with a signal strengthening activity (with no explicit signal detection) 
or a confirmatory study may follow a signal detection (with no signal strengthening stage). 
The approach should be tailored to the characteristics and existing knowledge for the specific 
•Passive surveillance
•Spontaneous reports 
•Case reports/case series
•Active surveillance
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pair of interest. These methods are briefly explained below with a particular focus on their 
use for evaluation of vaccine safety. The approach used in this thesis, near real-time 
surveillance using electronic health records, is presented in more detail.  
2.3.1 Signal detection 
2.3.1.1 Spontaneous reporting 
Post-licensure surveillance has relied on spontaneous reports, which are widely 
implemented. These systems require that health-care workers or others suspecting an AE to 
report it, hence they are described as passive systems.30 Spontaneous reporting systems are 
considered to be simple, low-cost, represent an opportunity for the public to report, and 
have a broad scope.2,30 They are useful for detecting new, extremely rare, and/or 
unanticipated AE but have limitations. These include report quality/completeness, 
under/over-reporting, and lack of population denominators.2 These issues are briefly 
presented below.  
Each case report is carefully reviewed by a clinical analyst in order to assess a possible 
association between the drug and the AE being studied. This assessment considers several 
aspects of the report (see below) and is limited when there is incomplete or poor quality 
information. Spontaneous reports rely on voluntary systems and therefore result in an 
undetermined level of under-reporting, which differs for each AE. Hence, it is not possible to 
calculate the denominators that are needed for calculating AE rates in the population. 
Moreover, temporal reporting trends are non-uniform and may not follow the frequency of 
the AE/drug in the population. Previous studies have shown that the frequency of reports 
for a given AE is higher in the first years after approval and declines thereafter. Other factors, 
such as strong media attention or a newly suspected AE, also affect the reporting behaviour 
leading to over-reporting.2,29,30 Despite these limitations several analysis can be performed, 
including review of case reports, reporting ratios, and data mining.30  
Review of case reports is a descriptive approach in which cases fulfilling a specified case 
definition are systematically reviewed and a possible causal relationship is ascertained (case 
causality assessment). For drugs, the temporal association, biological plausibility, and 
information on de-challenge (drug withdrawal) and re-challenge (drug re-introduction) are 
the aspects considered.30 Vaccines’ characteristics make this process more complex.28 There 
is usually no information on re-challenge (vaccines are administered once or with long 
intervals) or de-challenge (due to long-lasting immunological effects). Furthermore, 
24 
 
concomitant vaccine administration is common, making it difficult to attribute the AE to a 
specific vaccine. This issue also complicates other methods, such as those used for signal 
strengthening. Finally, live vaccines may cause the vaccine-preventable disease, which can 
be the source of the event, adding extra complexity. 
Several systems have attempted to standardise case causality assessment.31 The system 
proposed by the World Health Organization (WHO) Collaborating Centre for International 
Drug Monitoring (also known as the Uppsala Monitoring Center, WHO-UMC) and the Naranjo 
probability scale are the most widely used.31 WHO-UMC uses information on the temporal 
association, objective confirmation of the event, biological plausibility, de-challenge, and re-
challenge, and based on the presence/absence of these classifies reports as ‘certain’, 
‘probable/likely’, ‘possible’, ‘unlikely’, ‘conditional/unclassified’, and ‘unassessable/ 
unclassifiable’.32 The Naranjo scale includes questions on the same aspects of the WHO-UMC 
assessment criteria plus existence of previous reports and dose-response relationships. Each 
question is scored and a total score obtained.33 These systems have been criticised as neither 
produces a reliable quantitative estimate of the likelihood of a causal association between 
the outcome and the drug being assessed.31 However, they are considered to be useful as 
they decrease disagreement between assessors and facilitate report processing.   
Even with no denominators it is possible to calculate a relative measure, the reporting ratio:  
𝑅𝑒𝑝𝑜𝑟𝑡𝑖𝑛𝑔 𝑟𝑎𝑡𝑖𝑜 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐴𝐸/𝐴𝑅 
𝐷𝑟𝑢𝑔 𝑢𝑡𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒
. 
Drug utilization measures try to capture the number of individuals at risk and include 
dispensing data, the number of persons receiving the drug, or a combination of these with 
duration of treatment. Reporting ratios are not true incidence/prevalence measures but can 
be compared with background rates when the event is serious. Alternatively, reporting ratios 
for other drugs used for the same indication or from the same class can be used as 
comparators. Given the limitations of spontaneous reports and reporting ratios these 
comparisons should be made carefully.30 
Data mining techniques have become a popular option to analyse spontaneous reports and 
other data sources.29 These techniques try to identify patterns in existing data, mainly using 
disproportionality methods. The underlying principle is that any association between a drug 
and an event will lead to the occurrence of the drug-event pair disproportionately in the 
data, compared to what would be expected assuming no association. As all reports refer to 
a specific drug, for the purposes of these analyses the comparator is all other drugs (either 
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all drugs in the same drug class or simply all other drugs in the data). Disproportionality 
analysis includes frequentist and Bayesian measures and is based on a simple 2x2 
contingency table.26,29,30,34 Table 2.1 presents the structure commonly used. For frequentist 
measures, it is possible to calculate a hypothesis test of independence (𝜒2 or Fisher’s test) 
and confidence intervals. Nevertheless, these methods tend to become unstable with small 
number of events, leading to false positives. Bayesian measures were developed to address 
this issue, as they ‘shrink’ the measure of association towards the null, depending on the 
data variability. The most commonly used measures are briefly defined on Table 2.2.  
Table 2.1. Contingency table commonly used for signal detection  
 Adverse event 
Target drug  Yes No Total 
Yes a b n = a+b 
No c d z = c+d 
Total m = a+c b+d t = a+b+c+d 
 
Table 2.2. Measures commonly used for signal detection  
Measure Definition (notation on Table 2.1) Type 
Relative Reporting Ratio (RRR) (t.a)/(m.n) Frequentist 
Proportional Reporting Ratio  (a.z)/(c.n) Frequentist 
Reporting Odds Ratio  (a.d)/(c.b) Frequentist 
Information Component log2(RRR) Frequentist 
Bayesian Confidence Propagation 
Neural Network  
Bayesian version of the information 
component 
Bayesian 
Multi-item Gamma Poisson Shrinker  Posterior expectation of the relative 
reporting ratio distribution 
Bayesian 
 
The simplicity of 2x2 tables and the measures presented implies loss of information and 
makes it impossible to study drug-to-drug interactions or adjust for potential confounders. 
Other methods exist, such as extensions of disproportionality measures for 3-dimensional 
tables, logistic regression-based approaches and unsupervised machine learning.34 An in-
depth presentation of these techniques is beyond the scope of this text but is summarised 
in Harpaz et al.34  
Spontaneous reports systems are managed at the country level but some databases are 
aggregated worldwide/regionally. International spontaneous reports databases include: 
VigiBase – WHO-UMC and EudraVigilance – the European Union Drug Regulating Authorities 
Pharmacovigilance database.29 These receive reports for both vaccines and therapeutic 
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drugs. In the UK, the spontaneous reporting system is known as the Yellow Card system and, 
as the examples before, receives reports from vaccines and therapeutic drugs.35 Other 
systems focus on vaccines, such as the Vaccine Adverse Event Reporting System (VAERS, USA 
system, run in partnership by the Centers for Disease Control and Prevention (CDC) and the 
Food and Drug Administration (FDA)), and the Canadian Adverse Events Following 
Immunization Surveillance System (CAEFISS).35,36 In 1999, VAERS allowed the identification 
of a safety signal following a tetravalent rotavirus vaccine, later confirmed by epidemiologic 
studies, leading to the vaccine withdrawal.36 CAEFISS has the particularity of including 
specific case definitions (see 2.3.3) in its reporting structure.35 For analysis, WHO uses the 
Bayesian Confidence Propagation Neural Network, while in the UK the Multi-item Gamma 
Poisson Shrinker has been preferred (Table 2.2).34 
2.3.1.2 Case reports/case series 
Case reports/case series are often reported in the literature and can be used for 
pharmacovigilance purposes. Case reports simply describe a patient who experienced a given 
outcome following a certain exposure. Case series are similar but there are several patients 
either with the same exposure and whose outcomes are described or with the same outcome 
and whose exposures are investigated.37 These designs are useful to generate hypotheses 
about previously unknown or unsuspected events. It is noteworthy that the use of case-
series assembled to support a pre-existing hypothesis is not hypothesis-generating and can 
have detrimental consequences, such as in the case of the suggested association between 
MMR and autism in the late 1990’s.19 This led to a loss of confidence in the vaccination 
programmes and decreasing coverage (see Section 2.1).  
Case series can also be used to determine the incidence of a suspected outcome following 
introduction of a new drug. This can be done by recruiting physicians who report cases of the 
disease. Both case reports and case series are easy to conduct but they are limited by the 
absence of a control group. Hypotheses generated by these designs should be further tested 
using a more robust design. Alternatively, and in specific circumstances, data from a case 
series can be used to conduct a self-controlled case series. This design is presented in detail 
in Section 2.3.3.3.  
2.3.1.3 Active surveillance methods 
Active surveillance attempts to identify all AEFI of interest within a defined population and 
aims to overcome some of the limitations of spontaneous reports. Different approaches to 
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active surveillance have been proposed.38,39 The approaches used in the context of signal 
detection are briefly described. 
2.3.1.3.1 Targeted hospital-based surveillance 
This approach identifies conditions of interest that are retrieved daily from electronic health 
records and by contacting key clinicians at participant centres. Trained nurses assess whether 
the case meets the case definition criteria (previously decided) and can collect further 
information from relevant sources. Data generated by this process at each centre are then 
sent for central processing and analyses. Countries adopting this approach include Canada 
(the Canadian Immunisation Monitoring Program – IMPACT), Australia (the Paediatric Active 
Enhanced Disease Surveillance – PAEDS), and New Zealand.39,40 Important features of these 
systems include their ability to identify cases not identified by other sources, and collecting 
relevant data on them in a standardised way with regular updates.40 These initiatives 
investigate new safety concerns but also other vaccine-related aspects such as 
effectiveness.41 Relevant findings include a decrease in febrile seizures and hypotonic 
episodes with the replacement of diphtheria-tetanus-whole pertussis vaccine by diphtheria-
tetanus-acellular pertussis vaccine in 2003, and the increase in cases of acute 
thrombocytopenia following measles-containing vaccines in 2003.41 
2.3.1.3.2 Cohort recruitment after vaccination 
After administrating a vaccine, it is possible to recruit vaccinated individuals and follow them 
up with enquiries about AEFI. This approach requires setting up a study for each vaccine of 
interest but it allows surveillance of virtually any event following a certain vaccine. This 
contrasts with the previous approach (see 2.3.1.3.1) where the focus is on a previously 
defined outcome of interest. As with any cohort, detection of rare events requires the 
recruitment of a very large number of vaccinees, making this a costly option.  
There are different options when recruiting/contacting individuals, including: face-to-face 
interviews,42 short message service (SMS),43,44 e-mail,45 interactive voice response system,46 
computer-assisted telephone interviewing,46,47 and home telemonitoring.48 These options 
will not be presented in detail except for the studies using SMS/e-mail.  
The system using SMS and/or e-mail is one of the existing surveillance systems aimed at 
providing (near) real-time signals and makes use of specific statistical methods to look at 
data at repeated points in time. This is also the case for the method used throughout the 
project described in this thesis – near real-time vaccine safety surveillance. However, these 
two systems differ in the source of data used. Given the specificities in the use of electronic 
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health records data, throughout this work the expression near real-time vaccine safety 
surveillance refers to surveillance efforts using electronic health records and thus does not 
include the use of SMS/e-mail, which is explained below.  
Vaccine surveillance using SMS/e-mail has been led by Australia, where a system has been 
in place since 2011.44 After receipt of a vaccine, patients or their parents receive a SMS asking 
if they/their children have experienced any reaction and requesting a Yes/No reply via SMS. 
If there is an affirmative reply, patients are subsequently contacted by staff asking further 
details of the reaction. The system is mostly automated as the software retrieves vaccination 
information and automatically sends SMS to the number on the patient’s record. It also 
records replies received via SMS.44 The initial tool using SMS has evolved and it was adapted 
to send e-mails and to perform an on-line based survey instead of a phone survey. Currently, 
the two systems (using SMS and e-mail) run in parallel.45 An evaluation of this system showed 
that over 70% of patients responded to the initial SMS and over 80% of those who responded 
did so within 2 hours.44 It is thus distinct from other forms of cohort recruitment as it is less 
costly, enables a wide reach and allows near real-time information. Systems using SMS have 
also been implemented in low and middle-income countries.43  
2.3.1.3.3 Large population-based datasets 
Different sources of routinely collected data have been used to study vaccine safety, 
including information from hospital and/or primary care linked with vaccination history. 
These electronic health records are readily available and can achieve big sample sizes, thus 
having the power to detect rare adverse events. Furthermore, they have the potential to be 
population-based, ensuring representativeness not achieved during clinical trials.6 In the 
context of pharmacovigilance, electronic health records have been mainly used for signal 
strengthening and signal confirmation (see Sections 2.3.2 and 2.3.3) but a few studies have 
also explored applications for signal detection. Some use text mining techniques,49 while 
others have adapted existing disproportionality measures (see 2.3.1.1) for use in a 
longitudinal context.50-52 Examples include the Longitudinal Gamma Poisson Shrinker, 
adapted from the multi-Item Gamma Poisson Shrinker, which considers person-time instead 
of case counts to estimate the expected number of events52 and the Temporal Pattern 
Discovery which adapted the information component using a Bayesian approach and looks 
at the disproportionality measure at different times around the prescription.51 Both 
measures have been validated and the latter has been applied to MMR and a range of 
adverse events, with results consistent with previous knowledge.53 Mining electronic health 
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records has not received much attention for pharmacovigilance. One of the reasons might 
be the concern of using the same data to generate and confirm a signal. It remains unclear if 
this can lead to biased results.54  
2.3.1.3.4 Social media and other online reports 
Information generated by internet-related activities has started to be used for public health 
purposes.55 Pharmacovigilance is no exception and social media, web-search queries, and 
data from health forums have been suggested as real-time, low-cost sources of new safety 
signals.56 In the last few years, there has been an increasing number of publications in this 
area, mainly trying to explore how to make use of these data.56 Progress has been made and 
there are several options available to extract and use these data with the aim of identifying 
safety signals. Previous studies have also tried to validate their results by comparing them 
with data from spontaneous reporting systems. Results have shown a good agreement for 
Twitter and web-search queries data.57,58 These studies have mainly focused on therapeutic 
drugs but have also looked at some vaccines, for example influenza,58 human papillomavirus 
(HPV),57,58 tetanus-diphtheria-pertussis,57,58 and hepatitis B.57,58 Overall, they have identified 
mild AE such as injection site pain, fever and malaise.57,58 Nevertheless, challenges in 
identifying adverse events remain, related to the way people report the events and the 
drugs, but also with the need for human supervision for some of the existing techniques. In 
addition, multiple ethical questions have been raised, with no clear answers.56  
To clarify some of the existing questions, a 3-year project, Web-Radr, was launched in 2014. 
One of its work packages, led by WHO-UMC, aims at identifying new analytical tools for using 
social media in pharmacovigilance.59 Despite the progress made in technical terms to harness 
social media data, the latest publicly available information still questions the role of this data 
source in terms of signal detection. In particular, there have been discussions on whether it 
should be considered as a tool to support signal detection or whether it can be used on its 
own.60 The place of this data source for pharmacovigilance is yet to be determined.  
2.3.2 Signal strengthening  
2.3.2.1 Ecological studies 
The main feature of ecological studies is the use of aggregate data instead of individual level 
data. These studies can be conducted in several ways. One option is to perform a before-
after comparison, where the overall rate of an outcome of interest is compared before and 
after the introduction of the vaccine being assessed. This design was used to assess chronic 
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fatigue syndrome among girls aged 12-20 following introduction of HPV vaccine.10 Changes 
in diagnostic patterns and in the outcome incidence for other reasons can affect this type of 
analysis.  
A special case of this comparison is the one used in mass vaccination campaigns where by 
comparing incidence before, during, and after the campaign it may be possible to further 
assess a possible causal association. If a causal association exists, a marked increased 
incidence of the outcome should be observed. This was the case in Brazil where an increase 
in aseptic meningitis was detected following a mass campaign with a Urabe-containing MMR 
vaccine.61  
A less common situation where this design may be used is when there are changes in the 
vaccination schedule age and there is a causal association between the vaccine and the 
outcome. In those circumstances, the incidence of the outcome will decrease in the age 
group in which the vaccine was previously administered and will increase in the new age 
group.62  
Ecological studies usually provide quick results but there is limited ability to adjust for 
potential confounding factors. This study type is thus considered to provide less strong 
evidence compared to other epidemiologic designs (see 2.3.3). 
2.3.2.2 Observed-to-expected (O-E) analysis 
These analyses compare rates of observed events to what would be expected, based on rates 
of the adverse event in the absence of the vaccine. This tries to capture what would have 
been observed if the vaccine had not been administered and thus helps determine if events 
are indeed related with the vaccine or are coincidental. O-E analyses have been used to 
monitor safety concerns identified from signal detection methods where the magnitude of a 
possible risk is still unclear and rapid results are required.  
To identify the number of observed events one might use data from spontaneous reports63 
or prospectively collected data.64 Using spontaneous reports as a measure of the observed 
number of events is affected by limitations in spontaneous reports systems (see 2.3.1.1), 
particularly by underreporting. Different scenarios of underreporting can be assessed in 
sensitivity analyses.  
Expected events are based on a combination of information from background rates of the 
event and the person-time at risk. The former might be obtained from existing electronic 
health records or publications and should be drawn from a population as similar to the one 
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in which the events were observed. The latter should be determined based on the 
hypothesised period of risk following the vaccine and a measure of the number of doses 
administered. If there is no information on the doses given, the number of doses sold can be 
used.63  
Regardless of the data source used, the analysis is simply the ratio of the number of observed 
and expected events and it is possible to calculate a 95% Poisson exact confidence interval 
(95%CI). The disproportionality analysis presented in Section 2.3.1.1 is also a comparison of 
observed-to-expected events. It differs from the one presented here in the data used, as it 
only utilizes information from a single spontaneous reporting system, and also in the way it 
is used, as disproportionality analyses are usually applied for signal generation.63 O-E analysis 
is also the basis for some of the near real-time surveillance analysis presented in 2.3.2.3.  
2.3.2.3 Near real-time surveillance  
In 2005 the Vaccine Safety Datalink (VSD) proposed the use of sequential tests for timely 
detection of signals, accounting for repeated testing. VSD receives electronic data from 8 
participating centres in the USA, corresponding to a population of 9.2 million. Unlike most of 
the existing methods this type of surveillance usually starts shortly after a new vaccine has 
been introduced and data are examined at repeated points in time. To adjust for multiple 
testing, VSD uses sequential tests, initially the maximized probability ratio test (MaxSPRT) 
and then extensions of this test. In fact, the group developed new statistical tests to address 
some challenges in vaccine safety and also contributed to a deeper understanding of the 
properties of existing and new statistical tests. The method has been used to assess several 
vaccine/outcome pairs, and has allowed the identification of several safety signals, resulting 
in change of policy. It is now used routinely in the USA.9   
In the UK, NRVTSS has been implemented using spontaneous reports for observed events 
and electronic health records to calculate the number expected events.10 This approach 
inherits the limitations of spontaneous reports systems, as presented in 2.3.1.1. Given the 
availability of electronic health records in the country and country-specific vaccination 
schedules, it would be desirable to implement a system that allows for quick signal 
identification and that does not rely on spontaneous reports. This thesis thus focuses on 
assessing the feasibility of implementing a NRTVSS using UK electronic health records.  
Given that the vaccine/outcome pairs to study need to be set in advance, NRTVSS is best 
suited to study a set of events of special interest. These can be selected based on information 
from clinical trials, signals seen with previous versions of the vaccine (e.g. seasonal influenza 
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and Guillain-Barré syndrome (GBS), rotavirus vaccine and intussusception), or biological 
knowledge of the vaccine characteristics.  As it does not allow for confirmation of a signal, it 
is considered under the signal strengthening approach.  
The method was initially known as rapid cycle analysis, due to the file structure used in VSD.65 
Considering this designation is specific to the VSD structure and not self-explanatory, other 
terms were considered. For the purposes of this work the term near real-time vaccine safety 
surveillance using electronic health records, or simply near real-time vaccine safety 
surveillance, will be used as this was considered to better illustrate the type of surveillance 
conducted.  
This is not the only tool available to produce (near) real-time results. Other methods include 
the recruitment of cohorts via SMS/e-mail and the use of internet-related data; see Sections 
2.3.1.3.2 and 2.3.1.3.4, respectively, for a description of these other types of (near) real-time 
surveillance efforts. Unlike cohort recruitment, NTRVSS can be implemented if electronic 
health records are available with no need for additional data collection, but it is limited by 
the quality of these records. Furthermore, NRTVSS is a more robust and well-established 
method compared to the analysis of internet-related data, which is still being explored for 
this purpose. These two other methods also occupy a different place – they are both in the 
signal generation sphere, while NRTVSS is used for signal strengthening. NRTVSS is the focus 
of this thesis and thus more detail on its use is provided throughout this work. In particular, 
the statistical details of the tests used for this type of surveillance are presented in Section 
3.3. 
2.3.3 Signal confirmation 
Signals identified by a variety of sources usually require confirmation from a rigorous, well-
conducted epidemiological study.66 The increasing availability of electronic health records 
and their characteristics (in terms of size and representativeness, see 2.3.1.3.3) have become 
an attractive data source to perform such hypothesis-testing studies. The USA, Denmark and 
the UK are examples of countries using this data source.39 Despite its attractiveness, it is 
important to be aware of issues with data completeness and quality – both vaccination status 
and outcomes should be well captured. There should also be information regarding potential 
confounders of interest.66  
When trying to identify outcomes it is important to know the coding system in use and to 
identify all the relevant codes. These might be a mixture of diagnostic, symptom and drug 
codes. In the case of UK primary care data, involving a practising general practitioner (GP) 
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might be helpful to guide this choice. Code-lists developed will never be perfect and will 
capture cases with different levels of sensitivity/specificity. The issue of imperfect validity 
might thus be assessed by using code-lists with varying levels of sensitivity/specificity and 
comparing the results. Alternatively, new or pre-existing studies assessing the validity of 
these algorithms might be used.66,67 Validity assessment for CPRD data is explained in more 
detail in Section 3.1.1.4.  
In some cases, it is possible to access case notes for confirmation of a case identified using 
the method abovementioned. When inspecting these notes it is important to use standard 
definitions to ensure comparability of different studies. The Brighton Collaboration has had 
a fundamental role in guiding the development of such standard definitions. By bringing 
together professionals interested in vaccine safety and applying a systematic method, this 
collaboration has contributed to the development of several standard case definitions. 
Currently, definitions for 47 events of interest are available.68  
Additionally, information on the time of the vaccination and event are essential, as it is 
necessary to define a risk-window (time at risk of developing the adverse event).66 Defining 
a risk-window depends on the vaccine, the event itself and existing knowledge.  
Below, the main designs used in this context are explained, including the main advantages 
and disadvantages of each one. These confirmatory studies may also rely on other sources 
of data, such as data retrieved from targeted hospital surveillance or cohorts recruited 
following vaccination (see 2.3.1.3.1 and 2.3.1.3.2, respectively). As this thesis focuses on the 
use of electronic health records this Section briefly presents the main designs to conduct 
epidemiologic studies with a special focus on issues while using electronic health records. 
Figure 2.3 presents a comparison of the three designs covered (cohort, case-control, and 
self-controlled case series) for six individuals (3 with the outcome of interest and 3 without 
the outcome).  
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Figure 2.3. Comparison of a cohort, case-control and self-controlled case-series (SCCS) for 6 individuals (3 cases 
and 3 non-cases). Adapted from Nick A.66 
2.3.3.1 Cohort studies  
For this design, a cohort of individuals is established and cases occurring within and outside 
the exposure period are identified. The risk of developing the outcome is compared among 
the exposed and unexposed (Figure 2.3 A). Being a cohort, person-time is available and it is 
thus possible to obtain direct estimates of risk and attributable risk. Misclassification of the 
outcome can lead to biased results. The analysis is usually done using Poisson regression. 
While having person-time is the main advantage of this design, for rare events it requires 
large amounts of data and if these data is available, the analysis may be computationally 
intensive.66,67 For vaccine safety, an example of this design was the assessment of adverse 
pregnancy outcomes following the HPV vaccine, in Denmark.69   
2.3.3.2 Case-control studies 
For this design, cases of the disease are identified, followed by selection of suitable controls, 
and odds of exposure (vaccination) is compared in cases and controls. Controls can be 
matched to controls and exposure assessed based on a reference date/age at the event. It is 
also possible to use multiple controls per case (Figure 2.3 B). This design requires inclusion 
of a smaller number of individuals (as compared to a cohort study), which eases the data 
collection process or, in the case of electronic health records, reduces computational power. 
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This is of particular relevance for rare outcomes, as it is often the case for vaccine safety. As 
it does not consider follow-up time, in a case-control study data can be analysed as they 
become available. This is only an advantage if the comparison is made with a prospective 
cohort, as use of electronic health records data with an historical cohort design can also be 
analysed as soon as the data become available. The analysis is usually done using logistic 
regression. As with other case-control studies, selecting a control group might prove difficult. 
When using electronic health records this issue may be less problematic as it is always 
possible to establish a cohort and a case-control study is in fact nested within the cohort.66,67   
Case-control studies are generally considered to provide weaker evidence than cohort 
studies but if well conducted they can provide evidence as robust as cohort studies. One 
issue particularly relevant for case-control studies using electronic health records is 
identifying cases and controls. Cases are selected based on registered information, including 
codes on diagnosis and symptoms or drugs prescribed (see 2.3.3). However, absence of a 
relevant code might not mean absence of the disease of interest. This problem is the same 
as that of outcome ascertainment in cohort studies that use electronic health data. The issue 
of imperfect positive predictive value (PPV) of diagnostic codes is considered in Section 
3.1.1.4.  Nevertheless, for rare outcomes, this will have little impact when estimating odds 
ratios.66,67 Smeeth et al. used a case-control study in 2004 to assess a potential increase in 
autism following MMR.70 
2.3.3.3 Self-controlled case series studies  
The self-controlled case series (SCCS) method was developed by Prof. Farrington, at the 
Public Health Laboratory Service (now Public Health England), to assess suspected 
associations between a vaccine and an acute adverse event when only information from 
cases is available.66,71,72  
For a given study period, individuals experiencing the outcome of interest are identified and 
their vaccination histories are retrieved. Based on vaccination date, risk-windows are defined 
and the remaining of the study period is included as control period for a given individual 
(serving as the baseline risk). This is equivalent to a retrospective cohort design, conditioning 
on experiencing the event (Figure 2.3 C). The analysis is thus performed using conditional 
Poisson regression. The main advantages for this design include: (i) it only requires cases, 
while keeping similar power to a cohort study, and (ii) it intrinsically adjusts for time-invariant 
confounding (such as gender or ethnicity). While the method does not intrinsically adjust for 
time-variant confounders, such as age, it is still often possible to allow for these in the model.  
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Potential disadvantages follow from the assumptions of the method. First, the probability of 
the exposure should not depend on the occurrence of the event. For vaccine safety this will 
matter if (i) the event is a contra-indication for the vaccine (e.g. intussusception and rotavirus 
vaccine); (ii) the individual is more or less likely to be vaccinated after experiencing the event 
(e.g. Guillain-Barré syndrome and seasonal influenza); (iii) vaccination is delayed after the 
event (e.g. after a seizure episode).66,71,72 For (i) is it possible to use a pseudo-likelihood 
method, for (ii) using a SCCS will produced biased estimates only if the probability of 
vaccinations changes considerably while for (iii) the issue might be addressed by considering 
a low-risk period during the time before vaccinations.66,71 This assumption (event-
independent exposure) is also problematic when the outcome is death, as after dying there 
is no possible exposure. SCCS can still be used if the deaths are rare and time from exposure 
to the end of the planned observation period is considered. Secondly, this method is best 
suited to study events with short risk periods. It can be used for longer periods as in studies 
assessing the risk of autism following MMR73,74 but it is more prone to collinearity with age, 
reducing power.71 Thirdly, this method does not allow the estimation of absolute incidence, 
only relative incidence. Finally, it requires variability in the time or age at which the event 
occurs.  
While this method has been developed to study vaccine safety it has been widely applied, 
particularly in pharmacoepidemiologic studies.71 For vaccine safety, a review identified 40 
studies using SCCS until the end of 2010, looking at a variety of vaccines and adverse events.72 
Examples include autism following MMR vaccine,73,74 febrile convulsions and MMR75 and 
intussusception and rotavirus vaccine.76 For the former no association was shown while for 
the two last pairs an increased risk was observed. SCCS is a reference method in vaccine 
safety confirmatory studies.   
2.4 Thesis rationale, aim and objectives 
2.4.1 Thesis rationale 
In the UK, vaccine pharmacovigilance has relied largely on spontaneous reports and on 
epidemiologic studies aimed at confirming hypotheses generated by a variety of sources. 
NRVTSS has been implemented using spontaneous reports for observed events.10 As outlined 
in Sections 2.3.1.1 and 2.3.3, spontaneous reports under-report AE and are subject to biases, 
while hypothesis-testing studies are generally designed in response to suspicions raised 
some time after the vaccine’s introduction. In contrast, NRTVSS is usually started very soon 
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after vaccine delivery and its sequential nature ensures timely identification of signals. 
Electronic health records are required for a new UK NRTVSS that relies fully on routinely 
collected data; in the UK such research-level primary care electronic health records data are 
available, such as the CPRD,11 THIN,12 the RCGP RSC,13 and ResearchOne.14 It is then necessary 
to determine the NRTVSS methods available, their characteristics, and whether available 
electronic health records are adequate to perform this kind of surveillance. This PhD project 
explores these aspects, using CPRD as the main data source.  
2.4.2 Aim and objectives 
The overarching aim of this thesis is to assess the feasibility of implementing a near real-time 
vaccine safety surveillance system using CPRD data. Specific objectives include to: 
1. Review the methods currently used to perform NRTVSS using electronic health 
records (‘Systematic review’); 
2. Examine recording delays in CPRD for selected conditions, due to practices receiving 
and recording diagnosis made at secondary care (‘Recording delays’); 
3. Trial the implementation of NRTVSS using previously collected CPRD data (‘Trial 
implementation’); 
4. Assess how delays in recording outcomes and receiving data influence the power 
and time to detect a safety signal (‘Power’). 
The work conducted to address these objectives has been written as four papers, numbered 
1 to 4, in accordance to the corresponding objective number. The papers are presented in 
this thesis and Table 2.3 indicates the Chapter in which each paper can be found. This table 
also includes the secondary objectives for objectives 2 and 3, as well as the outcomes and 
vaccines considered for each main objective. Further information on the work conducted but 
not included in the papers has been placed alongside each paper and in intervening Chapters. 
This additional work is intended to provide the reader with a deeper understanding of the 
choices made regarding the work described in the papers. Before explaining the work 
conducted to address each of these objectives, in the next Chapter the data sources used 
(CPRD and Hospital Episode Statistics - HES) are presented, as well as how they were used to 
select the study population. The Chapter ends with a detailed presentation of the sequential 
tests used to perform NRTVSS.  
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Table 2.3. Thesis objectives 
Objective Chapter Secondary objectives Outcome(s) Vaccine(s) 
1. Systematic 
review 
4 - Any Any 
2. Recording delays 5 To evaluate completeness 
of recording of diagnoses in 
CPRD  
 GBS 
 Bell’s palsy 
 Optic neuritis 
 Febrile seizures 
No specific 
vaccines 
considered 
3. Trial 
implementation 
7 To assess: 
 the statistical test to use; 
 how to adjust for delays;  
 power to detect a signal. 
 GBS 
 Febrile seizures 
 Seasonal 
influenza 
 MMR 
4. Power 7 -  GBS  Seasonal 
influenza 
GBS – Guillain-Barré syndrome, MMR – Measles-mumps-rubella vaccine 
 
  
39 
 
3 RESEARCH METHODS 
3.1 Data sources  
3.1.1 CPRD  
In the UK, over 98% of the population is registered with a GP, who manages a variety of 
health conditions and acts as a gatekeeper for further care, including referring patients for 
secondary care when necessary. Following these assessments at secondary care, results are 
communicated back to GPs. GPs and other practice staff register information on their 
patients (including feedback from secondary care) onto dedicated software, where the 
information is stored for future reference.77,78 The main GP software systems include EMIS 
(Egton Medical Information System), SystmOne and Vision.78  
CPRD collects data from participating practices in the UK that use Vision software and it is 
one of the largest primary care databases in the world.77,78 It started in 1987, under the name 
of Value Added Medical Products (VAMP), and was initially restricted to London. It then 
expanded in 1993 when it was renamed the General Practice Research Database (GPRD) and 
again in 2012, when it received its current name, CPRD. As of July 2013, CPRD contained 
information on 4.4 million patients (6.9% of the UK population), with its population broadly 
following the UK population in age, sex, and ethnicity distributions. CPRD has been 
extensively used for research purposes, with almost 1800 research papers published79 on a 
wide range of topics, including (pharmaco)epidemiologic studies, health economics, health 
services research and pragmatic trials.77 Knowing the content and structure of these data as 
well as the data available is required in order to understand the findings from studies that 
use them. 
3.1.1.1 Data content 
CPRD data contain anonymised information on health-related diagnosis, tests, referrals, 
lifestyle factors, and prescriptions. Practice staff may enter information into GP systems 
using coded and free text. In Vision, information is coded with Read codes, a hierarchical 
thesaurus of clinical terms used in the National Health Service (NHS) since 1985.80 Free text 
can be added to these coded terms as a way to provide additional information. Alternatively, 
letters or e-mails can be attached. These usually document communication with other levels 
of care (to and from GPs) and are considered a distinctive type of free text.78 In the past, 
anonymised free text was available for purchase upon request, and was mainly used for 
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validation purposes and in some cases for improving diagnostic algorithms. CPRD also 
explored the use of natural processing language techniques to improve the usability of free 
text for research and, in 2012, there were plans to develop free text tools as a way to 
maximise the utility of this data source.78 However, due to changes in the information 
governance environment in the UK, in April 2016 CPRD stopped making free text data 
available to researchers (CPRD Knowledge Centre, personal communication). Prescriptions 
are identified in a different way from the remaining information. They receive a unique CPRD 
product code and information on the BNF (British National Formulary) code is also 
included.81,82 In addition to Read codes and product codes, immunisation information can 
also be recorded using specific information in a dedicated file. This includes two main 
variables, the immunisation type, which contains information on the vaccine type, and 
immunisation status, which indicates if the vaccine has been administered, advised or 
refused. CPRD data also comprise structured data fields, used to register test results and 
clinical information. This information is recorded using ‘entity types’ and CPRD provides 
information on what is recorded in each entity type together with look-up tables detailing 
what is recorded under each code.  
As CPRD diagnoses, tests, referrals, vaccinations and therapies are coded, when ascertaining 
cases of disease/drug exposure it is necessary to develop appropriate code-lists covering the 
codes that might have been used to identify the disease of interest/drug exposure. To 
facilitate identification of relevant Read codes and product codes CPRD provides customers 
with browsing tools. Section 3.2 details how these browsers were used to develop code-lists.   
3.1.1.2 Data structure 
CPRD contains medical information from patients in participating practices. This information 
is held in different files depending on its content, as presented in Table 3.1.82,83 These files 
can be linked to provide the entire medical history from a given patient. For the purposes of 
this work patient, practice, clinical, test, referral, immunisation and therapy files were used. 
Data from these files allowed identification of diagnoses and vaccinations of interest. Further 
details are provided in Section 3.2.  
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Table 3.1. Content of each CPRD file type82,83 
File  Content 
Patient Patient demographics and registration details.  
Practice Practice information (including when information was last collected).  
Staff Practice staff details.  
Consultation Information on the type of consultation. 
Clinical All medical history, including symptoms, signs and diagnoses. Data are coded 
using Read codes.  
Additional 
Clinical details 
Information entered in structured data areas in the GP’s software using entity 
types.  
Test Information on test data (e.g. results from blood tests). 
Referral Information on referrals to external care (e.g. hospital). 
Immunisation Information on vaccinations coded using Read codes and special 
immunisation information.  
Therapy Details of all prescriptions (including vaccines and therapeutic drugs). 
GP – General Practitioner 
 
To understand the medical history of a patient it is also important to know for which time 
period we have information available for. This is done using key dates, both at the practice 
and patient level, summarised in Table 3.2. For a given patient, information can be used from 
the time that the practice in which s/he is registered is deemed to be of research quality (up-
to-standard date, see 3.1.1.4) and from when the patient registered with that practice 
(current registration date). It has been demonstrated that in the first few months after a 
patient registers with a new practice GPs tend to record not only new diagnoses but also 
retrospectively record past diagnoses.84 It was therefore suggested that up to the first year 
after the current registration date should be excluded to avoid capturing retrospective 
recording.84 Data from a patient can thus be used for a study starting at the latest of up-to-
standard date and current registration date plus up to one year (depending on the specific 
condition). Data are available until they were last collected from the practice (last collection 
date), the patient transferred out of the practice (transfer out date) or the patient died 
(death date). Follow-up thus ends at the earliest of last collection date, transfer out date and 
death date. These beginning and end of follow-up are then adapted for each study depending 
on the design and study period. Records also contain specific dates which might be of 
interest. These include the system date, the date when a record was entered into the system, 
which is automatically assigned by the practice software and the event date, entered by the 
practice staff and which is deemed to represent the date the clinical event happened. The 
importance of these record-level dates is explained in more detail when assessed recording 
delays in Section 5.3 (Objective 2). 
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Table 3.2. Relevant dates in CPRD 
Date Content 
Practice level  
Up-to-standard date When the practice met certain quality requirements. 
Last collection date When the practice last uploaded data to CPRD. Available for each 
monthly release of CPRD. 
Patient level  
Current registration date When the patient registered with the practice. 
Transfer out date When the patient was transferred to another practice. 
Death date When the patient died. 
Record level  
Event date When the event is deemed to have occurred. Entered by the 
practice staff. Ideally represents the correct date of diagnosis or the 
date when the patient re-consulted for on-going or past events.  
However, can also be the date when the record of a past diagnosis 
was entered retrospectively into the GP system.  
System date When the record was entered into the system (automatically 
assigned by the software). 
CPRD – Clinical Practice Research Datalink, GP – General Practitioner 
 
3.1.1.3 Data available for analysis 
The London School of Hygiene and Tropical Medicine (LSHTM) holds a CPRD license and 
receives a new data release every 6 months. For these data, it is possible to search for eligible 
patients both on the basis of recorded Read codes or other characteristics in any of the file 
types. CPRD data are released on a monthly basis and it is also possible to access data from 
these monthly versions of the data. There is online access for licence holders and patients’ 
data can be extracted based on specific Read and therapy codes. Vaccination information is 
coded using a combination of Read, therapy and special immunisation codes (including the 
vaccine type and vaccination status, see 3.1.1.1). Therefore, it is not possible to use the 
online access provided to identify patients on the basis of their vaccination status. The study 
reported in this thesis required identification of vaccinated individuals and the current online 
search tool allows only limited identification of eligible patients because of the inability to 
search for the totality of immunisation coding. This limitation and the solutions applied to 
address it are presented in further detail and discussed in Section 6.2.  
3.1.1.4 Data quality 
CPRD size, information on medical history and long follow-up time make this data an 
attractive source. However, CPRD data are not collected for research purposes and, as with 
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any routine data source, it is important to understand the data available and their possible 
limitations.  
CPRD uses data quality markers both at the patient and practice level. For patients, CPRD 
includes an ‘acceptability flag’, based on indicators of potentially poor recording or 
discontinuous follow-up. Patients are considered acceptable if: (i) they have information on 
year of birth, (ii) there are no events registered before their birth year, (iii) gender is male, 
female or indeterminate, (iv) age is ≤ 115 years at last collection date or transfer out date, 
(v) first registration date is on or after the month/year of birth, (vi) current registration date 
is valid, on/after the month/year of birth and first registration date, and for permanent 
registration, (vii) the transfer out date exists when there is a reason for transfer out, and it is 
on/after the first and the current registration dates, (viii) there is at least one valid event 
date.78,83 At the practice level, each practice is assigned an up-to-standard date, which 
indicates when the practice was deemed as being of research quality. This date is established 
based on mortality rates and practice recording behaviour. For the former, CPRD compares 
the number of deaths in the practice to an expected range given the UK’s mortality rate and 
the practice size. The latter involves a practice-level assessment of recording gaps, 
considering the median number of events in the clinical, consultation and therapy files. Each 
practice should not have any significant gaps of low recording, i.e. five consecutive weeks in 
which there were less than 30% of the median number of events.78,83  
While the data quality markers help ensure that the data available are of good quality, 
further aspects need to be considered, including validity, timeliness, and secular trends. 
When ascertaining outcomes and exposures, the general principles outlined in 2.3.3 should 
be followed. A 2010 systematic review looking at studies attempting to validate diagnosis in 
CPRD identified 357 validations assessing 183 diagnosis.85 Validation studies were either 
internal (using only data from CPRD, for example by reviewing anonymised free text) or 
external (e.g. by contacting GPs to confirm a patient coded as a case did indeed have the 
condition identified, or by comparing measures of frequency with those obtained from 
another data source). Studies reporting quantitative measures of validity most often 
reported PPV, i.e. the proportion of cases identified from CPRD that were confirmed as true 
positives. Other measures of validity, such as sensitivity, specificity, and negative predictive 
value were usually not assessed. In general, diagnoses based on CPRD data were confirmed 
based on either internal or external information (median PPV of 89%). Despite assessment 
of validity relying mainly on PPV, CPRD has been extensively used for research purposes.   
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Completeness of recording of diagnoses is typically regarded as an aspect of validity 
(encompassing sensitivity and negative predictive value). Nevertheless, some authors 
examine completeness of diagnostic recording separately, as a distinct issue. For example, a 
previous study looking at myocardial infarction showed that using CPRD only identified 75% 
of all cases, as compared to linking several data sources (CPRD primary health care records, 
hospital records, disease registers and death certificates).86 This is highly dependent on the 
place of diagnosis and management of the condition of interest but also on its severity; 
conditions generally diagnosed and/or managed by GPs are likely to be well captured in 
CPRD. The same applies to vaccination information. Vaccines administered in GP practices 
(e.g. most childhood vaccines) are expected to have high levels of completeness while the 
remaining (e.g. HPV vaccine, administered in schools) may have lower levels of completeness 
or be recorded after long delays. Furthermore, completeness might change throughout time 
leading to secular trends. These changes may be due to modification in clinical practice or 
recording behaviour. One well-known reason for changes in recording behaviour is the 
Quality and Outcomes Framework (QOF), introduced in April 2004. This scheme provides 
financial incentives to record specific outcomes as a way to achieve certain indicators. 
Recording behaviour is likely to change depending on the specific indicators incentivised at 
specific periods, and thus increase/decrease completeness.87 Alternatively, secular trends 
might be due to patients’ health service use or changing epidemiology of the condition of 
interest. When using CPRD it is thus important to reflect on whether the condition(s) of 
interest are likely to be well captured and consider implications of incomplete recording over 
time. 
An issue that is less often discussed is timeliness. Delays in CPRD data might happen for 
several reasons: (i) delays in having a final diagnosis after patient presentation, (ii) delays in 
receiving or recording feedback from other levels of care (e.g. hospital), (iii) delays in 
practices uploading files to CPRD, (iv) delays in researchers receiving the latest updated data 
from CPRD. A previous study used THIN, another UK primary care database, to compare two 
successive releases of the dataset. In particular, the authors compared the number of events 
available in the later version of the data but not in the earlier version and assessed how these  
entries varied as function of time since the last collection date. This work showed that using 
a later version of the same data would capture more events, particularly in the month 
previous to the last collection date (9.6% additional events captured).88 This is particularly 
relevant for incidence/prevalence studies as not considering delays in receiving data from 
practices (reason (iii), above) would lead to underestimation of rates. For the purposes of 
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the work presented in this thesis, timeliness is of particular relevance as a near real-time 
time system relies on timely data. To assess timeliness, it is important to know how quickly 
data accrue in CPRD. The approach in the work by Sammon et al.88 is an initial step in 
recognizing the issue of delays in recording outcomes but it does not provide quantification 
of how long it takes for data to accrue. As a central aspect of a near real-time system 
implementation, timeliness was explored as part of this project and is reported in Section 
5.3. 
3.1.1.5 Data linkage 
CPRD data provide comprehensive information on the medical history of a patient but 
additional information might be only found or be better recorded in other databases. Hence, 
linked data from other data sources are available as a way to complement CPRD data. Linkage 
is performed by a Trusted Third Party (NHS Digital) in order to preserve anonymity of records. 
At the moment, CPRD is linked to hospital data (HES, only for 75% of the English practices), 
mortality data (from the Office for National Statistics - ONS), cancer registration data (from 
Public Health England - PHE), mental health data and deprivation data (Index of Multiple 
Deprivation - IMD). Further linkages are being planned.89  
For the purposes of the work presented in this thesis the information required is mainly on 
vaccines administered and possible outcomes of interest for vaccine safety. Most vaccines 
are administered in primary care and thus CPRD is a good data source to capture this 
information. As for events of interest, some are likely to be well captured in CPRD. For others, 
that are more serious and require hospitalisation (e.g. GBS), hospital data might provide 
additional records. Hospital data would thus be relevant to complement information 
available in CPRD. However, data are linked too infrequently to allow implementation of a 
near-real time system based on linked data (see 3.1.2.3). As such, I envisaged a system solely 
based on CPRD, and stand-alone CPRD data were used for most of the work presented. The 
exception is the work presented in Section 5.3, looking at completeness of records initially 
diagnosed in hospital. For that work, linked CPRD-HES data were used; HES data are thus 
reviewed below.  
3.1.2 HES 
Information from hospital activity in England is collected in several HES datasets: (i) HES 
Admitted Patient Care (HES APC), which collates information on hospital admissions; (ii) HES 
outpatient data, which contain information on outpatient appointments; (iii) HES Accident 
and Emergency (A&E), where details on A&E attendances are collected; and (iv) HES 
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Diagnostic Imaging Dataset, where details from diagnostic imaging tests (x-rays, magnetic 
resonance imaging, etc.) are maintained. These data are maintained by NHS Digital and 
anonymised for research use.89,90 Only a small proportion of diagnoses in HES Outpatient 
data and HES A&E are coded, limiting their use (Rachael Williams, CPRD, personal 
communication). For this work only HES APC was used and is explained in more depth below. 
It will be simply referred as HES.  
HES data started to be collected in 1987 and national coverage was attained in the financial 
year 1989/1990. It was initiated to inform management and planning of services and since 
2004/05 is the basis of a payment-for-performance system in place in the NHS. CPRD linkages 
with HES data only cover the period from 1997 onwards as this corresponds to the date when 
NHS numbers became a mandated return from hospitals and thus could be used in the 
linkage by the third trusted party.91 Given the universal coverage of these data, the long 
period of data collection and the possibility to follow-up individuals, HES has also been used 
for research purposes, including: disease incidence, vaccine safety, treatment patterns by 
different hospitals, impact of clinical guidelines and policies, therapy outcomes and factors 
associated with these outcomes, and risk prediction models.90 What follows is an explanation 
of the data characteristics with implications for this work.    
3.1.2.1 Data content 
HES contains clinical, demographic, and provider information for each hospital admission. 
This includes a unique CPRD identifier (to allow linkage with CPRD data) and information on 
the quality of linkage between HES and CPRD data. Hospital information collected includes 
coded diagnosis and relevant dates (e.g. admission and discharge dates). HES data are coded 
using the International Classification of Diseases, Tenth Revision (ICD-10). ICD-10 is a 
hierarchical coding system including diseases, disorders, injuries, and health-related 
conditions. It has been used worldwide to monitor disease incidence and prevalence, reasons 
of death, to evaluate guidelines implementation, and for reimbursement purposes.92  
3.1.2.2 Data structure 
In HES, each admission (an uninterrupted stay in a hospital) is known as a ‘spell’. For each 
spell there may be several Finished Consultant Episodes, i.e. periods during which a patient 
was under the care of a single consultant. Each episode has one primary diagnosis and may 
have up to 20 diagnoses in total; the episode must have at least one primary diagnosis, and 
the maximum number of diagnoses that can be recorded has changed over time (from seven 
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diagnoses until April 2002, to 14 between April 2002-March 2007, and 20 diagnoses ever 
then).  
As in CPRD, HES data are stored in multiple files. Files available in the linked data are 
presented in Table 3.3. For the purposes of this work, only the patient, hospitalisations, 
episodes and diagnosis files were used.  
Table 3.3. Content of Hospital Episode Statistics Admitted Patient Care (HES APC) file (linked data)89,90,93  
File  Content 
Patient Patient demographics and linkage quality.  
Hospitalisations Admission, stay and discharge details (dates, duration, etc.). 
Episodes Episode characteristics (dates, speciality, duration). 
Diagnosis Details of diagnoses (including ICD-10 codes), available by episode for each 
hospitalisation, including the primary diagnosis. 
Procedures Details of procedures received. Can be linked with episode or spell. 
Augmented care Specific information on time spent on intensive and/or high dependency levels 
of care. 
Critical Information on patients receiving critical care (type and duration). 
Maternity Birth and delivery information. 
Health Resource 
Group 
Information on the Healthcare Resource Group (and thus unit of cost) the 
episode was linked to.  
ICD-10 - International Classification of Diseases, Tenth Revision. 
 
3.1.2.3 Data available  
After a patient discharge, a physician responsible for the patient’s care fills in a discharge 
summary for the specific episode (including diagnosis and procedures). These summaries are 
then sent to a hospital coding department where they are entered in an electronic database. 
These data are extracted from each hospital on a monthly basis and sent to NHS Digital. NHS 
Digital performs data checks and cleaning procedures, and generates HES identifiers for each 
episode. Hospitals can submit an updated version of the data to correct data quality issues 
at the end of the financial year. NHS Digital thus produces a provisional annual HES extract, 
which is reviewed by the hospital, and after this a final revision is made available.  
CPRD-HES linked data are made available in sets which are released too infrequently to allow 
the implementation of a near real-time surveillance system. These datasets also suffer from 
delays in data received from the hospitals. For example, the linked data released in January 
2015 (Set 10) included HES hospitalisations only up to 31st March 2014. The subsequent 
release (Set 11) was made available to researchers in December 2015 and contained HES 
data up to 31st March 2015. Despite some improvement in this regard (for example, Set 12 
was released in March 2016 and included HES data up to 30th September 2015) a more timely 
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updating of the linkage is not envisioned in the near future. As such, CPRD-HES linked data 
were not considered an adequate data source for NRTVSS implementation. Instead, I used 
them to assess aspects of CPRD stand-alone data quality, as explained in Section 5.3. 
3.1.2.4 Data quality 
As with CPRD data, one of the main issues when using HES data is the quality of coding. 
Coders are trained to follow standardised rules when transcribing information from 
discharge summaries. However, the quality and completeness of these summaries may vary 
thus limiting the ability to apply the existing rules, particularly for comorbidities. Additionally, 
changes in financial incentives to improve coding depth may have led to an increase in the 
number of codes used and improvement in coding. This will affect validity of research 
findings in general. In particular it may bias time trend comparisons and comparability of 
studies conducted at different time periods, as validity of recording may not be constant over 
time.90  
HES collects data on admitted patients but admission thresholds might vary between 
hospitals or over time. For example, in 2004 the A&E waiting time target in England changed 
to a maximum of 4 hours, which might have triggered an increase in the number of 
admissions as a way to meet this target. This might influence characteristics of patients 
admitted and influence comparisons over time.90  
3.2 Identifying eligible individuals: development of code-lists 
As explained above, CPRD and HES contain coded information using Read codes or ICD-10 
codes, respectively. Analysis using these data require a prior identification of code-lists which 
allow ascertainment of cases and exposures. Analyses performed to address each of the 
study objectives included different study populations and had distinct inclusion and 
exclusion criteria. These are explained in the Chapters where the specific analyses are 
reported. In this Section, details are provided on how the code-lists were developed to 
identify eligible patients and how data were extracted.  
As explained in 3.1.1.1, CPRD provides browsers to facilitate the search of Read and product 
codes. I carried out searches in a two-stage process. First, a free-text search with terms 
relating to the condition of interest was performed. The results of the search were assessed 
individually and a decision made whether to include them. After selecting the codes to 
include, the relevant Read code hierarchies were identified and searched to identify further 
terms. Immunisation information also requires the identification of dedicated codes and is 
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detailed in Section 3.1.1.2 and below. A similar procedure was followed when developing 
code-lists to identify cases in HES but using ICD-10.  
For objective 2 of this project (examine recording delays in CPRD, due to practices receiving 
and recording diagnosis made at secondary care, for selected conditions) eligible patients 
had at least one of four outcomes: Bell’s palsy (BP), GBS, optic neuritis (ON) and febrile 
seizures (FS). The rationale for selection of these outcomes is presented in Section 5.2.  Table 
3.4 presents searches conducted for both Read terms (initial searches) and Read codes 
(based on the initial search). Prof. Sara Thomas developed an initial code-list for BP. Prof. 
Sara Thomas and Prof. Nick Andrews shared with me existing code-lists for FS. For both BP 
and FS, I conducted searches to update existing code-lists. I developed initial searches and 
code-lists using data (and thus browsers) released in July 2015. I conducted new searches in 
July 2016 with the view of updating these lists; no further codes were identified. The codes 
included in the code-lists were classified as being specific or not for the condition of interest. 
All codes were used in the main analysis, and then the sub-set of codes classified as specific 
were used to conduct a sensitivity analysis. This additional analysis was performed to assess 
the imperfect validity of diagnosis records, as suggested by previous studies and explained 
in Section 2.3.3. Final code-lists are available in Section 5.4.  
Table 3.4. Searchers performed to develop and/or update code-lists using Read codes  
Outcome Read terms Read codes 
BP† *bell*, *facial* 14*, 2BR*, F31* 
GBS *guillian*, *neuritis*, *neuropath*, 
*demyelin* 
F17*, F21*, F36*, F37*, Fyu*, N24* 
ON *optic*, *visual*, *demyelination*, 
*neuritis* 
F4H*, F21*, Fyu* 
FS† *seizure*, *convulsion*, *fit* 1B2*, 1B6*, 282*, F13*, F25*, Fyu*, 
Q48*, R00*, Ryu*, Eu4* 
*Any term is allowed, †Only for updating purposes. BP – Bell’s palsy, GBS – Guillain-Barré syndrome, 
ON – Optic neuritis, FS – Febrile seizures.  
 
Data from patients with a relevant code in the clinical, test, referral, or immunisation file 
during the study period (January 2005-July 2014) were extracted using data released in July 
2015. First-ever codes were used to capture incident cases and avoid counting the same 
events multiple times. After extraction, eligibility was further assessed by looking at 
beginning and end of follow-up dates. Beginning of follow-up was the latest of up-to 
standard date, current registration date plus one year (see 3.1.1.2) and the beginning of 
study period (specific to each study question), and end of follow-up was the earliest of date 
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of death, transfer out date, last collection date (see 3.1.1.2) or end of study period (also 
specific to each study question). Patients were included if they had at least a day of follow-
up. Further details and other eligibility criteria are available in the Section where each 
specific study is reported. 
Work conducted to address objective 2 (assessing recording delays in CPRD data) also 
included the analysis of linked CPRD-HES data. When analysing these linked data, individuals 
with one of the four outcomes of interest in HES were included, which thus required outcome 
ascertainment using HES data. Searches conducted in ICD-10 to identify relevant codes are 
available in Table 3.5. Final code-lists are available in Section 5.4. Patients with a first-ever 
code recorded in any diagnosis field during the study period (January 2005-March 2014) 
were included. First-ever code was used for both delay and completeness to simplify 
interpretation of the completeness analysis. Patients with no previous record of that 
outcome in CPRD were followed-up from the hospital episode date in which the outcome 
was first recorded until they had an outcome in CPRD or were censored (earliest of date of 
death, transfer out date, last collection date or July 2015). For patients in this cohort, 
recording in CPRD was then assessed using the code-lists developed for the main analysis.  
Table 3.5. Searches performed to develop code-lists using ICD-10 
Outcome Free text ICD-10 code 
BP Bell, bell G51 
GBS Guillain, demyelination G36, G61 
ON Optic, optic, bulbar G36, H46, H47 
FS seiz, convulsi, fit F44, R56 
BP – Bell’s palsy, GBS – Guillain-Barré syndrome, ON – Optic neuritis, FS – Febrile seizures. 
 
For objective 3 (trialling the implementation of a near real-time system using historical CPRD 
data) and objective 4 (assessing how delays influence the power and time to detect a safety 
signal) it was necessary to identify a cohort of vaccinated individuals. This included patients 
aged 65 years or older who were vaccinated against seasonal influenza, and children aged 
12-23 months receiving a first MMR dose. The rationale for the choice of these vaccines and 
the rationale for inclusion of only vaccinated individuals is presented in Section 5.6 and 
Section 8.3.2, respectively.   
As outlined in Section 3.1.1.1, immunisation information can be found in multiple files, using 
different fields: (i) in the clinical, referral, test, and immunisation files using Read codes; (ii) 
in the therapy file using therapy codes; and (iii) in the immunisation file using a combination 
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of specific vaccine codes (immunisation type) and codes indicating whether the vaccine was 
administered, simply advised or the patient refused it (immunisation status). Information 
contained in these files can be conflicting, for example with one code indicating the vaccine 
was administered and another one stating the vaccine was refused. It is thus necessary to 
first identify relevant codes for each of these scenarios and then develop a decision algorithm 
to determine whether to consider that an individual received the vaccine during the study 
period.  
Code-lists for seasonal influenza vaccine were based on an existing code-list, previously 
developed by Prof. Sara Thomas and Dr. Elizabeth Millett. I conducted a search to update 
this code-list, presented in Table 3.6. Read terms and Read codes search terms were used to 
identify relevant Read codes and the remaining terms were used to identify therapy codes.  
Table 3.6. Search terms used to identify relevant terms for influenza vaccine 
Coding system Search terms 
Read terms *flu*vac* 
Read codes 9OX*, 9N4*, 68N*, 65E*, 8I2*, 14LJ*, 8IA*, 8I6*, U60*, ZV0* 
Drug substance name *influen*, *agrippal*, *fluvirin*, *imuvac*, *influvac*, *optaflu*, 
*begrivac*, *fluarix* 
BNF code 14040200 
BNF – British National Formulary 
 
For the immunisation files the look-up for the entity immunisation type was consulted. 
Relevant codes for each vaccine were selected based on visual inspection of these codes. 
This information was used in conjunction with the immunisation status variable. Following 
this search, relevant codes were divided into codes indicating the vaccine had been 
administered or not.  
After finalising these code-lists, I extracted data from the following potentially eligible 
individuals: (i) individuals with a given Read code in the clinical, referral, test, and 
immunisation files; (ii) individuals with a product code in the therapy file; and (iii) individuals 
with one of the immunisation types for seasonal influenza and a status ‘given’.  
Following data extraction from potentially eligible individuals, I assessed the beginning and 
end of follow-up time (see above and Section 7.1 for further details). If they were eligible 
and had potentially received the vaccine during the study period, were aged 65 years or 
above, I applied a decision algorithm and made a final selection of vaccinated individuals. 
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The algorithm used is presented in Section 7.2.1.1.5. The code-lists were developed initially 
using data released in July 2015 and then updated using data released in July 2016. No 
further codes were identified.  
For MMR, code-lists were based on previous work by Prof. Sara Thomas and Dr. Jemma 
Walker, who kindly shared their code-lists. The procedure for data extraction was similar to 
the one described above. The algorithm used is presented in Section 7.2.1.2.5. 
To identify observed cases of GBS and FS, following seasonal influenza vaccine or MMR 
respectively, the code-lists presented Sections 5.4.1.1 and 5.4.4.1 were used. GBS was 
considered a ‘once only’ event and hence the first ever code was used (subsequent codes 
were deemed to represent retrospective recording of a past event). In contrast, in this 
analysis more than one episode for FS was allowed (see Sections 7.1 and 7.2.3 for details). 
Further inclusion and exclusion criteria are presented in Section 7.1. 
3.3 Sequential tests  
Near real-time vaccine safety surveillance makes use of sequential tests. In this Section the 
statistical aspects of sequential tests that are relevant for vaccine surveillance are presented. 
The first sequential test was proposed by Wald in the 1940’s and was known as the 
sequential probability ratio test (SPRT). He defined a sequential test as any statistical test 
that allowed one of three decisions at each observation of a given experiment: (i) accept the 
null hypothesis; (ii) reject the null hypothesis; or (iii) continue the experiment (make more 
observations). The sequential nature of these tests results in a fundamental difference in 
comparison to a non-sequential approach: the number of observations required is not fixed, 
but is a random variable, depending on the results of previous observations. This feature 
results in a reduction of the number of observations required before making a decision ((i) 
or (ii), above) and it intrinsically accounts for multiple testing. In the case of SPRT, Wald 
argued that for the same 𝛼 (or type I error, the probability of rejecting 𝐻0 when 𝐻0 is true) 
and 𝛽 (or type II error, the probability of accepting 𝐻0 when it is false) it allowed a reduction 
of about 50% in the number of observations required compared to a non-sequential test.94  
SPRT was originally developed for quality control in manufacturing94,95 but has been 
extended in several ways and applied in multiple contexts. One of its extensions, the family 
of group sequential tests, has been extensively used in the context of clinical trials.96,97 For 
vaccine safety it is important to detect a signal as early as possible. This need was emphasised 
in the late 1990’s, after the discovery of an increased risk of intussuception following 
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RotaShield® vaccine after its approval and licensure. In response to this discovery, several 
USA institutions came together and decided to build the capacity to detect adverse events 
during the post-licensure phase more rapidly. As stated in Section 2.3.2.3, this work has been 
led by VSD which started using sequential tests in 2005, as a way to reduce the number of 
observations required until a decision is made about whether to reject the null hypothesis.7 
Below is an explanation of SPRT, with a particular focus on vaccine safety.   
Consider 𝑝, the probability of an AE to the vaccine under study. Define 𝐻0: 𝑝 = 𝑝0, 𝐻1: 𝑝 =
𝑝1, 𝛼, the probability of rejecting 𝐻0 when 𝐻0 is true, and 𝛽, the probability of accepting 𝐻0 
when it is false. Define 𝐶𝑡 as the random variable representing the number of adverse events 
occurring within D days after the vaccine (risk window), administered in the period [0, 𝑡]. For 
the 𝑡-th observation, where 𝑐𝑡 events have been observed, the likelihood ratio (𝐿𝑅𝑡) is the 
test statistic, given by:7,8,94 
𝐿𝑅𝑡 =
𝑃(𝐶𝑡 = 𝑐𝑡|𝐻1)
𝑃(𝐶𝑡 = 𝑐𝑡|𝐻0)
=
𝑝1
𝑐𝑡(1 − 𝑝1)
𝑡−𝑐𝑡
𝑝0
𝑐𝑡(1 − 𝑝0)𝑡−𝑐𝑡
, (𝑡 = 1, 2, … ) 
More often the log-likelihood ratio ( 𝐿𝐿𝑅 ) is calculated as data accumulate; it can be 
calculated considering the last test result.7  
𝐿𝐿𝑅𝑡 = 𝐿𝐿𝑅𝑡−1 + log (
𝐿(𝐷𝑎𝑡𝑎𝑡 , 𝑝1)
𝐿(𝐷𝑎𝑡𝑎𝑡 , 𝑝0)
) 
The calculations above assume a binomial distribution but SPRT can also be used assuming a 
Poisson distribution. In this case consider RR, the relative risk, and 𝜇𝑡, the expected events, 
𝐻0: 𝑅𝑅 = 𝑅𝑅0, 𝐻1: 𝑅𝑅 = 𝑅𝑅1. For this situation the test statistic, 𝐿𝑅𝑡, is defined as: 
 
𝐿𝑅𝑡 =
𝑃(𝐶𝑡 = 𝑐𝑡|𝐻1)
𝑃(𝐶𝑡 = 𝑐𝑡|𝐻0)
=
𝑒−𝑅𝑅𝜇𝑡(𝑅𝑅𝜇𝑡)
𝑐𝑡/𝑐𝑡!
𝑒−𝜇𝑡𝜇𝑡
𝑐𝑡/𝑐𝑡!
= 𝑒(1−𝑅𝑅)𝜇𝑡(𝑅𝑅)𝑐𝑡 , 
 
and its log version by: 
𝐿𝐿𝑅𝑡 = ln(𝐿𝑅𝑡) = (1 − 𝑅𝑅)𝜇𝑡 + 𝑐𝑡 ln(𝑅𝑅). 
 
Given the sequential nature of the test, based on the 𝐿𝐿𝑅𝑡, at each time point it is possible 
to evaluate if there is evidence to accept/reject 𝐻0  or if it is necessary to continue 
surveillance. A decision is made by comparing 𝐿𝐿𝑅𝑡  to the previously defined upper (UL) and 
lower limits (LL). For SPRT, UL is defined as: 
𝑈𝐿 =
1 − 𝛽
𝛼
, 
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and LL as: 
𝐿𝐿 =
𝛽
1 − 𝛼
. 
Possible scenarios and associated decisions include: 
{
𝐿𝐿𝑅𝑡 < ln(𝐿𝐿) → 𝐴𝑐𝑐𝑒𝑝𝑡 𝐻0
ln (𝑈𝐿) < 𝐿𝐿𝑅𝑡 < ln (𝐿𝐿) → 𝐶𝑜𝑛𝑡𝑖𝑛𝑢𝑒 𝑠𝑢𝑟𝑣𝑒𝑖𝑙𝑎𝑛𝑐𝑒
𝐿𝐿𝑅𝑡 > ln (𝑈𝐿) → 𝑅𝑒𝑗𝑒𝑐𝑡 𝐻0 (𝑠𝑖𝑔𝑛𝑎𝑙 𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑)
 
Figure 3 exemplifies the use of SPRT for a known signal (intussusception following rotavirus 
vaccine). The surveillance period started in January 1999 and there was no signal until 2nd 
April 1999 (10th week of surveillance). At that time, 𝐿𝐿𝑅𝑡  surpassed the upper limit, thus 
generating a signal. It is important to observe the decrease in the 𝐿𝐿𝑅𝑡 following that time 
point. A signal should be raised irrespective of a subsequent decrease bringing the 
𝐿𝐿𝑅𝑡  down to the surveillance range.
7  
 
Figure 3.1. Use of Sequential Probability Ratio Test to detect a signal (intussusception) after introduction of 
rotavirus vaccine. The upper limit is crossed after 10 weeks of surveillance and the null hypothesis rejected7 
 
SPRT requires a pre-specified probability/RR of the AE. 7,8,94 Previous knowledge regarding 
the AE and its public health importance can guide the choice.32 However, the final test result 
depends highly on this choice: if 𝐻1 is too far from the real value the signal might be missed 
(accepting 𝐻0). Being conservative might delay signal detection. These characteristics limit 
the applicability of SPRT to NRTVSS, where timely identification of signals is crucial. An 
alternative version of this test has thus been formulated – the maximized sequential 
probability ratio test (MaxSPRT).96 MaxSPRT uses a composite alternative hypothesis 
(𝐻1: 𝑅𝑅 > 1) thus requiring only one critical limit (CL). This test was developed for two 
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distributions – the Poisson (PMaxSPRT) and the binomial (BMaxSPRT), as presented in 
Sections 3.3.1 and 3.3.2.96  
3.3.1 PMaxSPRT 
When assuming a Poisson distribution and the notation previously used, the 𝐿𝑅𝑡  is given 
by:8,96 
𝐿𝑅𝑡 = max
𝐻1
𝑃(𝐶𝑡 = 𝑐𝑡|𝐻1)
𝑃(𝐶𝑡 = 𝑐𝑡|𝐻0)
= max
𝑅𝑅>1
𝑒−𝑅𝑅𝜇𝑡(𝑅𝑅𝜇𝑡)
𝑐𝑡/𝑐𝑡!
𝑒−𝜇𝑡𝜇𝑡
𝑐𝑡/𝑐𝑡!
= max
𝑅𝑅>1
𝑒(1−𝑅𝑅)𝜇𝑡(𝑅𝑅)𝑐𝑡 , 
and the 𝐿𝐿𝑅𝑡 is 
𝐿𝐿𝑅𝑡 = ln(𝐿𝑅𝑡) = max
𝑅𝑅>1
[(1 − 𝑅𝑅)𝜇𝑡 + 𝑐𝑡 ln(𝑅𝑅)] = (𝜇𝑡 − 𝑐𝑡) + 𝑐𝑡 ln (
𝑐𝑡
𝜇𝑡
), 
as the maximum likelihood estimate of RR is 𝑐𝑡/𝜇𝑡 and 𝑐𝑡 ≥ 𝜇𝑡. 
For PMaxSPRT, there is no lower limit to decide when to stop surveillance; this happens when 
a predetermined number of expected events (EV) is reached. Figure 3.2 exemplifies the use 
of PMaxSPRT to study seizures following concomitant use of inactivated influenza 
vaccine/23-valent pneumococcal conjugate vaccine in 6-23 month old children. Only one 
critical limit is used and a signal was detected on the seventh test.98  
 
Figure 3.2. Use of Poisson-based maximized sequential probability ratio test to study seizures following inactivated 
influenza vaccine/23-valent pneumococcal conjugate vaccine in 6-23 month olds (adapted from Yih et al. 98) 
 
To implement a PMaxSPRT it is necessary to calculate a CL. There are several options but 
Kulldorff et al.96 proposed to calculate the CL based on the probability of rejecting 𝐻0 if 𝐻0 is 
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true (𝛼) at the end of surveillance, when at least 𝑛 events have occurred. Consider the log-
likelihood ratio, calculated at the latest possible time when 𝐻0  can be rejected, after 𝑛 
adverse events, denoted as 𝑠𝑛. The log-likelihood at 𝑠𝑛, 𝐿𝐿𝑅𝑠𝑛, is given by:  
𝐿𝐿𝑅𝑠𝑛 = (𝜇𝑠𝑛 − 𝑛) + 𝑛𝑙𝑛 (
𝑛
𝜇𝑠𝑛
) = 𝐶𝐿 
𝐿𝐿𝑅𝑠𝑛  also gives our CL of interest. Given that we stop surveillance when  𝑠𝑛 > 𝐸𝑉 and 𝑛 
gives us the number of adverse events required to reject 𝐻0, we can thus determine the 
probability of rejecting 𝐻0 based on the probability of having 𝑛 or more events at 𝐸𝑉. As we 
run tests at repeated points in time, the probability of having 𝑛 or more events at 𝐸𝑉 is 
conditional on the probabilities observed at 𝑠𝑛−1. The diagram below (Figure 3.3) illustrates 
this for 𝑛 = 3. At 𝑠3 we can only have three or more events if we had observed zero events 
at 𝑠1 and zero or one events at 𝑠2.The probability of having three or more events at 𝑠3 (and 
thus rejecting 𝐻0) is thus given by that same probability, conditional on having zero events 
at 𝑠1 and zero or one events at 𝑠2. As we assume a Poisson distribution to represent our 
variable of interest, we can calculate this same distribution to calculate these probabilities. 
To do that we need to know the mean of the Poisson distribution of interest (𝜇𝑠3 in this 
particular example, 𝜇𝑠𝑛  for any 𝑛 of interest). This mean can be obtained by re-arranging the 
equation above:  
𝜇𝑠𝑛 = −𝑛𝑊(−𝑒
−1− 𝐶𝐿/𝑛) 
𝑊 is known as Lambert's function, which solves the equation 𝑦 = 𝑥𝑒𝑥 for 𝑥. In other words,  
𝑊(𝑥𝑒𝑥) = 𝑥.  
Figure 3.3. Probability tree for rejection of H0 after we have observed three events 
 
Observed 
events 
0 
0 
0 
1 
3+ Reject 𝐻0 
1 
2+ Reject 𝐻0  
1 Reject 𝐻0  
2 𝑠1 
𝑠2 
𝑠3 
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The approach just described would allow us to calculate 𝛼 but given that 𝛼 is previously set, 
we can use these principles to determine the critical limit using an iterative process based 
on two initial CL (𝐶𝐿𝑖  and 𝐶𝐿𝑖−1) and their corresponding 𝛼 (𝛼(𝐶𝐿𝑖) and 𝛼(𝐶𝐿𝑖−1)). This 
process is followed until it converges to the desired precision.  
𝐶𝐿𝑖+1 = 𝐶𝐿𝑖 − (𝐶𝐿𝑖 − 𝐶𝐿𝑖−1)
𝛼(𝐶𝐿𝑖) − 0.05
𝛼(𝐶𝐿𝑖) − 𝛼(𝐶𝐿𝑖−1)
 
Using this method our critical limit only depends on the expected number of events and 𝛼. 
It is also possible to use this same reasoning to determine the existing power to detect an 
increased RR at the end of surveillance. For power, we are interested in 𝛽, in this case the 
probability of having less than 𝑛 events at 𝑠𝑛 considering a Poisson with a mean of 𝜇𝑠𝑛 ∗ 𝑅𝑅.  
3.3.2 BMaxSPRT 
If one decides to use the BMaxSPRT, a comparison of the exposed to unexposed period is 
assumed. Both a self-controlled and a matched cohort design can be used. Considering the 
observed number of events at a given moment as 𝑛  (exposed plus unexposed), 𝑐𝑛  the 
number of events among the exposed, and 𝑧  the length of the unexposed to exposed 
matched time periods, then the 𝐿𝑅 of a number of events, 𝐿𝑅𝑛 is given by: 
𝐿𝑅𝑛 = max
𝐻1
𝑃(𝐶𝑛 = 𝑐𝑛|𝐻1)
𝑃(𝐶𝑛 = 𝑐𝑛|𝐻0)
= max
𝑅𝑅>1
[𝑅𝑅/(𝑧 + 𝑅𝑅)]𝑐𝑛[𝑧/(𝑧 + 𝑅𝑅)]𝑛−𝑐𝑛
[1/(𝑧 + 1)]𝑐𝑛[𝑧/(𝑧 + 1)]𝑛−𝑐𝑛
, 
and the 𝐿𝐿𝑅𝑛 is given by: 
𝐿𝐿𝑅𝑛 = ln(𝐿𝑅𝑛)
= 𝑐𝑛𝑙𝑛 (
𝑐𝑛
𝑛
) + (𝑛 − 𝑐𝑛) ln (
𝑛 − 𝑐𝑛
𝑛
) − 𝑐𝑛 ln (
1
𝑧 + 1
) − (𝑛 − 𝑐𝑛) ln (
𝑧
𝑧 + 1
), 
with 𝑧𝑐𝑛/(𝑛 − 𝑐𝑛) being the maximum likelihood estimate of RR. The formula only applies 
when 𝑧𝑐𝑛/(𝑛 − 𝑐𝑛) > 1, otherwise 𝐿𝐿𝑅𝑛  will be zero. Figure 3.4 presents an example of 
BMaxSPRT. This used the same data as that used in Figure 3.2, to study seizures following 
concomitant use of inactivated influenza vaccine/23-valent pneumococcal conjugate vaccine 
in 6-23 month old children, but considering a self-controlled design. Unlike PMaxSPRT, 
BMaxSPRT did not signal.98  
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Figure 3.4. Use of binomial-based maximized sequential probability ratio (BMaxSPRT) test to study seizures 
following inactivated influenza vaccine/23-valent pneumococcal conjugate vaccine in 6-23 month olds (adapted 
from Yih et al.98) 
 
When using BMaxSPRT, the CL is calculated as detailed above (considering the last possible 
point at which the null might be rejected) but using an iterative Markov chain approach 
(instead of a Poisson distribution). The critical limit depends on the matching ratio, the 
observed number of events, and 𝛼. 
Tables with CL for commonly used values have been published96 and exact calculations are 
available in the package Sequential,99  R software.100  
3.3.3 Other tests 
Near real-time vaccine safety surveillance was initiated in the USA in 2005 using SPRT and 
then its maximized version. Further methodological work was conducted to develop new 
versions of these tests. An example is the development of a conditional test to account for 
uncertainty in the use of historical data, which the PMaxSPRT is sensitive to. Another area of 
methodological research has been the assessment of the properties of the methods 
employed. For example, Maro et al.101 assessed how outcome misclassification impacted 
timeliness of signal detection. Overall, this work has been led by VSD and NRTVSS use has 
grown since its introduction.9 Further tests, their characteristics and use are presented in the 
next Chapter. 
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3.4 Statistical software 
Data were extracted, cleaned and analysed using STATA/MPTM 14,102 except for analyses 
involving the use of sequential tests. For these, the R package Sequential was used (version 
2.3.1).99 Sequential includes several functions which allow implementation of a system and 
evaluation of a system performance. The functions that I used during the course of this work 
are summarised in Table 3.7. 
During the first attempts to code my analyses I identified bugs in the CV.Poisson and 
AnalyzeSetUp.Poisson functions. When running these functions with a small number of 
expected events there were error messages indicating programming errors (intermediate 
values not specified). I explored the reasons behind these by carefully looking at the R code 
running behind the functions. I then contacted the authors of the package detailing the 
issues identified and their possible reasons. The authors corrected the bugs identified and I 
was able to use the corrected functions for all the analyses performed. 
I also attempted to verify the results obtained when using the package, as the package has 
been recently developed and includes non-standard functions. In particular, I calculated the 
log-likelihood ratio test for PMaxSPRT using the formula presented in Section 3.3.1 and 
compared my results with the ones obtained from the function Analyze.Poisson. 
Additionally, I used the values published in Lieu et al.65 (which include the critical limit 
considered in their analysis) to confirm the calculation of critical limits using the function  
CV.Poisson yielded the same numbers as reported in the original publication.  For BMaxSPRT, 
I also verified the results from Analyze.Binomial using the formula presented in Section  3.3.2, 
for a situation with a constant matching ratio.   
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Table 3.7. Description of the functions in the package Sequential used for the analysis of the project99 
Function General description Inputs Outputs 
Relevant thesis 
sections/references 
Analyze.Binominal  Allows the implementation of a 
system based on the observed 
number of cases and controls, and 
the matching ratio (using 
BMaxSPRT). The results of a test run 
are automatically stored and can be 
used for a subsequent test, helping 
to facilitate the implementation of a 
system. Requires the set-up of the 
parameters to be considered 
through AnalyzeSetUp.Binominal 
Name of the analysis (should match 
the one given when setting the 
parameters), test number, number of 
controls matched to each case or the 
probability of a case under the null 
hypothesis, number of cases, number 
of controls, alpha spending function (if 
different from the one specified in the 
set-up).  
Summary table and plots including 
information on: the test number, 
number of cases and controls (by test 
and cumulative), estimated relative risk 
by test, log-likelihood by test, target 
alpha spent for each test, actual alpha 
spent for each test, number of cases 
required to reject the null hypothesis at 
each test, decision on the null hypothesis 
(reject or not).  
3.3.2, 7.18,99 
AnalyzeSetUp.Binominal Used to set up the parameters when 
using Analyze.Binominal   
Name of the analysis, level of 
significance, minimum number of 
events before rejecting the null, type 
and shape of alpha spending function 
No specific output; parameters are 
stored for later use.  
3.3.2, 7.18,99 
Analyze.Poisson Similar to the Analyze.Binomial 
function but using the PMaxSPRT 
and thus based on the number of 
observed and expected events at 
each test. It also requires an initial 
set-up using the function 
AnalyzeSetUp.Poisson. 
Name of the analysis (should match 
the one given when setting the 
parameters), test number, expected 
number of events under the null, 
number of observed events, alpha 
spending function (if different from the 
one specified in the set-up). 
Summary table and plots including in-
formation on: the test number, number 
of expected and observed events (by test 
and cumulative), estimated relative risk 
by test, log-likelihood, target alpha spent 
for each test, actual alpha spent for each 
test, number of events required to reject 
the null hypothesis at each test, decision 
on the null hypothesis (reject or not).  
3.3.1, 7.18,99 
(Continues) 
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Table 3.7. (Continued) 
Function General description Inputs Outputs Relevant thesis 
sections/references 
AnalyzeSetUp.Poisson Used to set up the parameters when 
utilising Analyze.Poisson 
Name of the analysis, level of 
significance, minimum number of 
events before rejecting the null, type 
and shape of alpha spending function 
No specific output; parameters are 
stored for later use. 
3.3.1, 7.18,99 
CV.Binomial  
 
Used to calculate the critical limit of 
a continuous BMaxSPRT.  
Level of significance, expected sample 
size, number of events before rejecting 
the null hypothesis, and matching ratio 
or probability of having a case under 
the null hypothesis. 
Critical value, type I error given the 
critical value. When there is not a critical 
value corresponding to the type I error 
established in the input (level of 
significance) the largest conservative 
value is returned.   
3.3.2, 7.18,99 
CV.Poisson Used to calculate the critical limit of 
a continuous PMaxSPRT.  
Level of significance, expected sample 
size, number of events before rejecting 
the null and number of expected 
events before the first look at the data. 
Critical value. When there is not a critical 
value corresponding to the type I error 
established in the input (level of 
significance) the largest conservative 
value is returned.   
3.3.1, 7.1, 7.48,99 
Performance.Binominal 
 
Allows assessment of the 
performance of a system based on a 
continuous BMaxSPRT. 
Number of events at the end of the 
surveillance period, number of events 
before rejecting the null hypothesis, 
the critical limit (calculated using 
CV.Binomial), matching ratio or 
probability of having a case under the 
null hypothesis and the relative risk to 
detect. 
Power, expected time to signal if the null 
hypothesis is rejected, expected sample 
size at the end of surveillance (whether 
the null hypothesis is rejected or not). 
3.3.2, 7.18,99 
(Continues) 
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Table 3.7. (Continued) 
Function General description Inputs Outputs Relevant thesis 
sections/references 
Performance.Poisson 
 
Similar to Performance.Binomial to 
assess the performance of a system 
based on continuous PMaxSPRT. 
Expected number of events at the end 
of the surveillance period, number of 
events before rejecting the null 
hypothesis, expected number of 
events under the null at the first look 
at the data, the critical limit (calculated 
using CV.Poisson), and the relative risk 
to detect. 
Power, expected time to signal if the null 
hypothesis is rejected, expected sample 
size at the end of surveillance (whether 
the null hypothesis is rejected or not). 
3.3.1, 7.1, 7.4 8,99 
BMaxSPRT – Binomial-based Maximized Probability Ratio Test, PMaxSPRT – Poisson-based Maximized Probability Ratio Test 
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3.5 Ethics 
Approval for this project was obtained from the Independent Scientific Advisory Committee 
(ISAC) of the Medicines and Healthcare Products Regulatory Agency (MHRA) (ISAC number: 
15_230) and from the Ethics Committee of the London School of Hygiene & Tropical 
Medicine (LSHTM reference: 10421).  
 
When considering the development of the existing methods to perform near real-time 
vaccine safety surveillance, it is important to understand not only their statistical properties 
but also how to best apply them in practice. Such understanding is crucial when deciding 
how to approach the implementation of a system using a new data source. The next Chapter 
presents a systematic review conducted to ascertain existing methods to perform near real-
time vaccine safety surveillance and how they have been applied.   
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4 METHODS AVAILABLE TO PERFORM NEAR REAL-TIME VACCINE 
SAFETY SURVEILLANCE 
4.1 Introduction to Paper 1 
This paper was published in Pharmacoepidemiology and Drug Safety in January 2016 and 
reports the results of a systematic review I conducted to identify methods currently used 
worldwide to perform near real-time vaccine safety surveillance.  
To assess existing methods, I conducted searches to identify both published and unpublished 
studies. For the former, I developed a search strategy for use in Medline and EMBASE. The 
search strategy was also used in Web of Science to identify conference abstracts. Further 
conference abstracts were ascertained by searches of relevant conferences abstract books. 
Unpublished studies were identified through contacts with vaccine safety experts. For this 
step, I developed an on-line questionnaire which was sent via e-mail to a list of experts. In 
this questionnaire, I asked if the expert had been involved or was aware of any relevant 
studies. If the answer was yes, the questionnaire included several questions to capture the 
details of those studies. 
This review identified 31 near real-time systems (i.e. a combination of a data source and 
statistical methods used to analyse it and produce results in near real-time), mainly from the 
USA, spanning from May 2005 to April 2015. These systems focussed mainly on influenza 
vaccine, particularly the 2009 H1N1 vaccine. The review allowed the identification of several 
statistical tests. The choice of statistical test changed over time but it was generally guided 
by the frequency of electronic health records and the adverse event studied. PMaxSPRT was 
the test that was most often selected, followed by BMaxSPRT and a conditional version of 
MaxSPRT. The review also revealed only limited strategies to account for confounding 
factors. Studies adjusting for potential confounders used mainly an adjusted expected rate. 
Despite the development of these methods, NRTVSS is not yet widely used outside the USA.  
The results presented in the paper are based on a search I conducted on 6th January 2015. In 
order to update these results I re-ran the search on 14th June 2017. The new results are 
presented in Section 4.3.  
The search terms, a detailed explanation of the search strategy used to review abstract books 
of selected conferences, the online questionnaire I designed to identify unpublished studies 
and the table with detailed characterization of the studies were all published as supporting 
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information for the paper (Appendix A to D). In this thesis appendices A to C (search terms, 
a detailed explanation of the search strategy to review abstract books, and the online 
questionnaire) are included immediately after the paper, in Section 4.2. Appendix D (a table 
with detailed characterization of the studies) is presented in Section 4.4 after the results 
from the systematic review update, as the studies identified in the update were added to 
this table. 
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REVIEW
Near real-time vaccine safety surveillance using electronic health
records—a systematic review of the application of statistical methods†
Andreia Leite1*, Nick J. Andrews2 and Sara L. Thomas1
1Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
2Statistics, Modelling and Economics Department, Public Health England, London, UK
ABSTRACT
Purpose Pre-licensure studies have limited ability to detect rare adverse events (AEs) to vaccines, requiring timely post-licensure studies.
With the increasing availability of electronic health records (EHR) near real-time vaccine safety surveillance using these data has emerged as
an option. We reviewed methods currently used to inform development of similar systems for countries considering their introduction.
Methods Medline, EMBASE and Web of Science were searched, with additional searches of conference abstract books. Questionnaires
were sent to organizations worldwide to ascertain unpublished studies. Eligible studies used EHR and regularly assessed pre-speciﬁed AE
to vaccine(s). Key features of studies were compared descriptively.
Results From 2779 studies, 31 were included from the USA (23), UK (6), and Taiwan and New Zealand (1 each). These were
published/conducted between May 2005 and April 2015. Thirty-eight different vaccines were studied, focusing mainly on inﬂuenza
(47.4%), especially 2009 H1N1 vaccines. Forty-six analytic approaches were used, reﬂecting frequency of EHR updates and the AE studied.
Poisson-based maximized sequential probability ratio test was the most common (43.5%), followed by its binomial (23.9%) and conditional
versions (10.9%). Thirty-seven of 49 analyses (75.5%) mentioned control for confounding, using an adjusted expected rate (51.4% of those
adjusting), stratiﬁcation (16.2%) or a combination of a self-controlled design and stratiﬁcation (13.5%). Guillain-Barré syndrome (11.9%),
meningitis/encephalitis/myelitis (11.9%) and seizures (10.8%) were studied most often.
Conclusions Near real-time vaccine safety surveillance using EHR has developed over the past decade but is not yet widely used. As more
countries have access to EHR, it will be important that appropriate methods are selected, considering the data available and AE of interest.
© 2016 The Authors. Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.
key words—electronic health records; safety; sequential tests; statistical process control; vaccines; pharmacoepidemiology
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INTRODUCTION
Vaccines are considered to be one of the most cost-
effective interventions in public health.1,2 As with
other drugs, vaccines are not totally safe,3 but safety
requirements are particularly high as vaccines are
given to healthy individuals, most often children.4
All vaccines go through extensive safety assessment
before licensure; however, pre-licensure studies have
limited ability to detect rare adverse events (AEs) to
vaccines (with frequency <1/10000-1/100000)5, AE
occurring among speciﬁc sub-populations who were
not included in clinical trials, and long-term AE.6 To
overcome these limitations, timely post-licensure stud-
ies are required. These can be broadly divided into
passive (spontaneous reports) and active studies and
should be followed by conﬁrmatory epidemiologic
studies. While spontaneous reporting of AE is widely
implemented worldwide as a simple and low-cost
method, useful to detect new, unanticipated AE, it
has limitations.2 These include difﬁculties in denomi-
nator calculation, potential reporting biases (e.g. over-
reporting of potential AE receiving extensive media
coverage) and incomplete reporting. In contrast, active
surveillance tries to identify all those experiencing
(or at least seeking medical attention for) a potential
AE to vaccines. This approach includes analyses
of large population datasets (using electronic health
records (EHR)), targeted hospital-based surveillance
*Correspondence to: A. Leite, Department of Infectious Disease Epidemiology,
London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT,
London, UK. E-mail: andreia.leite@lshtm.ac.uk
†Prior postings and presentations statement: This work has not been submitted
or accepted elsewhere. Preliminary results have been presented at the NIHR
Health Protection Research Unit on Immunisation annual meeting in March
2015 and have been presented as a poster presentation to the 31st International
Conference on Pharmacoepidemiology & Therapeutic Risk Management.
© 2016 The Authors. Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.
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This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution
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(where trained health workers daily seek potential
cases of conditions of interest) and recruitment of vac-
cinated cohorts for detection of AE (using face-to-face
interviews, phone interviews, short-message services
or web-based tools).7,8 With the increased availability
of large population datasets, near real-time vaccine
safety surveillance (NRTVSS) has emerged as an
option.9
Near real-time vaccine safety surveillance, also
known as rapid cycle analysis, involves regular inter-
rogation of EHR to investigate pre-speciﬁed AE to
vaccines.2 By testing these AE on a regular basis after
introduction of a new vaccine, these methods ensure a
timely detection of possible safety problems.10 When a
signal is detected by this approach, it needs to be fur-
ther analysed, including a signal reﬁnement stage and
eventual conﬁrmatory analyses. These steps should
be predetermined and will lead to the decision of
whether to validate or invalidate the signal. NRTVSS
is thus part of a systematic approach to signal detec-
tion, with a dual role of signalling possible AE to vac-
cines and reassuring authorities and populations that
events are being monitored.11 For a given vaccine,
NRTVSS only considers a small number of suspected
AE (e.g. 5 to 10); complementary information is pro-
vided by existing methods such as spontaneous
reports.12
The growing use of NRTVSS methods, along with
the increasing availability of EHR, highlights the need
to review studies using this approach. Such a review
can provide crucial information on the development
of systems for vaccine safety surveillance for countries
considering their introduction.
OBJECTIVE
The aim of this study was to carry out a systematic re-
view of published and unpublished data on the
methods used for NRTVSS using EHR.
METHODS
Studies were included in the review if they (i) used
routinely collected health data (at least for the ex-
pected number of events); (ii) studied pre-speciﬁed
outcome(s) to assess the safety of one or more vac-
cines; and (iii) regularly tested the outcomes.
Studies (i) including only information based on
spontaneous reporting systems, (ii) aimed at testing
hypothesis/conﬁrming previously generated/suspected
signals or (iii) aimed at developing new methods for
NRTVSS (unless a speciﬁc application of the new
method was given) were excluded. No limits were im-
posed in terms of language or year.
Medline and EMBASE were searched for studies
published until 6 January 2015, using a combination
of thesaurus and free-text terms (search strategy is pro-
vided in Supporting Information Appendix A). Titles
and abstracts were reviewed to determine eligibility
status, followed by the full text for those considered
potentially eligible. References from the papers col-
lected were also reviewed. Reviews of the topic were
selected for reference mining. A.L. was responsible
for evaluating eligibility of the identiﬁed studies. To
ensure quality, eligibility of a random sample of 10%
of the results was evaluated by S.T. and N.A. When
eligibility was unclear, the study was discussed among
the authors until a consensus was reached.
To complement the database searches, a citation
search was conducted. To the best of our knowledge,
the methods under study were ﬁrst applied to the ﬁeld
of vaccine safety by the Vaccine Safety Datalink
(VSD). Two key VSD papers that describe the testing
and implementation of rapid cycle analysis using rou-
tinely collected health data were selected to perform a
citation search.9,13
The same search strategy was used in the Web of
Science Core Collection to cover meetings and confer-
ences, restricting the search to meeting abstracts or
proceedings papers. Also, the Annual Conference on
Vaccine Research and the Vaccine and ISV Congress
abstract book and programme, respectively, were analysed
(Supporting Information Appendix B). The Brighton
Collaboration newsletter was also searched as a potential
source of relevant new studies or contacts.14
A second stage of the review included contacting
experts in vaccine safety, as follows:
• Specialists in vaccine safety (from the Global Advi-
sory Committee on Vaccine Safety (GACVS),15
Brighton Collaboration16 and Accelerated Devel-
opment of Vaccine beneﬁt–risk collaboration in
Europe (ADVANCE) 17) were asked if they were
aware of work being conducted in the area and
fulﬁlling our inclusion criteria.
• Authors with known work using routinely collected
data and the potential to have implemented/conducted
eligible studies were contacted (Medicines and
Healthcare products Regulatory Agency (MHRA),18
VSD19 and Statens Serum Institute20). Further con-
tacts were also asked for at this stage.
• Finally, authors with a previous published work but
incomplete information, and those suggested by
other experts, were contacted to ask for further
information to characterize the methods.
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An online questionnaire was used to capture infor-
mation on studies conducted (Supporting Information
Appendix C). When other sources of information
(e.g. reports) were available and shared by the con-
tacts these were used. Expert contacts took place
from February to March 2015.
The information identiﬁed was extracted using a
standardized extraction form. Data extracted included
timeline, country/institutions where the study was con-
ducted, vaccines studied, study population, outcomes
assessed and their method of ascertainment, methods
used to perform the analyses, frequency of assessment,
confounding, data-accrual lag (i.e. delays in the data
available to perform surveillance, which may affect
the results), assessment of the validity of the outcomes
of interest (e.g. chart review) and main results. A de-
scriptive summary of country/institution, vaccines,
outcomes studied, confounding and data-accrual lag
handling was drawn up.
RESULTS
A total of 29 reports were included for data extrac-
tion (including information provided by expert
contacts),9,13,21–45 representing 31 studies/systems
(Figure 1). A brief description of the studies/systems in-
cluded by country, methods used and adjustment for
confounding strategies is given in Table 1. A detailed
characterization of the studies is provided in Supporting
Information Appendix D.
Near real-time vaccine safety surveillance using
EHRs was ﬁrst reported by Davis et al. in 2005, when
a retrospective study assessing the feasibility of
implementing such methods was published. Since this
time, we identiﬁed a further 13 studies conducted
by the VSD and 17 other studies in three countries
(Figure 2). The ﬁrst study conducted outside the
VSD was conducted in New Zealand and published
in 2007. The report from the last study included
was published online in 2015. Four studies (all in
the USA) were conducted completely or partially
in a retrospective manner, to test the feasibility of
implementing this kind of system (Table 1). Two
of these studies attempted to replicate known sig-
nals (rotavirus vaccine and intussusception and
acellular diphtheria-tetanus-pertussis (DTaP)/whole
cell diphtheria-tetanus-pertussis vaccine and febrile
seizures). Of the prospective studies, most were
conducted in the USA (n=20), with studies also
conducted in the UK (n=6), and Taiwan and
New Zealand (n=1 for each). The prospective
studies looked mainly at inﬂuenza vaccines (n=16), es-
pecially the 2009 H1N1 pandemic inﬂuenza vaccine
(n=7). Rotavirus (n=5), DTaP-based (n=3) and human
papillomavirus vaccines (n=3) also received attention.
The outcomes studied were most often neurological
(58.5%). Looking at speciﬁc outcomes, Guillain-Barré
syndrome (GBS) (11.9% of studied known outcomes),
meningitis/encephalitis/myelitis (11.9%) and seizures
(10.8%) were the most often included. Outcome ascer-
tainment for the near real-time analysis was, in most
cases, based on automated data (with no a priori con-
ﬁrmation of the diagnosis). In these cases, chart review
and conﬁrmation were used whenever a potential AE
was signalled. Only two studies performed this kind
of conﬁrmation for the near real-time analysis,21,35
and one compared the analysis considering the chart-
reviewed and non-reviewed outcome for GBS.33 From
the outcomes studied, 11 signals were identiﬁed, but
only three conﬁrmed (measles-mumps-rubella-vari-
cella combination vaccine and febrile seizures,27
2010–2011 trivalent inactivated inﬂuenza vaccine
and febrile seizures,37 and monovalent rotavirus vac-
cine and intussusception41).
Table 2 summarizes the methods used by the stud-
ies included in this review. These can be broadly di-
vided into continuous sequential testing, which
allows examination of the data as often as desired
(n=25),9,13,22–34,37,38,40–43,45 group sequential testing
(n=4)35,36,38,39 and statistical process control (SPC;
n=3).21,44 The choice of the group of methods has
been determined by the frequency of updates to the
EHR data used (Table 2).
When considering speciﬁc versions of the tests
available, the choice has been guided by the increasing
availability of new methods and knowledge of these
methods over time, as shown in Figure 2, as well as
the frequency of AE studied. In VSD, the sequential
probability ratio test (SPRT) was ﬁrst applied9 being
subsequently replaced by its maximized version
(MaxSPRT) with the advantage of not having to spec-
ify a single alternative hypothesis.13 The use of
MaxSPRT and its variations also evolved over time.
While in the beginning the Poisson and binomial ver-
sions were simultaneously used for the same out-
come,13 from 2010, a targeted selection of the test
version and its extensions, based on the strengths of
each method (Table 2) and the characteristics of the
outcome under study, was preferred.24,33,34,42,43 In
particular, Poisson-based MaxSPRT (PMaxSPRT)
has been used when less than 50 events were antici-
pated and the conditional version when the ratio of ob-
served historical events to upper limit was ≤2.5.
Outside VSD, a pattern in the use of continuous sequen-
tial methods was less clear. Overall, these tests were the
most often employed—PMaxSPRT (45.7%),10,50
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followed by the binomial (BMaxSPRT—23.9%)10,50
and conditional (10.9%) versions.51
More recently, four studies used group sequential
testing. Two of these used an alpha-spending ap-
proach,38,39 (a function controlling how much of the
alpha will be ‘spent’ every time a new analysis is
run52), one the Updating Sequential Probability Ratio
Test53 and other the Abt’s modiﬁcation of SPRT.54
An alpha-spending approach was thus preferred over
the two other tests employed in a group sequential
way. Both the Pocock-type and O’Brien–Fleming-type
functions have been used.12,55 The remaining methods
did not follow a clear evolution and include use of
SPC56 at different times by two non-USA institutions
(New Zealand Ministry of Health, Health Protection
Scotland).21,44
Thirty-seven of 49 analyses (75.5%) mentioned con-
trol for confounding. Strategies chosen were often
design-based and included (alone or in combination)
the following: (i) using a self-controlled design, which
automatically addresses time-invariant confounders;
(ii) matching baseline confounders, through a concur-
rent comparator design; (iii) adjusting the expected
rate obtained from a historical comparison group
based on the confounders’ distribution in the study
cohort (iv) stratifying the results according to relevant
confounder categories. Analyses adjusting for poten-
tial confounders used mainly an expected rate adjusted
Figure 1. Flowchart of included studies. Studies were excluded for (i) not considering vaccines (nonvaccine), (ii) not analysing the safety of a vaccine (not
safety), (iii) considering safety issues but not applying the methods of interest (other safety), (iv) only developing new methods (methods only) and (v) having
no abstract available (not available)
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for potential confounders (51.4% of those adjusting),
stratiﬁcation (16.2%) or a combination of a self-
controlled design and stratiﬁcation (13.5%). The
choice of approaches also depended on the analytical
method selected. For group sequential methods and
SPC, strategies to deal with confounders were even
more limited. When employing group sequential
methods, only expected rate calculations based on
the confounders’ distribution and stratiﬁcation were
considered. For SPC, only stratiﬁcation was used. Po-
tential confounders considered include age, sex, geo-
graphic site, concomitant vaccine administration,
season and trend (Table 1).
Some of the prospective studies considered data-
accrual lags in their analysis. Most often, the analysis
was delayed by some weeks (n=7). Others adjusted
for partially elapsed risk intervals and delays in the ar-
rival of inpatient data (n=3).46 For studies using spon-
taneous report for the observed number of events (and
EHR for the expected number of events), sensitivity
analyses with several degrees of underreporting were
conducted (n=4).28,31,40 Updates to the previous
datasets already analysed were not considered a spe-
ciﬁc strategy to adjust for data-accrual lags as they
would not reduce the time to signal. The majority of
studies did not mention ways or did not adjust for
data-accrual lags (n=11).
DISCUSSION
Our comprehensive systematic review has identiﬁed
an increasing number of studies and systems
implementing NRTVSS. All the studies identiﬁed
were performed in high-income countries/regions with
most in the USA. This might reﬂect limited capacity in
many settings to provide registry data in a timely fash-
ion and the infra-structure required to set up the
system.
A clear effort was put into using these methods to
assess pandemic inﬂuenza vaccine safety. This vaccine
Figure 2. Studies included in the review, ordered by the year of publication. Continuous sequential test are underlined with single line, group sequential with
bold line, and statistical process control with dashed line. Grey background indicates non-published studies. *Results with previous published results.
maxSPRT – Maximized Sequential Probability Ratio Test, P – Poisson version (†use of the conditional version), B – binomial version (‡use of self-controlled
case-series or extensions of the test). DMSS – Defense Medical Surveillance System, DTaP – acellular diphtheria-tetanus-pertussis vaccine, DTwP – whole
cell diphtheria-tetanus-pertussis vaccine, GBMV – Group-B Meningococcal Vaccine, HPS – Health Protection Scotland, HPV2 – bivalent human papillomavirus
vaccine, HPV4 – quadrivalent human papillomavirus vaccine, IHS – (US) Indian Health Service, IPV – inactivated poliovirus vaccine, MCV –meningococcal
conjugate vaccine, MHRA – Medicines and Healthcare products Regulatory Agency, MMRV – Measles-Mumps-Rubella-Varicella combination vaccine,
PCV13 – 13-valent pneumococcal conjugate vaccine, PRISM – Post-Licensure Rapid Immunization Safety Monitoring, RRV – Rhesus-Rotavirus vaccine,
RV5 – pentavalent rotavirus vaccine, VA – Veteran’s Affaires, VSD – Vaccine Safety Datalink
near real-time vaccine safety surveillance 231
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is a good example of the importance of post-licensure
surveillance due to potential safety concerns.32 Menin-
gococcal group B vaccine in New Zealand21 repre-
sents a similar situation, where NRTVSS, along with
enhanced passive surveillance and other active
methods, was implemented after the vaccine was ap-
proved without phase III trials. Other situations where
these methods have been particularly useful include
vaccines/AE of concern due to experiences with
previous versions of the vaccine—for example,
rotavirus/intussusception25 and inﬂuenza/GBS.32 For
previously suspected AE, the set of methods here
reviewed has the advantage of informing in a timely
manner the existence of a safety concern or reassuring
regulatory authorities and the public about vaccine
safety.
In this review, we have identiﬁed different methods
to perform NRTVSS using EHR and the way these
have been applied, both by VSD and by other institu-
tions. All the methods identiﬁed are derived from
Wald’s sequential test.50,59,60 When choosing a partic-
ular method, it is important to be aware of its proper-
ties. Properties of the continuous and group
sequential methods have been studied in the context
of drug safety.12 Group sequential methods were
deemed to be more appropriate when data updates
are less frequent,12 but more recent work comparing
these methods has found that for any group sequential
design, there is a better continuous method and recom-
mended that the data are looked at as frequently as
possible.58 After selecting the methodological ap-
proach, it is necessary to choose the speciﬁc test to em-
ploy. For example, using the PMaxSPRT and
BMaxSPRT simultaneously might be a more robust
approach owing to complementary strengths. How-
ever, as previously suggested, BMaxSPRT might fail
to identify a signal when investigating very rare
events. Hence, an alternative is to use PMaxSPRT
when less than 50 events are anticipated and the condi-
tional version when the ratio of observed historical
events to upper limit is ≤2.5. The use of a targeted
approach has been considered in VSD’s more recent
work.24,33,34,42,43
On the other hand, the properties of SPC-based
methods applied to vaccine safety have not been ex-
tensively studied. Both Kulldorff et al.50 and Musonda
et al.61 have argued that SPC-based methods such as
cumulative sum are not appropriate to perform surveil-
lance for newly introduced products as the aim is to
detect a safety problem that is already present and
not a sudden change. These authors defend the use of
such methods in the context of surveillance for
batch-related problems (problems arising at the timeTa
bl
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of manufacture rather than related to the product
itself). However, we should consider that at the time
of introduction, if there is a safety problem with that
speciﬁc vaccine and an appropriate comparison group
is used, a sudden change would be observable as well.
Given its ease of implantation, SPC is attractive, but
recommendations on the use of SPC are deferred until
further research on their properties is available.
Control for potential confounders has been limited
in both the strategies employed and factors adjusted
for. This observation is in agreement with Nelson
et al.,12 who have argued for better methods for con-
founder adjustment, in particular at the analysis stage.
Recent work has been performed in this area, adapting
group sequential methods with regression adjustment
and comparing this to existing approaches.62,63 To
the best of our knowledge, these promising approaches
are still at the development stage and have not yet
been applied to new studies. As pointed out by
Yih,11 it might not be possible to adjust for all possi-
ble confounders in this setting, which can lead to
spurious signals. However, it should be noted that,
as a near real-time analysis, aimed at quickly
identifying/strengthening signals, priority is given
to rapid results. As such, confounding adjustment is
not deemed as critical—more complete analyses
can be performed at conﬁrmatory stages.11 These
might include adjusting for additional confounders
or a more detailed adjustment (e.g. using ﬁner cate-
gorization of a variable) to avoid residual confound-
ing. The speciﬁc confounders to adjust for should be
decided on the basis of the vaccine, outcome and age
groups studied. In addition to those factors consid-
ered by studies, adjustments for day-of-the-week
effects or co-morbidities might be required.11 Never-
theless, 12 studies13,24–27,29,30,35,36 did not refer to
potential confounding in at least one of the analyses
reported in their published texts.
Best practice using EHR apply equally to NRTVSS
as to any study using these kind of data. For example,
Lanes et al. provide an approach to identify outcomes
in healthcare databases.64 One of the aspects to consider
while doing so is misclassiﬁcation. In some occasions,
manual review of individual medical records can be
used, particularly if a signal is found. In this review,
only two studies21,35 performed this conﬁrmation before
running the NRTVSS analysis, as doing so might delay
the surveillance process. Alternatively, multiple algo-
rithms might be developed, providing a trade-off be-
tween sensitivity and positive predictive values (PPV).
In the NRTVSS, an algorithm with higher sensitivity
and moderate PPV is generally considered to be timelier
than algorithms with moderate sensitivity algorithm and
high PPV. This should be considered for the speciﬁc
outcome under study, its seriousness and the data
available.65 Misclassiﬁcation of the exposure might
also be problematic. A possible approach is to restrict
the analysis to vaccinated individuals, avoiding poten-
tial biases.11
A key aspect to consider while using these methods is
the availability of timely data. ‘Real-time’ analyses are
difﬁcult to achieve, and thus, the expression ‘near real-
time’ is preferred. In fact, delays can occur at various
stages, including delays in diagnosis (e.g. for conditions
with more insidious onset), recording (e.g. retrospective
recording of vaccination administration or diagnosis),
receiving the data for analysis (due to either incomplete
data accrual or partially accrued risk windows) and
reporting. The timeliness of data should thus be con-
sidered. Some studies have delayed the analysis for
some weeks.13,23,25,27,41–43 While this approach gives
time for data to accrue, it will not reduce the time to
signal. The use of group sequential methods with less
frequent testing portrays a similar situation where
more time has been given for data to accrue.35,38,39
Nevertheless, for events occurring closer to the time
of testing, data-accrual lags may still be problematic.
Finally, adjustments for partially elapsed risk interval
and delays in the arrival of inpatient data have been
proposed (through the expected number of events)46
or integrated in the critical limits calculation36. These
can decrease the time to signal, based on previously
observed data-accrual patterns. They have been ap-
plied in a few, inﬂuenza vaccine, studies. Inﬂuenza
vaccines pose particular challenges when using de-
layed data as failure to detect a signal before the
season ends will impede adequate action. Strategies
proposed so far do not speciﬁcally address delays
between illness onset and diagnosis.
Only three of the 11 outcomes identiﬁed in the pro-
spective studies were conﬁrmed as true signals. In ad-
dition to issues already raised (confounding factors
that have not been considered, misclassiﬁcation of
the outcome), unconﬁrmed signals were due to (i)
changes in the true incidence or coding practices; (ii)
inappropriate comparison groups; (iii) uncertainty in
background rates; and (iv) type I errors.11,33 For type
I errors, additional strategies to reduce the false dis-
covery rate are available at the planning stage: these
include delaying the ﬁrst test,66 requiring a minimum
number of events to occur before rejecting the null hy-
pothesis67 or, in the case of group sequential tests,
selecting an O’Brien–Fleming threshold. The latter
spends less alpha in earlier tests and was used by
Nelson et al.38 During the surveillance period, it is im-
portant to update the critical limits as data arrive, as the
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observed data might differ from those planned.66 As in
the case of outcome identiﬁcation, these consider-
ations should be balanced against the importance of
detecting signals in a timely manner. Even after care-
ful consideration of all these aspects before and during
surveillance, possible spurious signals may still arise.
This emphasizes the need for a predetermined plan of
action for signal reﬁnement if a signal is found.11
The plan should include a careful decision on the data
source to use to test the hypothesis in subsequent anal-
yses if needed, owing to potential biases with the use
of the same data to identify and test the signals.
NRTVSS is thus not a stand-alone method but part
of the signal detection and evaluation process.
This review aimed at capturing studies and systems
worldwide using EHR to perform NRTVSS. Our rig-
orous search strategy and further contacts with many
experts on vaccine safety from different countries
and institutions (with a satisfactory response rate,
70.6%) should have minimized the risk of missing sys-
tems currently in use. However, we cannot exclude the
existence of similar systems elsewhere. Furthermore,
some information was missing from the studies in-
cluded, which we have tried to reduce by contacting
the authors. The missing information most often re-
lated to confounding control strategies and the data-
accrual lag adjustment employed. This might reﬂect
the limited options to address these issues, especially
for the earlier studies.
Countries considering introduction of these methods
should beneﬁt from the work developed so far and
from strategies under development. There should be
a cautious reﬂection on the availability of timely data
and their characteristics (including discussion with
the data providers), the vaccine(s) and outcome(s) to
be studied and the infra-structure needed in case a sig-
nal is detected. Future directions for research might
include further development and application of strate-
gies for adjustment for confounding and data-accrual
lag, as well as consideration of other methods not yet
applied to observational settings but in use in clinical
trials, for example, Bayesian approaches to group se-
quential tests.68 Bayesian methods can incorporate
previous information (such as the data generated by
pre-licensure studies) and potentially provide a more
ﬂexible approach.
In conclusion, NRTVSS using EHR to assess the
safety of newly introduced vaccines is being increas-
ingly used in the USA, with limited introduction in a
few other countries. These methods ensure timely de-
tection of safety signals. New methods have been inte-
grated over time, but strategies to account for potential
confounders and data-accrual lags have received less
attention. As new vaccines are expected to be intro-
duced and the public questions vaccine safety, the
demand for strong post-licensure surveillance systems
will increase.
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KEY POINTS
• Near real-time vaccine safety surveillance using
electronic health records (EHR) is one of the op-
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• Timeliness and allowing for data-accrual lag
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EHR. Lags have only been addressed in a
few studies.
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4.2 Supporting information 
4.2.1 Search strategy 
4.2.1.1 Medline 
1. Vaccin* or Immuni#ation 
2. exp Vaccination/ or exp Vaccines/ or exp Immunization/ or Immunization Programs/ 
3. 1 or 2 
4. safety or monitor* or Postauthori#ation or Post authori#ation or Post-authori#ation or 
Post-licensure or Postlicensure or Post licensure or Post-market or Postmarket or Post 
market or adverse event* or adverse effect* or assessment or risk 
5. exp Product Surveillance, Postmarketing/ or exp Adverse Drug Reaction Reporting 
Systems/ or "Drug-Related Side Effects and Adverse Reactions"/ or exp Population 
Surveillance/ or Risk/ or Risk assessment/ 
6. 4 or 5 
7. ("Sequential test*" or "sequential analys*" or (sequential adj4 method*) or "sequential 
monitor*" or "Rapid cycle analys*" or "rapid risk assessment" or ((Active or Real-time) adj4 
surveillance) or (real-time adj4 monitor*) or "early detection" or "sequential probability ratio 
test*" or maxSPRT or SPRT or "cumulative sum chart*" or "Sequential case series" or "signal 
refinement" or "signal adjudication" or "signal strengthening" or "signal identification" or 
"signal generation" or "observed-expected" or "observed-to-expected" or "observed vs. 
expected" or "observed vs expected" or "observed versus expected" or "observed-vs.-
expected" or "observed-vs-expected" or "current-historical" or "current versus historical" or 
"current-vs-historical" or "current-vs.-historical" or "current vs. historical" or "current vs 
historical" or "standardi#ed incidence ratio" or "vaccine safety datalink" or "Post-Licensure 
Rapid Immunization Safety Monitoring" or "Canadian Immunisation Monitoring Program" or 
"Paediatric Active Enhanced Disease Surveillance") 
8. Poisson Distribution/ 
9. 7 or 8  
10. 3 and 6 and 9 
 
4.2.1.2 Embase 
1. Vaccin* or Immuni#ation 
2. exp vaccination/ or exp vaccine/ or exp immunization/ or exp preventive health service/ 
3. 1 or 2 
4. safety or monitor* or Postauthori#ation or Post authori#ation or Post-authori#ation or 
Post-licensure or Postlicensure or Post licensure or Post-market or Postmarket or Post 
market or adverse event* or adverse effect* or assessment or risk 
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5. exp adverse drug reaction/ or exp postmarketing surveillance/ or risk/ or risk assessment/ 
or exp health survey/  
6. 4 or 5 
7. ("Sequential test*" or "sequential analys*" or (sequential adj4 method*) or "sequential 
monitor*" or "Rapid cycle analys*" or "rapid risk assessment" or ((Active or Real-time) adj4 
surveillance) or (real-time adj4 monitor*) or "early detection" or "sequential probability ratio 
test*" or maxSPRT or SPRT or "cumulative sum chart*" or "Sequential case series" or "signal 
refinement" or "signal adjudication" or "signal strengthening" or "signal identification" or 
"signal generation" or "observed-expected" or "observed-to-expected" or "observed vs. 
expected" or "observed vs expected" or "observed versus expected" or "observed-vs.-
expected" or "observed-vs-expected" or "current-historical" or "current versus historical" or 
"current-vs-historical" or "current-vs.-historical" or "current vs. historical" or "current vs 
historical" or "standardi#ed incidence ratio" or "vaccine safety datalink" or "Post-Licensure 
Rapid Immunization Safety Monitoring" or "Canadian Immunisation Monitoring Program" or 
"Paediatric Active Enhanced Disease Surveillance") 
8. Poisson distribution/ 
9. 7 or 8  
10. 3 and 6 and 9 
4.2.1.3 Web of Science core collection  
#11 #9 AND #6 AND #3 
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)  
DocType=All document types; Language=All languages; 
#10 #9 AND #6 AND #3  
DocType=All document types; Language=All languages; 
#9 #8 OR #7  
DocType=All document types; Language=All languages; 
#8 TS=(((Sequential testing or sequential analys* or (sequential NEAR/4 method*) or 
sequential monitor* or Rapid cycle analys* or rapid risk assessment or ((Active or Real-time) 
NEAR/4 surveillance) or (real-time NEAR/4 monitor*) or early detection or sequential 
probability ratio test* or maxSPRT or SPRT or cumulative sum chart* or Sequential case series 
or signal refinement or signal adjudication or signal strengthening or signal identification or 
signal generation or "observed-expected" or "observed-to-expected" or "observed vs. 
expected" or "observed vs expected" or "observed versus expected" or "observed-vs.-
expected" or "observed-vs-expected" or "current-historical" or "current versus historical" or 
"current-vs-historical" or "current-vs.-historical" or "current vs. historical" or "current vs 
historical" or standardi?ed incidence ratio or vaccine safety datalink or Post-Licensure Rapid 
Immunization Safety Monitoring or Canadian Immunisation Monitoring Program or 
Paediatric Active Enhanced Disease Surveillance)))  
DocType=All document types; Language=All languages; 
#7 TS=(Poisson Distribution/)  
DocType=All document types; Language=All languages; 
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#6 #5 OR #4  
DocType=All document types; Language=All languages; 
#5 TS=(exp Product Surveillance, Postmarketing/ or exp Adverse Drug Reaction 
Reporting Systems/ or "Drug-Related Side Effects and Adverse Reactions"/ or exp Population 
Surveillance/ or Risk/ or Risk assessment/)  
DocType=All document types; Language=All languages; 
#4 TS=(safety or monitor* or Postauthori?ation or Post authori?ation or Post-
authori?ation or Post-licensure or Postlicensure or Post licensure or Post-market or 
Postmarket or Post market or adverse event* or adverse effect* or assessment or risk)  
DocType=All document types; Language=All languages; 
#3 #2 OR #1  
DocType=All document types; Language=All languages; 
#2 TS=(Vaccin* or Immuni?ation)  
DocType=All document types; Language=All languages; 
#1 TS=(exp Vaccination/ or exp Vaccines/ or exp Immunization/ or Immunization 
Programs/)  
DocType=All document types; Language=All languages; 
 
4.2.2 Search strategy followed while reviewing abstract books of 
selected conferences 
Annual Conference on Vaccine Research (ACVR) abstracts books are available online103 under 
different formats. For the first to third ACVR, titles were searched using the browser search 
engine for words (only title) ‘safety’, ‘risk’, ‘adverse’, ‘real-time’, ‘monitor’, ‘surveillance’, 
‘rapid cycle’, and ‘AEFI’ and results checked for eligibility. For the fourth ACVR, abstract book 
titles were manually read, followed by revision of the abstract if considered as potentially 
relevant. Fifth to 16th ACVR abstracts books were searched using the pdf search engine for 
the words (title and abstract) abovementioned, followed by manual revision of the results.  
Vaccine & ISV Congress provides the Congress history including the list of oral 
communications and posters presented each year.104 For each pdf file (one file for 
communications and another for posters, for each year, totalising 14 files) a search was 
conducted using the built-in pdf function. Terms searched included safety’, ‘risk’, ‘adverse’, 
‘real-time’, ‘monitor’, ‘surveillance’, ‘rapid cycle’, and ‘AEFI’. Titles including any of these 
terms were considered. If a title was considered as relevant a further online search was 
conducted using that same title, trying to identify publication of a full manuscript. When that 
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same search did not produce any compatible result the first author’s last name was searched 
together with relevant terms of the title (such as the name of the vaccine evaluated and 
safety). Finally if no result was obtained, authors discussed the relevance of the result, which 
was either discarded or added to the contacts list.  
4.2.3 On-line questionnaire 
Near "real-time" vaccine safety surveillance 
As part of a partnership between Public Health England and London School of Hygiene and 
Tropical Medicine we are carrying out a systematic review of methods used to assess 
postlicensure vaccine safety. We are looking specifically at studies that are conducting near 
“real­time” vaccine safety surveillance for early detection of adverse events associated with 
vaccination. To clarify,  
we are NOT looking for… 
• Anything based solely on passive pharmacovigilance data (for example, the UK yellow card 
system); 
• Methods that have been developed but never actually used in near “real­time"; 
• Data mining methods.  
We ARE looking for systems/studies that have the following attributes: 
• They use routinely collected health data (electronic health record/administrative claims) 
at least for the expected number of events;  
• They use pre­specified outcome(s) of interest; 
• They regularly look for an excess in the observed number of events; 
• They have been used or are in the process of being implemented. 
So far, reviewing the published literature, we have identified studies conducted in the USA  
(Vaccine Safety Datalink), UK (Medicines and Healthcare products Regulatory Agency), and 
Taiwan (Taiwan Centers for Disease Control). We are contacting you because of your area 
of expertise to ask if you have information on any other eligible studies that you might have 
conducted or be aware of.  
We kindly ask you to fill in the questionnaire provided (even if you have not done any 
studies). It should take no more than 5-10 minutes (or 1 minute if you have no studies). 
Please press the submit button when you have finalised entering your responses. If you have 
any documents describing the work you have conducted and you prefer to share these 
documents (rather than completing the form) please send them to Andreia Leite 
(andreia.leite@lshtm.ac.uk). Please use also this contact if you have any queries regarding 
the study or this form. 
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Thank you for your time. 
Andreia Leite 
on behalf of London School of Hygiene & Tropical Medicine/Public Health England 
Health Protection Research Unit on Immunisation 
*Required 
1. Please provide your name. * 
 
2. Which institution are you affiliated to? * 
 
3. Please provide your e-mail * 
 
4 Have you ever been involved in a study using routinely collected health data to assess 
the safety of one or more vaccines regarding pre-specified outcome(s) [potential 
adverse events] and regularly tested the outcomes? * Mark only one oval. 
 Yes  Skip to question 5. 
 No  Skip to question 26. 
Stop filling out this form. 
Eligible studies 
5. Are you willing to share information on the design of the study to be included in a 
systematic review? * 
The level of detail reported in the final review will be agreed with each author of 
unpublished data. Please contact Andreia Leite (andreia.leite@lshtm.ac.uk) for further 
questions. 
Mark only one oval. 
 Yes  Skip to question 6. 
 No  Skip to question 26. 
Studies details 
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If you have conducted more than one study please give the answers considering all the 
studies you have been involved with unless stated otherwise. 
6. What was/were the age groups 
included in your study(ies)? * 
 
7. Which sex(es) did you include? * Mark only one oval. 
 Male 
 Female 
 Both 
8. If your study(ies) population(s) included any other relevant characteristics apart from 
age and sex please provide details. Relevant characteristics might include specific 
morbidities, health plans, geographic regions, etc. 
 
9. What vaccine(s) was/were included in your study(ies)? * 
 
10 Which data source(s) did you use to identify the vaccination status? * 
 
11. Which outcome(s) did you look for? * 
 
12. Which data source(s) did you use to identify the outcome(s)? * 
 
13. How were the outcomes defined? * 
Tick all that apply. 
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 ICD-9 codes 
 ICD-10 codes 
 Read codes 
 Algorithm (combination of diagnosis, codes, and/or tests)  
Other:  
14. Which statistical method(s) did you use to analyse the data? * Tick all that apply. 
 SPRT (Sequential Probability Ratio Test) 
 Poisson-based maxSPRT (Maximized Sequential Probability Ratio Test) 
 Binomial-based maxSPRT (Maximized Sequential Probability Ratio Test) 
 Group sequential testing 
 Statistical Process Control 
 Other:  
 
15. Please provide details regarding the reasons to chose the methods used. * Please also 
include details on any extensions to the method(s) you used to analyse the data 
 
Comparison group 
16 Did you use a comparison group? (e.g. historical comparator, concurrent comparator) * 
Mark only one oval. 
 Yes, between-person comparison  Skip to question 17. 
 Yes, within-person comparison  Skip to question 19. 
 No  Skip to question 19. 
 
Comparison group details 
17. Which kind of comparison group did you considered? * 
Tick all that apply. 
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 Historical comparison group 
 Concurrent comparison group 
 Other:  
 
18. Please briefly state who the comparison group was. * 
 
Confounding 
19. Did you consider potential confounding factors? * Mark only one oval. 
 Yes  Skip to question 20. 
 No  Skip to question 22. 
Confounding details 
20. How did you account for potential confounders? * Please consider the study design used 
for signal detection. Tick all that apply. 
 Stratification 
 Matching 
 Self-controlled case series 
 Other:  
21. Which factor(s) did you account for? * Tick all that apply. 
Age 
Sex 
Geographic site 
Concomitant vaccine administration 
Time-invariant factors (Self-controlled case-series)  
Other:  
 
Safety signal 
22. Did you find any evidence of a safety signal? * Mark only one oval. 
 Yes  Skip to question 23. 
 No  Skip to question 26. 
 Study ongoing  Skip to question 26. 
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Skip to question 26. 
Safety signal details I 
23. For which combination vaccine/outcome was the signal identified? * 
 
24. Did you perform (or are you performing) further analyses to confirm the signal 
identified? * 
Mark only one oval. 
 Yes  Skip to question 25. 
 No  Skip to question 26. 
Skip to question 26. 
Safety signal details II 
25. Was the signal confirmed with these analyses? * Mark only one oval. 
 Yes  Skip to question 26. 
 The analyses are not yet completed  Skip to question 26. 
 No  Skip to question 26. 
Further contacts 
26. Are you aware of anyone else who has conducted such a study? * 
Eligible studies include those using routinely collected health data to assess the safety 
of one or more vaccines regarding pre-specified outcome(s) and regularly tested the 
outcome(s). We are already aware of the work in the USA by the Vaccine Safety Datalink, 
in the UK by the Medicines and Healthcare products Regulatory Agency, and in Taiwan 
by the Taiwan Centers for Disease Control. Mark only one oval. 
 Yes  Skip to question 27. 
 No  Stop filling out this form. 
Skip to question 27. 
Providing contacts 
27. Please provide any contact or publication details about the work you are familiar with in 
the space provided. * 
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4.3 Systematic review update 
With the view to identifying more recent studies that were not included in the initial 
systematic review, I re-ran the search strategy drawn up to identify studies in Medline and 
EMBASE on 14th June 2017. After deduplication, the search yielded 513 results. After 
title/abstract screening, six papers where selected for full-text review. Two studies were 
excluded as they were aimed at confirming hypotheses previously generated (see inclusion 
and exclusion criteria in 4.1). Of the four eligible results, two105,106 reported results of the 
same study, which had been included in the original systematic review (through a report 
identified from contacts with vaccine safety experts). An updated flowchart, with the results 
from both the initial search and the update conducted, is presented in Figure 4.1. The two 
new studies are briefly reviewed below.107,108 In the next Section (4.4), a table with the details 
of all eligible studies is presented. This table corresponds to Appendix D of the supporting 
information of Paper 1, which was updated to include the characteristics of the two new 
studies identified.  
Both studies were conducted in the USA (using VSD107 and Medicare108 data) and assessed 
Guillain-Barré syndrome following seasonal influenza vaccine (Sandhu et al.108 for seasons 
2010/11 to 2013/14 and Li et al.107 for season 2013/14 and 2014/15). Additionally, Li et al.107 
monitored six other outcomes in relation to seasonal influenza vaccine: acute disseminated 
encephalomyelitis, anaphylaxis, Bell’s palsy, encephalitis, febrile seizures, and transverse 
myelitis. With regards to the specific methods, Li et al.107 used PMaxSPRT and BMaxSPRT 
simultaneously and adjusted for delays and partially accrued risk windows. Analyses using 
PMaxSPRT were also adjusted for age and geographical site. Sandhu et al.108 used the 
Updating Sequential Probability Ratio Test (USPRT), which includes an adjustment for delays 
in the critical limit calculation. Both studies identified a signal: Li et al.107 for febrile seizures 
during the 2014/15 season in children aged 6-23 months, and Sandhu et al.108 for GBS in the 
season 2010/11. The former was confirmed in a subsequent confirmatory study but not the 
latter.107,108  
The new studies I identified from the updated search are in accordance with the results 
presented in the original systematic review. No new methods or aspects of their utilisation 
were identified, which suggests that within USA institutions, the methods presented and 
explored in depth in the systematic review became a standard; they are routinely used, 
particularly to assess seasonal influenza vaccine. It is noteworthy that Li et al. used PMaxSPRT 
and BMaxSPRT simultaneously, owing to their complementary strengths. The issue of 
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deciding between these two tests has been discussed in the original systematic review and 
approaches have been shown to change over time. As referred in Section 4.1 and mentioned 
by Li et al. the simultaneous use of both tests might provide a more robust option than 
deciding on one specific test.107  
Figure 4.1. Updated flowchart of included studies. *Includes 513 additional studies identified from the search 
conducted on 14th June 2017.  
Identified from the 
database searches 
n = 2616* 
Records after 
duplicates removed 
n = 3292 
 
Identified from 
experts  
n = 6 
 
Identified from 
conference 
abstracts n = 622 
Number of full 
texts/abstracts 
included to review  
n = 135 
Titles/abstracts excluded  
n = 3157 
Non vaccine – 1667 
Not safety – 742 
Other safety – 717 
Methods only – 28 
Not available – 3 
Full text excluded n = 97 
(All other safety) 
Texts/systems 
eligible 
n = 38 
Identified from 
reference mining  
n = 78  
Texts/systems 
included 
n = 31 
Excluded for reporting results 
on the same study  
n = 7 
Expert contact 
n = 34 (institutions) 
Studies/Systems 
included 
n = 33 
Texts reporting on more than 
one system  
n = 2 
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The results of this update point out the importance of having included grey literature and 
unpublished studies in the original systematic review, as shown by the subsequent 
identification of published studies that were previously identified and included through 
contact with vaccine safety experts. Searches for unpublished studies and requests for 
information from vaccine safety experts allowed not only identification of work that had not 
yet been disseminated through formal publications but also the most recent studies.  Overall, 
the main conclusions from the original systematic review remain valid.   
 
The systematic review allowed the identification of methods currently under use to perform 
NRTVSS and how they have been selected and applied. This information is crucial when 
envisaging implementation of a NRTVSS, as in the case of this thesis. Yet, before proceeding 
to the actual implementation of a system, is important to select which vaccine/outcome pairs 
to include in the trial implementation and to reflect on how the data characteristics of CPRD 
are likely to influence implementation. These aspects are explored in the next two Chapters, 
starting in the next Chapter with details of the framework used to select vaccine/outcome 
pairs to include in the implementation study. 
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4.4 Details of studies included in the systematic review 
Table 4.1. Studies included in the systematic review 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
Davis, 
20057 
USA, VSD Children from 4 
HMO 
DTaP and RRV; 
Vaccine 
administration 
data 
DTaP – 63,367 
doses, 52w, 
1997-2000; 
RRV – 26,069 
doses, 43w, 
1999 
DTaP – DTwP 
(1995-96) 
Background rate 
(1995-99) 
DTaP – fever, FS, 
other neurologic 
outcomes. 
RRV – 
intussusception. 
ICD-9 codes 
SPRT Risk-
adjustment - 
site, age, 
time, season, 
and sex 
Weekly Conducted 
retrospectively 
Known 
associations 
verified after 
varying 
numbers of 
weeks.  
Lieu, 
200765¶ 
USA, VSD 11-17.99yr from 8 
geographically 
diverse HMO 
MCV; counts 
of MCV 
administration 
preventive 
visits; 
Rotashield®    
MCV – 
119,972 
doses, 106w, 
2005-06; 
Rotashiled® – 
36w, 1999 
MCV – Non 
exposed controls 
(going to 
preventive visit) 
or background 
rates;  
Rotashield® – 
background rates 
MCV – GBS, BP, 
seizures, TCP. 
Rotashield® – 
intussusception. 
ICD-9 codes 
MCV – 
BMaxSPRT 
(all 
outcomes)  
PMaxSPRT 
(all but 
seizures);  
Rotashield - 
PMaxSPRT 
BMaxSPRT – 
Matching by 
age, week, 
and 
geography; 
PMaxSPRT – 
none; 
Unclear for 
Rotasheild 
Weekly MCV – Analyses 
waited at least 6 
weeks from the 
vaccination or 
preventive visit; 
Intussusception 
used as example 
and conducted 
retrospectively. 
No signal 
identified for 
MCV; known 
intussusception 
signal verified 
McNicholas, 
2007109 
New 
Zealand, 
MoH 
<19yr from 3 
hospitals (Auckland 
City, Middlemore, 
and Whangarei) 
serving the regions 
where the vaccine 
was implemented  
Meningococcal 
Group B; 
immunisation 
registry 
719,790, c. 
70w, 2004-05 
Background rates 
(Acute flaccid 
paralysis and 
encephalopathy 
– 1998-2002, for 
the remaining – 
published data) 
Acute flaccid 
paralysis, 
encephalopathy, 
seizures, TCP (all 
confirmed by 
trained nurses). 
ICD-9 codes 
SPC Stratification 
for age 
Weekly Daily review of 
databases, 
medical charts, 
discharge letters 
and laboratory 
records 
No signal 
identified 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
Brown, 
2009110 
(and 
Moore111) 
USA, i3 
Drug 
Safety/FDA 
>10 m old from a 
13.5 million, 
multistate, health 
insurance plan – 
excluded if sex or 
year of birth 
missing or multiple 
claims for influenza 
vaccination on the 
same day 
2006-07 
Influenza 
season 
(TIV+LAIV);  
only 2nd dose 
if 2; procedure 
codes 
 
 
897,229 
doses, 26w, 
2006-07 
season 
2005-06 seasonal 
influenza 
Anaphylaxis, 
urticaria, allergic 
reactions, 
angioneurotic 
edema, DD, GBS, 
seizures, DPNSN, 
meningoen-
cephalitis, ataxia, 
paralytic syn-
dromes, CND. 
ICD-9 codes 
PMaxSPRT Expected # 
adjusted for 
sex, age, 
region, 
month, and 
concomitant 
vaccination 
Monthly Conducted 
retrospectively; 
lags assessed at 
the end of the 
study 
Signal detected 
for urticaria but 
not confirmed 
after chart-
review 
Yih, 2009112 USA, VSD 10 to 64 yr old 
from 7 HMO (3.3 
million enrolled 
during the study 
period) 
DTaP; 
immunisation 
status 
660,000 
doses, 145w, 
2005-08 
2000-04 TD 
recipients except 
in GBS (overall 
rates used) 
Encephalopathy/
encephalitis/ 
meningitis, GBS, 
paralytic 
syndromes, 
seizures, CND 
(including BP). 
ICD-9 codes 
PMaxSPRT Expected # 
adjusted for: 
- Age (GBS/ 
seizures) 
- Age/sex 
(remaining) 
Weekly Analysis started 
≥ 8 weeks from 
the date of 
vaccination113 
and redone at 
the end of the 
study 
No signal 
identified 
Belongia, 
2010114¶ 
USA, VSD 4 to 48 w old from 
8 HMO with 8.8 
million members 
and an annual birth 
cohort of 95000  
RotaTeq® 
(Pentavalent 
rotavirus 
vaccine); 
immunisation 
data 
207,621 
doses, 104w, 
2006-08 
Background rates 
(1991-2004 for 
intussusception, 
myocarditis and 
Gram- sepsis, 
2000-04 for the 
remaining) 
Intussusception, 
seizures, 
meningitis/ 
encephalitis, 
myocarditis, 
Gram- sepsis. 
ICD-9 codes 
PMaxSPRT Intussuscep-
tion expected 
# adjusted for 
trend/age/ 
site (Poisson 
regression); 
others for 
site 
Weekly Analysis started 
at least 8 weeks 
from the date of 
vaccination113 
No signal 
identified 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
Bryan, 
2010115 
(and 
Seabroke, 
2010116) 
UK, MRHA Numerator –   
potentially all 
vaccinees, CPRD for 
denominator 
H1N1; cases 
based on 
spontaneous 
AE reports 
>4 million, 
2009-10 
season 
CPRD age, 
gender specific 
rates 
GBS, facial palsy, 
ITP, epilepsy, 
transverse 
myelitis, ON, 
stillbirth. 
Read codes 
PmaxSPRT Age-gender 
adjusted 
expected # 
Weekly Adjusted for 
underreporting 
(yellow-card 
data) 
No signal 
identified 
Enger, 
2010117 
USA, i3 
Drug 
Safety 
Large US insurance 
health plan 
H1N1 vaccine 982,352 
doses, 2009-
10 season 
Same season 
seasonal flu and 
4 previous 
seasons 
GBS+13 
outcomes not 
listed. 
Not available 
SPRT 
(specific 
test 
unclear) 
Unclear Weekly Unclear No signal 
identified 
Greene, 
2010118¶ 
USA, VSD ≥6 m old from 8 
HMO* with more 
than 9 million 
TIV; 
vaccine 
administration 
5,969,508 
doses, 35w in 
each season 
(2005-06 to 
2007-08) 
Background rates 
for Poisson-
based analysis 
(previous 
seasons – from 
2000-01). 
Seizures, 
meningoen-
cephalitis, BP, 
OCND, DD, 
DPNSN, ataxia, 
anaphylaxis, 
allergic reactions 
other than 
anaphylaxis, GBS. 
ICD-9 codes 
SCCS and 
DID with 
BMaxSPRT 
for all 
outcomes 
except GBS; 
PMaxSPRT 
for GBS 
BMaxSPRT –  
stratified for 
age/season;  
SCCS – time-
invariant 
confounders; 
PMaxSPRT – 
expected # 
adjusted for 
age/site 
Weekly Data assumed to 
accrue without 
delay 
No signal 
identified 
Huang, 
2010119¶ 
Taiwan, 
Taiwan 
CDC 
Taiwanese 
population (≥6m) 
LAMV, MIV; 
vaccination 
registry 
5,667,176 
doses, 22w, 
2009-10 
season 
Background rates 
among ≥6m 
(2004-08) 
Group 1 – GBS, 
ODD (6m-17yr), 
encephalitis/ 
myelitis, 
anaphylaxis. 
Group 2 – ODD 
(≥18yr), seizures, 
BP (≥18yr).  
ICD-9 codes 
Group 1 – 
PMaxSPRT; 
Group 2 – 
SCCS 
BMaxSPRT 
SCCS – Time-
invariant; 
stratification 
for age 
Weekly Database 
updated daily 
No signal 
identified 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
DMSS120-123 USA, DoD 17-64yr, military 
personnel (around 
1.4 million people 
monitored) 
H1N1; 
vaccination 
history 
1,288,353 (as 
of  April 24, 
2010), 2009-
10 season 
 
Background rates 
(2004-08) 
GBS, ON, BP, 
myelitis/en-
cephalomyelitis/
encephalitis, 
anaphylaxis, TCP. 
ICD-9 codes 
PMaxSPRT Unclear Weekly Unclear Weak signal 
found for 
thrombocy-
topenia (not 
confirmed after 
review) 
VA121-123 USA, VA Veterans 
(Northeastern and 
Western States – 
around 2 million 
people monitored) 
H1N1; VA 
immunisation 
package 
334,897 (as of 
April 24, 
2010), 2009-
10 season 
Background rates 
for 2007, 2008 
and 2009  
GBS, ON, BP, 
myelitis/en-
cephalomyelitis/
encephalitis, 
anaphylaxis, TCP. 
ICD-9 codes 
PMaxSPRT Unclear Unclear Unclear Weak signal 
found for 
thrombocy-
topenia (not 
confirmed after 
review) 
IHS121-124 USA, 
IHS/FDA 
IHS user population 
(around 1.4 million 
people monitored) 
H1N1; 
vaccination 
history 
321,305 (as of 
April 15, 
2010), 2009-
10 season 
Unclear All flu vaccines –   
GBS, ON, BP, 
myelitis/en-
cephalomyelitis/
encephalitis, 
anaphylaxis, TCP; 
LAMV – asthma/ 
wheezing. 
ICD-9 codes 
PMaxSPRT Unclear Unclear Unclear Weak signal 
found for 
thrombocytope
nia and Bell’s 
palsy (not 
confirmed after 
review) 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
PRISM121-123 USA, 
FDA/NVPO 
Members of 
several health 
plans (total 
membership – 38 
million) 
H1N1; 
immunisation 
registries 
2,555,639 (as 
of April 17, 
2010), 2009-
10 season 
Background 
rates, 2007-
08/2008-09 
seasons 
Group 1 – GBS, 
DD (including 
ON), DPNSN, 
seizures, BP, 
OCND, ataxia, 
myelitis/en-
cephalomyelitis/
encephalitis, 
anaphylaxis; 
Group 2 – 
abortion, 
stillborn, (pre-) 
eclampsia; 
Group 3 – 
myocarditis, 
pericarditis. 
ICD-9 codes 
Group 1 
and 3 –   
PmaxSPRT, 
CmaxSPRT 
and SCCS 
BmaxSPRT; 
Group 2 – 
only counts 
monitored 
Unclear Biweekly  Unclear No signal 
identified 
Klein125¶ USA, VSD 12 to 23 m from 7 
HMO† (belonging 
to a group of 8 
HMO with over 9 
million members in 
total) 
 
MMRV  430,00 during 
c. 79w (2006-
07) 
MMR and 
varicella vaccine 
administered 
separately (2000-
06) 
Seizures, TCP, 
encephalitis/ 
meningitis, 
ataxia, allergic 
reactions, and 
arthritis. 
ICD-9 codes 
BmaxSPRT Matching on  
age group, 
site, calendar 
year, and 
respiratory 
virus season 
Weekly Analysis delayed 
for ≥ 8 weeks 
from date of 
vaccination113 
Signal found for 
seizures 
(febrile) and 
confirmed 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
Gee, 
2011126 
USA, VSD 9 to 26 yr old 
females from 7 
HMO† 
HPV4; 
vaccination 
status 
600,558, 79-
164w 
(depending on 
the outcome), 
2006-08 
Background rates 
for Poisson based 
analysis and non-
vaccinated 
individuals going 
to preventive 
visits (2000-06) 
Group 1 – 
anaphylaxis; 
Group 2 – allergic 
reactions, 
seizures, first 
ever seizures, 
syncope; 
Group 3 – 
appendicitis, 
GBS, stroke, VTE. 
ICD-9 codes 
Group 1 – 
not 
formally 
tested due 
to low 
counts; 
Group 2 – 
exact 
sequential 
analysis, 
Group 3 – 
PMaxSPRT 
Group 2 – 
matching on 
age, site and 
vaccination 
date;  
Group 3 – 
expected # 
adjusted for 
age and site 
Weekly Unclear Signal for 
appendicitis but 
it was not 
confirmed after 
review 
Lee, 2011127 
(and CDC, 
2009128) 
USA, VSD ≥ 6 m (for MIV, TIV, 
and LAIV) or 2 to 
49 years old 
(LAMV) from 8 
HMO* (around 9.2 
million in total) 
2009-10 
seasonal 
influenza and 
H1N1 (analysis 
by specific 
type – MIV, 
TIV, LAIV, 
LAMV); 
ascertained 
from the 
claims 
4,512,366 
doses, 26w 
 
Background rates 
for Poisson-
based analysis 
(2000-01/2008-
09 seasons after 
TIV or overall 
rate) 
Group 1 – GBS, 
encephalomyeli-
tis, ataxia, 
anaphylaxis, 
allergic reactions 
other than 
anaphylaxis;  
Group 2 – DD 
(central nervous 
system), DPNSN, 
BP, OCND, 
seizures; 
myocarditis/ 
pericarditis for 
LAIV and LAMV. 
ICD-9 codes 
SCRI, 
BMaxSPRT 
if ≥ 50 AE 
anticipated; 
PMaxSPRT 
if < 50 AE 
anticipated; 
CMaxSPRT 
when 
observed 
historical 
AE:upper 
limit ≤ 2.5. 
SCRI – time 
invariant; 
PMaxSPRT 
and 
CMaxSPRT– 
expected # 
(age and 
site). For MIV 
and TIV and 
outcomes in 
group 2 
stratification 
by age group 
Weekly Adjusted for 
partially elapsed 
risk interval and 
delays in the 
arrival of 
inpatient data   
Signal for Bell’s 
palsy not 
confirmed 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
Bryan, 
2011¶ 
UK, MRHA Numerator -  
potentially all 
vaccines, CPRD for 
denominator (Only 
<5 years) 
Seasonal 
influenza 
(2010/11); 
cases based on 
spontaneous 
AE reports 
72,000, c. 23w  CPRD data (age-
specific rates, 
2000-10)  
FS.  
Read codes 
PmaxSPRT Age adjusted 
expected # 
 
Weekly Adjusted for 
underreporting 
(yellow-card 
data) 
No signal 
identified 
Burwen, 
2012129 
(and 
Burwen, 
2010130)  
USA, FDA/ 
Centers for 
Medicare 
and 
Medicaid 
Services 
Medicare 
population (38.8 
million >64 yr and 
7.8 million disabled 
or end-stage renal 
disease) 
2009-10 
seasonal 
influenza and 
H1N1; 
ascertained 
from the 
claims 
14 million 
doses for 
seasonal and  
3.3 million for 
H1N1 
Seasonal 
influenza 
recipients in the 
5 previous 
seasons 
GBS. 
ICD-9 codes 
USPRT No Weekly 
after the 
100,000 
vaccines 
Critical limits 
adjusted for 
delays in the 
claims (based on 
previous 
seasons) 
No signal 
identified 
Loughlin, 
2012131¶ 
 
USA, 
OptumInsi
ght/Merck 
<1yr from large 
geographically 
diverse health plan  
RV5; 
ascertained 
from the 
claims 
>210,000 
doses, 2006-
07 
 
DTaP recipients, 
2000-05 
Intussusception 
and KD (chart-
confirmed). 
ICD-9 codes 
Group 
sequential 
(Abt's 
modification 
of SPRT) 
No Infants 
identified 
quarterly 
No No signal 
identified 
Tse, 2012132 
(and 
replaces 
Tse, 
2012133) 
USA, VSD 6w-17yr from 8 
HMO* (belonging 
to a 10 HMO group 
with around 9.2 
million people) 
TIV; 
immunisation 
information 
590,272, 27w, 
2010-11 
 
Background rates 
during previous 5 
seasons (2005-06 
to 2009-10) 
FS. 
ICD-9 codes 
SCRI - 
BMaxSPRT, 
CMaxSPRT 
SCRI – Time-
invariant, 
CMaxSPRT - 
stratification  
(age and site) 
Weekly Adjusted for 
partially elapsed 
risk interval and 
delays in arrival 
of inpatient data 
Signal identified 
and confirmed 
Donegan, 
201310¶ 
UK, MHRA Numerator –   
potentially all 
vaccinees, CPRD for 
denominator (only 
females 12 to 18 yr 
old) 
HPV2; cases 
based on 
spontaneous 
AE reports 
1,536,995 
doses, 104w, 
2008-10 
Background rates 
(10 previous year 
CPRD) 
Fatigue 
syndromes, GBS, 
facial palsy, 
encephalitis. 
Read codes 
PMaxSPRT Stratification 
for age in the 
1st yr of 
surveillance 
(fatigue syn-
dromes). 
Weekly Sensitivity 
analyses 
assuming various 
degrees of 
underreporting 
No signal 
identified 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
Nelson, 
2013134 
USA, VSD 6w-2yr from 7 
HMO‡ 
(belonging to a 10 
HMO group with 
around 9.2 million 
people) 
DTaP-IPV-Hib 
(combination);  
vaccination 
history 
149,337 
(c. 78w for 
MAF and 
seizures and c. 
116w for the 
remaining), 
2008-10 
DTaP-containing 
vaccine 
recipients 
background rates 
(2007-09 or 
2005-09  for very 
rare outcomes) 
 
MAF, seizure, 
meningitis/en-
cephalitis/myeli-
tis, serious 
nonanaphylactic 
allergic reaction; 
Not formally 
tested – invasive 
Hib disease, GBS, 
anaphylaxis, all 
hospitalizations.  
ICD-9 codes 
Group 
sequential 
testing 
(Pocock 
boundary) 
and 
PMaxSPRT 
Expected # 
adjusted by 
site, gender, 
age group, 
and 
interaction 
site-age 
(Poisson 
regression).  
GS – 1st test 
after 1yr of 
introduction 
and then 11 
evenly 
spaced tests 
based on # 
of vaccines 
given; 
PMaxSPRT – 
weekly 
Analysis based 
on the number 
of doses 
No signal 
identified 
Tseng, 
2013135 
USA, VSD 1mo-2yr from 8 
HMO* 
PCV13; 
vaccination 
records 
599,229 
doses, 90w, 
2010-12 
PCV7 recipients 
background rates 
(2007-09 or 
2005-09 for 
anaphylaxis and 
encephalopathy) 
Encephalopathy, 
urticaria and 
angioneurotic 
edema, asthma, 
anaphylaxis, TCP, 
FS, KD. 
ICD-9 codes, 
platelet counts. 
Group 
sequential 
analysis 
(O’Brien-
Fleming 
boundary) 
For urticaria/ 
angioneurotic 
edema, FS 
and asthma 
stratification 
by age/dose 
number. 
None for the 
remaining 
GS – 12 
evenly 
spaced tests 
based on # 
of vaccines 
given. 
 
Analysis based 
on the number 
of doses 
Signal identified 
for 
encephalopathy 
and KD but not 
confirmed. No 
more signals 
identified. 
Daley, 
2014136¶ 
USA, VSD 4-6yr from 4 HMO DTaP-IPV 
(combination) 
201,116 
doses, 176w, 
2009-12 
Background rates 
in DT and IPV 
recipients 
separately on the 
same day (group 
1) or all children 
(group 2), (2005-
08 or 2000-08 for 
GBS) 
Group 1 – 
Meningitis/en-
cephalitis, 
seizures, stroke 
Group 2 – GBS, 
SJS, anaphylaxis, 
serious allergic 
reactions, serious 
local reactions. 
ICD-9 codes 
PMaxSPRT 
for all but 
serious 
allergic and 
local 
reactions 
(CMaxSPRT 
used) 
Expected # 
adjusted for 
site (except 
GBS and SJS – 
weighted 
average 
used) 
Weekly Exclusion of the 
most  
recent 14 weeks 
of data9 
No signal 
identified 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
Kawai, 
2014137 
USA, VSD 6mo-17yr (TIV) and 
2-49yr (LAIV) old 
from 8 HMO* 
(belonging to a 9 
HMO group with 
over 9 million 
people) 
TIV, LAIV (first-
dose vaccine) 
>3.5 million 
doses IIV, 
256,406 doses 
LAIV, 19w, 
2012-13 
influenza 
season 
Historical 
controls 
Seizures, GBS, 
encephalitis, 
anaphylaxis. 
ICD-9 codes 
Seizures – 
SCRI 
BMaxSPRT; 
GBS – 
PMaxSPRT; 
Encephali-
tis and ana-
phylaxis – 
CMaxSPRT 
SCRI – time-
invariant, 
stratification 
– age; for the 
remaining – 
expected #  
adjusted for 
age and site 
Weekly Delayed analysis 
until estimated 
data lag accrual 
and follow-up 
time was 
completed 
No signal 
identified 
Weintraub, 
2014138¶ 
USA, VSD 4-34w from 6 
HMO§ 
Rotarix; 
vaccination 
information 
207,955 
doses, 260w, 
2008-13 
Background rates 
2001-05 
Intussusception PMaxSPRT Expected # 
adjusted for 
age and site 
Weekly Analyses delayed 
2 weeks 
Signal identified 
after 156660 
doses and 
confirmed 
Murdoch, 
2014139¶  
UK, HPS Rotavirus - < 2 
years 
 
Rotavirus; 
Scottish 
Immunisation 
Recall System 
Rotavirus – 
9,000 vaccines 
administered 
/month 
Background rates Intussusception, 
KD, anaphylaxis, 
haematochezia. 
ICD-10 codes. 
SPC Stratification 
– age, sex, 
geographical 
site 
Monthly No Rotavirus – 
signal for 
haematochezia, 
not confirmed 
Yih, 201598 USA, FDA ≥6 m (TIV) and 2-
49yr (LAIV) 
members from 3 
geographically 
diverse health 
plans (with up to 
110 million 
individuals) 
Seasonal 
influenza 
(2012-13 - 
pilot and 2013-
14 seasons, 
TIV and LAIV 
separately); 
data partners 
and 
immunisation 
information 
systems 
7,464,461 
doses  
Background rates 
previous seasons 
Anaphylaxis, FS. 
ICD-9 codes 
SCRI 
BMaxSPRT 
(only 
seizures) 
and 
PMaxSPRT 
PMaxSPRT – 
expected # 
adjusted by 
age and data 
partner 
(seizures); 
SCRI – time-
invariant; 
Seizures – 
stratification 
by age and 
concomitant 
PCV13 in the 
6-23m group 
Bimonthly  Adjusted for 
partially elapsed 
risk interval and 
delays in the 
arrival of 
inpatient data 
Signal for 
seizures 
following 
concomitant 
PCV13 and TIV.  
           (Continues) 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
HPS¶ UK, HPS HPV – Female 
adolescents; 
Herpes zoster - >70 
years 
HPV2, HPV4, 
and Herpes 
zoster; 
Scottish 
Immunisation 
Recall System 
HPV – 62,000 
doses/year 
Herpes zoster 
– 47,000 
doses in 2013-
14 
Background rates 
(HPV – 2004-08, 
Herpes zoster – 5 
years before 
introduction) 
HPV – >60 out-
comes, from TCP 
to juvenile onset 
of diabetes.  
Shingles – zoster, 
ataxia, GBS, ana-
phylaxis, menin-
gitis, encephali-
tis, encephalopa-
thy, events: 
cardiovascular, 
cerebrovascular 
and respiratory. 
ICD-10 codes. 
SPC Stratification 
– age, sex 
(not for HPV), 
geographical 
site 
Monthly for 
Herpes 
zoster, 
annually for 
HPV 
No HPV – signal for 
Bell’s palsy, not 
confirmed 
MHRA¶ UK, MRHA Numerator –  
potentially all 
vaccinees, CPRD for 
denominator 
Rotavirus, LAIV 
(2013-14), 
Herpes zoster; 
cases based on 
spontaneous 
AE reports 
First year of 
the 
programme 
evaluated 
(introduced in 
2013)  
 
CPRD age-
specific rates 
Rotavirus – SID, 
intussusception. 
LAIV – AID, BP 
narcolepsy, FS, 
respiratory 
events.  
Herpes zoster – 
death, GBS, BP.  
Read codes 
PmaxSPRT Expected # 
adjusted by 
age; 
Rotavirus – 
stratification 
by dose 
Weekly Adjusted for 
underreporting 
(yellow-card 
data) 
No signal 
identified 
Li, 2016107 USA, VSD ≥6m old from 6 
integrated 
healthcare 
organizations§  
Influenza 
vaccines (TIV, 
QIV, LAIV4); 
Immunisation 
history 
Doses 2013-
14: 4,029,951; 
Doses 2014-
15: 3,988,644; 
c. 41w each 
season 
Background rates 
for Poisson-
based analysis 
based on TIV 
vaccinees in prior 
seasons (2005–
06 to 2012–13) 
Acute dissemi-
nated en-
cephalomyelitis, 
anaphylaxis, BP, 
encephalitis, 
GBS, FS, trans-
verse myelitis. 
ICD-9 codes 
SCRI 
BMaxSPRT 
and 
PMaxSPRT 
Expected # 
adjusted by 
age and site; 
Weekly Adjusted for 
partially elapsed 
risk interval and 
delays in the 
arrival of 
inpatient data 
Signal identified 
for FS following 
TIV (children 6-
23mo, season 
2014-15) and 
confirmed with 
concomitant 
PCV13. 
           (Continues) 
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Table 4.1. (Continued) 
First 
author, 
year 
published 
Location 
(Country, 
institution) 
Study population Vaccine 
studied; 
ascertainment 
if available 
Doses, weeks 
and time 
frame 
evaluated  
Comparison 
group (for 
between-person 
analyses) 
Outcomes 
studied and 
method of 
ascertainment 
Method 
used 
Confounding: 
method and 
factors 
Frequency 
of 
assessment 
Adjustment for 
data-accrual lag 
Main findings 
Sandhu, 
2017108 
USA, FDA 
and 
Centers for 
Medicare 
and 
Medicaid 
Services 
Medicare 
population 
(individuals aged 
≥65yr those with 
disability or end-
stage renal disease; 
c. 50 million 
individuals each 
season) 
Influenza 
vaccine; 
procedure 
codes  
Doses  
 2010-11: 
15,460,544; 
 2011-12:   
15,474,830; 
 2012-13: 
16,220,362; 
 2013-14: 
16,189,893; 
c. 46w each 
season 
Prior seasons 
 2010-11: 2005-
06 to 2009-10; 
 2011-12: 2006-
07 to 2009-10 
 2012-13: 2006-
07 to 2009-10 
 2013-14: 2010-
11 to 2012-13 
GBS USPRT Unclear 20 consecu-
tive weekly 
tests, 5 ad 
hoc tests, 
and a 26th 
final end of 
season test 
Test statistic 
adjusted for 
delays in 
receiving the 
claims and 
partially elapsed 
risk interval 
Signal identified 
for GBS in the 
season 2010/11 
but not 
confirmed 
AE – Adverse Event, AID – Auto-immune disorders, BMaxSPRT – Binomial-based Maximized Sequential Probability Ratio Test, BP – Bell’s palsy, CDC – Centers for Disease Control and Prevention, 
CMaxSPRT – Conditional Maximized Sequential Probability Ratio Test, CND – Cranial nerve disorders, CPRD – Clinical Practice Research Datalink, DD – Demyelinating disorders, DID – Difference-in-
difference, DMSS – Defense Medical Surveillance System, DoD – Department of Defense, DPNSN – Disorders of the peripheral nervous system and neuropathy, DT – diphtheria-tetanus vaccine, DTaP – 
acellular diphtheria-tetanus-pertussis vaccine, DTwP – whole cell diphtheria-tetanus-pertussis vaccine, FDA – Food and Drug Administration, FS – Febrile seizures, GBS – Guillain-Barré syndrome, GS – 
Group sequential, Hib – Haemophilus influenza type B, HMO – Health Maintenance Organizations, HPS – Health Protection Scotland, HPV2 – Bivalent human papillomavirus vaccine, HPV4 – Quadrivalent 
human papillomavirus vaccine, ICD-9 – International Classification of Diseases Ninth Revision, ICD-10 – International Classification of Diseases Tenth Revision, IHS – Indian Health Service, IPV – inactivated 
poliovirus vaccine, ITP – Immune thrombocytopenia purpura, KD – Kawasaki Disease, LAIV – seasonal trivalent live attenuated vaccine, LAMV – H1N1 monovalent live attenuated vaccine, MAF – 
medically attended fever, MCV – meningococcal conjugate vaccine, MHRA – Medicines and Healthcare products Regulatory Agency, MIV – H1N1 monovalent inactivated vaccine, MMRV – Mumps-
measles-rubella-varicella vaccine, mo – months, MoH – Ministry of Health, NVPO – National Vaccine Program Office, OCND – Other Cranial Nerve Disorders, ODD – Other Demyelinating disorders, ON 
– Optic neuritis, PCV7 – 7-valent pneumococcal conjugate vaccine, PCV13 – 13-valent pneumococcal conjugate vaccine, PMaxSPRT – Poisson-based Maximized Sequential Probability Ratio Test, PRISM 
– Post-Licensure Rapid Immunization Monitoring System, QIV – Seasonal quadrivalent inactivated vaccine, RRV – Rhesus-Rotavirus vaccine, RV5 – Pentavalent rotavirus virus, SCCS – Self-controlled case 
series, SCRI – Self-controlled risk interval, SID – Sudden infant death, SJS – Stevens-Johnson syndrome, SPC – Statistical Process Control, SPRT – Sequential Probability Ratio Test, TCP – Thrombocytopenia, 
TIV – Seasonal trivalent inactivated vaccine, UK – United Kingdom, USA – United States of America, USPRT – Updating Sequential Probability Ratio Test, VA – Veteran’s Affairs, VSD – Vaccine Safety 
Datalink, w – weeks, yr – years, # – number. *Geographic location: Seattle - Washington, Boston - Massachusetts, Minneapolis - Minnesota, Denver - Colorado, Oakland - California, Pasadena - California, 
Marshfield - Wisconsin, Portland – Oregon. †Geographic location: Seattle - Washington, Boston - Massachusetts, Minneapolis - Minnesota, Denver - Colorado, Oakland - California, Marshfield - 
Wisconsin, Portland – Oregon. ‡Geographic location: Seattle - Washington, Boston - Massachusetts, Denver - Colorado, Oakland - California, Southern California, Marshfield - Wisconsin, Portland – 
Oregon. §Geographic location: Seattle - Washington, Denver - Colorado, Oakland - California, Southern California, Marshfield - Wisconsin, Portland – Oregon. ¶ Additional information obtained from 
the authors. 
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5 IMPLEMENTING A SYSTEM – PREPARATORY STEPS  
This Chapter details the process used to select the vaccine/outcome pairs to assess in the 
trial implementation study. It does not include the actual implementation of the new system, 
which is presented in Chapter 7. Rather, it establishes the foundation of the actual 
implementation. Chapter 6 complements the current Chapter, by presenting data-related 
aspects of implementing a system using previously collected data. 
Timeliness is a key feature of a data source envisaged to implement NRTVSS. However, it is 
also necessary that a data source has certain electronic health record characteristics, 
including that it is population-based, has appropriate size, and has good validity for both 
exposure and outcomes. Data sources meeting these requirements would be considered 
ideal for NRTVSS implementation. These characteristics were used as a starting point to 
guide the feasibility study, and together with the results from the systematic review, to 
support the decision of which vaccines/outcome pairs to select for the implementation study 
(Chapter 7). The current Chapter starts with an overview of the framework used to select 
pairs to study, followed by an in-depth assessment of data accrual delays for selected 
outcomes. The latter has been written as a paper, included here. The Chapter finishes with 
a discussion of the findings and conclusion on the vaccine/outcome pairs to assess in the 
implementation step (Chapter 7).  
5.1 Framework 
As stated above, a data source to implement NRTVSS should be population-based, have 
appropriate size, have good validity for both exposure and outcomes, and be timely. As 
presented in 3.1.1, CPRD data are known to be population-based, but it is important to 
evaluate the remaining characteristics in this context.   
When implementing NRTVSS, outcomes can be selected based on previous information, 
expert opinion, and/or biological plausibility.134 As this thesis aims to provide general 
information on the use of CPRD to perform NRTVSS, a selection of pairs based on 
vaccine/outcome characteristics that influenced implementation of a system (for example, 
the frequency of the outcome) seemed more appropriate. Furthermore, it would not be 
possible to assess all potential vaccine/outcome pairs of interest within the time frame of 
this project. It was thus necessary to perform an initial feasibility assessment for a range of 
possible outcomes of interest, followed by a more detailed feasibility assessment and 
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implementation of a NRTVSS for the selected vaccine/outcome pairs (identified by the initial 
assessment), as summarised in Figure 5.1.  
 
Figure 5.1. Workflow to study the feasibility of implementing a near real-time system. 
 
The steps included: 
1. For the initial assessment a list of outcomes was generated from the studies 
identified in the systematic review (presented in Section 4.1). Those studied more 
than 3 times were selected. This criterion was used as outcomes studied more often 
were more likely to be events of interest for the implementation of a future system. 
As mentioned, when implementing a near real-time system in practice this choice 
should be guided by previous knowledge of the vaccine under study (e.g. results from 
clinical trials, previous versions of the vaccine, biological plausibility).134  
2. Outcomes selected were characterized in terms of their diagnostic validity in CPRD, 
incidence, and the data accrual process in CPRD, as follows: 
a. Validity – Studies validating the selected outcomes in CPRD were identified, 
using a previous systematic review of the topic85 and the CPRD 
bibliography.79 The authors from the systematic review on validity kindly 
shared the data they extracted and the list of outcomes was inspected to 
allow identification of the outcomes of interest for the current project. 
Subsequently, I conducted searches in the CPRD bibliography to identify 
studies that had validated the diagnosis of one or more outcome from the 
3. Implementation and power
Using the tests and confounding control methods 
available, for selected outcomes (based on step 2)
2. Characterization of selected outcomes
According to key characteristics (diagnostic validity, 
incidence and data accrual process)
1. Outcome selection
Based on outcomes identified from the systematic 
review and studied >3 times
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list generated from step 1 but that had not been included in the 2010 
systematic review. These searches were based on searching the publication 
title as this was the only information available in the bibliography. As 
discussed in 3.1.1.4, studies attempting to validate diagnosis of outcomes in 
CPRD and that provided quantitative measures often only calculate the 
positive predictive value of a diagnostic code or diagnostic algorithm.85 This 
measure provides limited assessment of validity but given it is the most 
often used it was the aspect of validity extracted, when provided in the 
publication. 95% confidence intervals for proportions were calculated if not 
provided by the original publication. When positive predictive value was not 
calculated, information on other forms of validation (e.g. comparison of 
rates obtained from CPRD to those from other sources) was extracted. The 
results are presented in Section 5.2. 
b. Incidence – Even when large volumes of data are available there might be 
not enough power to detect a signal for rare outcomes or exposures with 
short risk windows. It was not possible to assess power for all outcomes in 
the list obtained from step 1 as such assessment required the full 
implementation of a system (including decision of which pairs to assess, 
statistical tests, and control for confounding strategies). Therefore, power 
was only assessed for pairs included in the trial implementation (see step 3). 
The concerns regarding power to detect a signal for rare outcomes guided 
my decision to include at least one uncommon outcome in the trial 
implementation. Hence, I used incidence as a proxy for power and to guide 
the choice of pairs to assess during the trial implementation. Information on 
incidence was not required to be CPRD-specific as it was used as an 
indication of the outcome frequency. Nevertheless, priority was given to 
information generated from CPRD data, following by other UK data and then 
from other sources if neither CPRD nor other UK data were identified. The 
results are presented in Section 5.2. 
c. Data accrual process (delays) – Delays in recording outcomes in the GP data 
were assessed in a two-stage process. The initial stage considered the 
characteristics of the outcome as a proxy of the data accrual process. 
Characteristics were based on factors likely to affect data accrual, including 
place of diagnosis (GP vs. hospital) and onset of symptoms (acute vs. 
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insidious). For example, a condition diagnosed in hospital might be less well 
captured in CPRD or recording might be more delayed than a GP-diagnosed 
condition. Similarly, outcomes with more insidious onset might take longer 
to be diagnosed and thus captured. All the outcomes identified from step 1 
were classified according to these categories. Results from this first 
assessment are presented in Section 5.2. 
Based on results from the validity and initial stage of assessing delays, a 
subset of outcomes were selected to conduct an in-depth analysis of delays. 
This selection considered outcomes deemed to represent broadly a range of 
characteristics (in terms of onset and place of diagnosis). Outcomes selected 
for this assessment included GBS, Bell’s palsy, optic neuritis, and febrile 
seizures. Further explanation of the selection of these outcomes is provided 
in Section 5.2; the in-depth delays assessment was published as a paper, 
presented in Section 5.3.  
 
After the initial assessment, outcomes were considered potentially suitable/not 
suitable for NRTVSS in CPRD. In particular, those with low diagnostic PPV and/or very 
delayed data accrual were deemed non-suitable. In the event of having many 
suitable outcomes, a selection was made encompassing a variety of characteristics 
and additional considerations (e.g. the relevance of the outcome for vaccines that 
are well captured in CPRD data). For outcomes deemed to be not feasible, changes 
necessary to allow future feasibility were discussed. A final choice on the 
vaccine/outcome pairs to include in the implementation step was then made and 
rationale for this is provided in Section 5.6.  
3. Trial implementation was performed for the selected vaccine/outcomes pairs. This 
included definition of the details of the system for the pairs selected (e.g. which 
statistical test to use, adjustment for delays, control for confounding strategies) and 
calculation of power to detect a signal. Just as in step 2, for outcomes deemed as not 
being feasible (those that had issues with implementation or low power), the 
changes necessary to allow feasibility are discussed. This work in presented in 
Chapter 7.    
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5.2 Initial feasibility assessment: results 
Studies included in the systematic review analysed 218 outcomes. Table S 1 (Appendix A) 
lists the outcomes considered ≤3 times and thus excluded. The remaining outcomes, along 
with their main characteristics, are presented in Table 5.1. These outcomes have been 
investigated in association with different vaccines. All outcomes except for intussusception 
have been studied following influenza vaccines, highlighting the importance of near real-time 
vaccine safety surveillance to assess influenza vaccine. Conversely, the remaining vaccines 
have been assessed for fewer outcomes, which might be due to these methods having been 
used less often to assess other vaccines or an interest only on specific outcomes following 
these vaccines. A particular example is rotavirus vaccine which has only been studied to date 
in relation to intussusception.  
Regarding the outcomes, demyelinating disease and disorders of the peripheral nervous 
system/neuropathy were examined exclusively for influenza vaccines, others such as allergic 
reactions, encephalitis and seizures have been considered for several vaccines, including 
childhood vaccines. In addition, a variety of outcomes was included – both acute and 
insidious events, and outcomes potentially diagnosed by GPs and in hospital.  
Overall, CPRD data have been used to assess all the outcomes of interest listed in Table 5.1, 
except for ataxia. I identified several studies that validated the recorded diagnosis of some 
of these outcomes in CPRD and that provided a quantitative measure, namely PPV. For 
outcomes with this information, PPV was generally high, the exception being idiopathic 
peripheral neuropathy which had an estimated PPV of 41%. This outcome was therefore 
deemed as non-suitable for inclusion in later stages of the study. For allergic reactions, 
ataxia, cranial nerve disorders, encephalitis/encephalopathy/meningitis/myelitis, Guillain-
Barré syndrome, and thrombocytopenia, no studies were identified that validated the 
diagnosis in the GP data and that provided a quantitative validation measure. It was possible 
to identify validation studies using external data (i.e. comparing the rates of the outcome 
based on CPRD data to the rates from other sources) for trigeminal neuralgia (a type of 
cranial nerve disorder) and Guillain-Barré syndrome. No validation studies of the diagnosis 
of allergic reactions, encephalitis and thrombocytopenia were identified. 
For most outcomes, data on incidence was identified. Polyneuritis, GBS, and transverse 
myelitis were the rarest conditions. Some of the studies estimating incidence of these 
outcomes used CPRD data.115,140 As stated above, this was not considered an essential 
requirement as information on incidence was merely used as an indication of the outcome  
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Table 5.1. Analysis of outcome/vaccine pairs of potential interest according to selected characteristics 
 Requirements 
Outcome 
Vaccines Validity (in CPRD) 
Volume of data (incidence/100,000 PY, 
unless indicated otherwise) 
Factors affecting data accrual 
(onset, place of diagnosis) 
Serious allergic 
reactions (including 
anaphylaxis) 
DTaP-IPV, DTaP-IPV-Hib, pandemic 
and seasonal influenza, HPV, MCV, 
GBMV, MMRV, PCV13, RV, zoster 
No studies found. CPRD previously 
used to estimate anaphylaxis 
incidence.141 
Increase in anaphylaxis incidence.142 
UK: 21.28 (10-79 yr)143; Spain: 313.58 
and 74.43 among the 0-4 and 5-9 yr144 
Acute, GP/hospital 
Ataxia Pandemic and seasonal influenza, 
MMRV, zoster 
No studies found. UK (HES): 45.95 diagnosis/100,000 
admissions* in 2014/2015145  
Acute/insidious, GP/hospital 
Bell's palsy/Facial 
palsy 
pandemic and seasonal influenza, 
HPV, MCV, zoster 
PPV: 77% (95%CI: 67-85)146 Bell’s palsy140 
Usually acute, GP/hospital 
0–17 years 11.98 
18–44 years 28.92 
45–65 years  36.28 
 >65 years  44.91 
Cranial nerve 
disorders 
Pandemic and seasonal influenza, 
TDaP 
Trigeminal neuralgia: incidence in 
CPRD higher than other studies147 
Age- and sex-adjusted incidence in 
London: 6.00. 
Acute/insidious (depending on the 
cause), GP/hospital 
Demyelinating 
disease 
Pandemic and seasonal influenza PPV for multiple sclerosis (incident 
and prevalent cases): 82% (95%CI: 
79-85)148  
Multiple sclerosis149 
Insidious, hospital 
 Female Male 
0–19 years 0.54 0.40 
20–39 years 19.86 6.57 
40–59 years  23.57 9.74 
 ≥60 years  10.60 7.06 
Optic neuritis115 
 Female Male 
0–15 years 0.85 0.54 
16–64 years 8.26 3.13 
≥65 years 2.18 2.40 
(Continues) 
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Table 5.1. (Continued)  
 Requirements 
Outcome 
Vaccines Validity (in CPRD) 
Volume of data (incidence/100,000 PY, 
unless indicated otherwise) 
Factors affecting data accrual 
(onset, place of diagnosis) 
Disorders of the 
peripheral nervous 
system and 
neuropathy 
Pandemic and seasonal influenza PPV for idiopathic peripheral 
neuropathy: 41% (95%CI: 21-
63)150 
Acute infectious and post-infectious 
polyneuritis140 
Acute/insidious, hospital 
 
 Female Male 
0–17 years 0.79 0.70 
18–44 years 1.57 1.63 
45–65 years  2.07 2.50 
 >65 years  2.52 4.57 
Encephalitis/ 
encephalopathy/ 
meningitis/ myelitis 
DTaP-IPV, DTaP-IPV-Hib, pandemic 
and seasonal influenza, HPV, 
GBMV, MMRV, PCV13, RV, zoster, 
Tdap 
CPRD previously used to 
estimate transverse myelitis 
incidence.115 
Encephalitis151 
Acute/insidious, hospital 
<1 year 11.63 
1-4 years 6.06 
5-19 years 2.86 
20–44 years 3.23 
45–64 years 4.46 
≥65 years 6.06 
Transverse myelitis115 
 Female Male 
0–15 years 0.22 0.12 
16–64 years 1.55 0.88 
≥65 years 0.46 0.83 
Guillain-Barré 
Syndrome 
DTaP-IPV, DTaP-IPV-Hib, pandemic 
and seasonal influenza, HPV, MCV, 
zoster, DTaP 
Similar incidence reported in 
CPRD and external sources.85 
CPRD previously used to study 
GBS as a possible AE to 
vaccines115,152,153 
Guillain-Barré Syndrome115 
Acute, hospital 
 Female Male 
0–15 years 0.65 0.70 
16–64 years 1.66 1.79 
≥65 years 2.31 4.30 
    (Continues) 
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Table 5.1. (Continued)  
 Requirements 
Outcome 
Vaccines Validity (in CPRD) 
Volume of data (incidence/100,000 PY, 
unless indicated otherwise) 
Factors affecting data accrual 
(onset, place of diagnosis) 
Intussusception RV PPV: 88% (95%CI: 82-93)154,155 UK: 24.8 cases/100,000 live births156 Acute, hospital 
Seizures (including 
febrile)  
DTaP-IPV, DTaP-IPV-Hib, pandemic 
and seasonal influenza, HPV, MCV, 
GBMV, MMRV, PCV13, RV, DTaP 
PPV: 80% (95%CI: 68-94)157 Age- and sex-adjusted incidence in 
London for single seizures: 11.00158 Acute, GP/hospital 
Thrombocytopenia/ 
ITP 
Pandemic influenza, HPV, MCV, 
GBMV, MMRV, PCV13 
No studies found. CPRD 
previously used to study ITP as a 
possible AE to vaccines159 
Autoimmune thrombocytopenia140 
Acute, GP/hospital 
 Female Male 
<18 years 3.7 4.7 
18–64 years 3.8 2.0 
≥65 years 7.1 7.8 
*Diagnosis for “Ataxia, unspecified” and “Other and unspecified lack of coordination”. AE – Adverse Event, CPRD – Clinical Practice Research Datalink, DTaP – acellular diphtheria-tetanus-
pertussis vaccine, GBMV – Group-B meningococcal conjugate vaccine, GP – General Practitioner, HES – Hospital Episode Statistics, HPV – human papillomavirus, IPV – inactivated poliovirus 
vaccine, ITP – Immune thrombocytopenic purpura, MCV – meningococcal conjugate vaccine, MMRV - Measles-Mumps-Rubella-Varicella vaccine, PCV13 – 13-valent pneumococcal conjugate 
vaccine, PPV – Positive Predictive Value, PY – Persons-year, RV – Rotavirus vaccine, UK - United Kingdom, yr - years. 
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frequency and exact figures were not required at this stage. Nevertheless, the use of CPRD 
in this context illustrates how widely these data have been used. 
For the in-depth delays assessment, only a few outcomes were selected in an attempt to 
cover different characteristics that might influence delays (i.e. onset of symptoms and place 
of diagnosis). Bell’s palsy was selected as an example of an acute condition, generally 
diagnosed and managed by GPs. Guillain-Barré syndrome was deemed to exemplify a 
condition generally diagnosed and managed in hospital, with an acute presentation. Optic 
neuritis was one of the few conditions with an insidious onset and was thus selected to 
represent this group of outcomes. Finally, febrile seizures were included as an example of an 
acute condition that can present in both hospital and general practice. This outcome was 
also selected as it is of particular importance following childhood vaccines.  
The next Section (5.3) comprises Paper 2, published in Pharmacoepidemiology and Drug 
Safety. This paper presents the methods and results of the in-depth delays assessment.  
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5.3 In-depth delays assessment (Paper 2) 
This paper was published in Pharmacoepidemiology and Drug Safety in February 2017 and 
reports the results of the in-depth delays analysis. 
For the main analysis presented in the paper, I used stand-alone CPRD data from individuals 
with an outcome of interest (Guillain-Barré syndrome, Bell’s palsy, optic neuritis and febrile 
seizures) and compared the event date (deemed to represent when the event occurred) and 
the system date (date when the record was entered in the general practice records). The 
difference between these dates allowed the description of the data accrual process in CPRD 
for the outcomes of interest. The results showed that most diagnoses examined were 
recorded with delays of 30 days or less. Furthermore, and as a secondary objective, I 
conducted an analysis of completeness of recording of diagnosis in the CPRD data and further 
analysis of delays, using CPRD-HES linked data. For this analysis, I considered a cohort of 
individuals with an outcome of interest first recorded in HES and followed them up until they 
had the same outcome recorded in CPRD or until they were censored. This analysis showed 
that less than 50% of individuals with a record in HES had a corresponding record in CPRD 
after 1 year, indicating low completeness of records in CPRD.  
Despite low completeness of recording, the results indicate that CPRD data are timely 
enough to implement a near real-time vaccine safety surveillance system. The material 
published as supporting information is reproduced in this thesis in Sections 5.4 (Appendix A 
from the supporting information) and 5.5.  
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ORIGINAL REPORT
Assessing recording delays in general practice records to inform
near real-time vaccine safety surveillance using the Clinical
Practice Research Datalink (CPRD)
Andreia Leite1* , Nick J. Andrews2 and Sara L. Thomas1
1Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
2Statistics, Modelling and Economics Department, Public Health England, London, UK
ABSTRACT
Purpose Near real-time vaccine safety surveillance (NRTVSS) is an option for post-licensure vaccine safety assessment. NRTVSS
requires timely recording of outcomes in the database used. Our main objective was to examine recording delays in the Clinical Practice
Research Datalink (CPRD) for outcomes of interest for vaccine safety to inform the feasibility of NRTVSS using these data. We also
evaluated completeness of recording and further assessed reporting delays for hospitalized events in CPRD.
Methods We selected Guillain–Barré syndrome (GBS), Bell’s palsy (BP), optic neuritis (ON) and febrile seizures (FS), from January 2005
to June 2014. We assessed recording delays (e.g. due to feedback from specialist referral) in stand-alone CPRD by comparing the event and
system dates and excluding delays >1 year. We used linked CPRD-hospitalization data to further evaluate delays and completeness of
recording in CPRD.
Results Among 51 220 patients for the stand-alone CPRD analysis (GBS: n = 830; BP: n = 12 602; ON: n = 1720; and FS: n = 36 236),
most had a record entered within 1 month of the event date (GBS: 73.6%; BP: 93.4%; ON: 76.2%; and FS: 85.6%). A total of 13 482
patients, with a ﬁrst record in hospital, were included for the analysis of linked data (GBS: n = 678; BP: n = 4060; ON: n = 485; and FS:
n = 8321). Of these, <50% had a record in CPRD after 1 year (GBS: 41.3%; BP: 22.1%; ON: 22.4%; and FS: 41.8%).
Conclusion This work shows that most diagnoses in CPRD for the conditions examined were recorded with delays of ≤30 days, making
NRTVSS possible. The pattern of delays was condition-speciﬁc and could be used to adjust for delays in the NRTVSS analysis. Despite low
sensitivity of recording, implementing NRTVSS in CPRD is worthwhile and could be carried out, at least on a trial basis, for events of
interest. © 2017 The Authors. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons Ltd.
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INTRODUCTION
The Clinical Practice Research Datalink (CPRD) is a
UK primary care database widely used for epidemio-
logical research, including monitoring disease rates
over time and assessing the post-licensure safety of
several vaccines using epidemiological designs.1–9
Near real-time vaccine safety surveillance (NRTVSS)
using electronic health records is a post-licensure vac-
cine surveillance tool that involves monitoring rates
of adverse events over time to identify changes associ-
ated with vaccine use. NRTVSS is ideally started at the
time a vaccine is introduced in a population by looking
at data at repeated time points to ensure timely signal
identiﬁcation. This type of surveillance is now used
by the Vaccine Safety Datalink in the USA and has
been implemented by a few other countries.10 In the
UK, NRTVSS has been carried out using spontaneous
reports to calculate the observed number of events and
CPRD data to calculate the expected number of
events.11 However, CPRD data have not been used as
the sole data source to perform NRTVSS.
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The CPRD data are currently updated monthly and
are therefore a potential data source for implementing
NRTVSS. For near real-time surveillance, timeliness
is paramount. One way of dealing with delays is to
delay the analysis until sufﬁcient data accrue. A more
timely approach12 is to know how long it takes for data
to accrue and then use the pattern of delays to adjust
the expected number of events.
Data accrual delays in CPRD can be due to the
following: (i) delays in making the diagnosis after an
initial consultation, (ii) practices receiving and record-
ing diagnoses made at secondary care and (iii) delays
in uploading the data for researchers. Different out-
comes of interest might have different sources and
levels of delay, depending, for example, on whether
the onset of the condition is acute or insidious and
the healthcare setting in which it is diagnosed and
managed.13 Given CPRD’s structure, it is likely that
an acute condition that is usually diagnosed and man-
aged by general practitioners (GPs) will accrue more
quickly than a condition diagnosed and managed in
hospital. Conversely, a more insidious condition and
which tends to be diagnosed in secondary care might
take longer to accrue. Understanding recording delays,
by knowing the time it takes for data to accrue and
how this differs by condition, helps to determine the
feasibility of implementing NRTVSS in CPRD. In this
paper, we focus on delays in practices recording diag-
noses made elsewhere (aforementioned scenario ii).
It is also important to understand the sensitivity of
CPRD for capturing outcomes of interest. Feedback
from secondary care (e.g. hospital admissions and
outpatient consultations) may not be completely
captured as coded diagnoses in CPRD, for example,
if GPs do not code these events but simply scan in
hospital letters without adding diagnostic codes to
the patient record. The information from hospital
admissions in England is recorded in the Hospital
Episode Statistics (HES) database and linked to
CPRD for a subset of practices. Previous studies have
shown that the use of linked data (including primary
and secondary care information) improves sensitivity
of diagnoses.14–16 However, these linkages are cur-
rently updated too infrequently to allow their use for
surveillance purposes. To the best of our knowledge,
no previous studies have investigated completeness
of recording for conditions of interest for NRTVSS
that are typically diagnosed in secondary care such
as Guillain–Barré syndrome (GBS).
Our main objective was thus to examine recording
delays for selected conditions, due to practices receiv-
ing and recording diagnoses made at secondary care,
in stand-alone CPRD, to inform the feasibility of
implementing NRTVSS in England using these data.
Secondary objectives were to further assess delays
and evaluate completeness of recording of diagnoses
in CPRD using linked hospitalization data.
METHODS
Data sources
For our main analysis, we used data from CPRD,
which comprises anonymized UK primary care health
records for >11.3 million patients from 674 general
practices, with information on demographics, diagno-
sis, therapies, vaccines, health-related behaviours and
referrals to secondary care.1 Patient information is
recorded using Read codes, and when a new record
is entered, the software automatically assigns it the
current date, the system date. Practice staff also enters
an event date, the date generally considered to
represent the time the event has occurred. Monthly
updates of CPRD data include the date information
was last collected from each practice (last collection
date).13
Despite being assigned when new records are
entered, the system date can be changed when mass
transfer of records occurs. These might occur when
(Rachael Williams, personal communication) (1) the
practice changes software to Vision (and joins
CPRD) or updates their version of Vision: previous
system dates will be updated for all patients to the
date the change has occurred; (2) patients’ records
are transferred from their previous practice (or an in-
ternal transfer of a patient occurs within a practice);
the system dates for that patient’s records will then
all be changed to the date the transfer occurred.
Our secondary analysis used CPRD–HES linked
data, which includes patient-level information from
58% of all CPRD practices.1 HES data are coded
using International Classiﬁcation of Diseases, version
10 (ICD-10), and each hospitalization includes ≥1
episode, corresponding to the time a patient is
under the care of a single consultant.17 Information
available includes date of hospital admission and
discharge and, for each episode, a starting date
(episode date).
Outcomes
We selected four outcomes of interest for NRTVSS10:
GBS, Bell’s palsy (BP), optic neuritis (ON) and febrile
seizures (FS). These represent different characteristics
that might affect delays; GBS is an acute condition,
diagnosed and managed in hospital; BP is typically
diagnosed and managed by GPs; ON is a more
a. leite et al.438
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insidious condition, likely to be diagnosed in
outpatient hospital settings; and FS can be diagnosed
and managed in both primary and secondary care.10
For each outcome, a speciﬁc and a broader (potentially
more sensitive but less speciﬁc) code lists were
considered (Appendix A). These different versions
were used to explore the effect of imperfect validity
of different code lists to identify the outcomes. It has
been previously suggested that for NRTVSS, a more
sensitive code list generates more timely signals.18
We thus considered the broader code list in our main
analysis and the speciﬁc code list in a sensitivity
analysis.
Analysis
System dates and event dates were compared to assess
delays in recording. To avoid overestimation of delays
because of mass transfers of system dates to later
dates, we ﬁrst studied which records were likely to
have been part of such transfers and excluded these
from remaining analyses.
We assumed that (i) an unusually high number of
records with the same system date was due to a mass
transfer; (ii) mass transfers are infrequent, so only a
small proportion of patients will have records af-
fected by mass transfers; (iii) there is a threshold
number of repeated system dates above which mass
transfers can be identiﬁed. To identify this threshold,
we created a within-patient proportion of records
with the same system date used s times (psi), using
eligible patient records from the clinical, test, referral
and immunization ﬁles. psi is given by tsi/ri, where tsi
is the number of records with a given number of re-
peat system dates and ri the total number of records
for that patient. For example, if we consider a patient
with a total of 300 records and if this patient has
four records registered on one shared system date
and four others on a different shared system date,
p4 is given by 8/300≈0.03. This means that 3% of
all this patient’s records are recorded in blocks of
four records.
The patient-level psi was averaged across all patients
(aps ¼ ∑ni¼1psi=n). This average proportion of records
with the same system date s was displayed graphically,
and we selected candidate thresholds, on the basis of
our assumptions about mass transfers.
For each threshold, we took a sample of 10 pa-
tients with that number of repeated dates (e.g. if
threshold = 100, we selected the 100 records with
the same system date for 10 patients). We then
looked at these records to assess the likelihood that
they had been involved in mass transfers. We
considered that records with the same system dates
that had codes that could feasibly refer to the same
condition or a related procedure/test result and which
all had the same event date were likely to have been
entered on the same day. Conversely, if the codes
were unrelated, with varying event dates, this would
suggest a mass transfer. To evaluate the inﬂuence
of the ﬁnal threshold decision, we calculated the per-
centage of the outcomes assigned as mass transfers
and excluded using the selected threshold.
After excluding system dates likely to have been
part of mass transfers, we used a forward approach
to assess delays, that is, considering the time from
the event date (the assumed date of diagnosis) until
the system date (the date the diagnosis was entered
in the practice system). Delays were calculated as
the difference between the system and event dates
(Figure 1(A)). We excluded diagnoses with a delay
>1 year as these would be of limited utility for
NRTVSS and could be ignored if NRTVSS was only
based on events recorded within a year. To give
enough time for data to accrue, we considered re-
cords with an event data up to June 2014 (using
CPRD data released in July 2015). Diagnoses within
a year of registration (6 months if aged <1 year)
with the practice were excluded to avoid counting
past diagnoses recorded retrospectively.19 We
described delays in terms of their cumulative distri-
bution and further described these by year of diagno-
sis to assess whether this distribution was constant
over time.
The secondary analysis focused on completeness
and delays in recording for patients with an outcome
of interest in HES. We considered a cohort of patients
with an outcome ﬁrst recorded in HES. Patients were
followed up from the hospital episode date in which
the outcome was ﬁrst recorded until they had an out-
come in CPRD (noting the system date) or were cen-
sored (earliest of date of death, date of leaving the
practice, last collection date or July 2015) (Figure 1
(B).). We excluded patients with a previous record of
the outcome in CPRD, as these would be captured
by a system on the basis of CPRD. We conducted a
sensitivity analysis to evaluate the effect of adding
these patients. Patients with diagnoses within a year
of their registration date (6 months if aged <1 year)
with the practice were also excluded, unless a relevant
diagnosis was made in HES during that period (as the
latter is not subject to retrospective recording of this
type). Kaplan–Meier analysis of the time until
recording the condition in CPRD was used to describe
completeness and delays, truncating the curves at
1 year (considered the period of interest for NRTVSS).
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RESULTS
Analysis of mass transfers
We identiﬁed 54 252 eligible patients for the mass
transfer analysis, with 24 905 375 records. Repeated
system dates ranged from 1 to 3958. Figure 2 shows
the proportion (and cumulative proportion) of records
with a unique date, ranging from 2 to 3958 on the
same date, averaged across patients. The average pro-
portion of records with repeated dates decreased until
50 records, after which it stabilized. The vast majority
(Figure 2 bottom) of records were recorded at the same
time as <49 other events.
We thus selected 50, 100 and 150 as candidate
thresholds, which resulted in losses of 7.7%, 4.5%
and 3.1% of records, respectively. Some of the code
lists with 50 repeated dates were a mixture of blood
tests and diagnosis codes, all with the same event
date. These were considered a plausible combination
of codes to have been entered on the same system
Figure 2. Average proportion (top) and cumulative average proportion of repeated system dates (number of records is represented in the logarithmic scale)
Figure 1. Schematic representation of the analysis undertaken for describing recording delays in CPRD (A) and completeness and delays in HES-CPRD
linked data (B). (A) includes patients with no delay (1), varying delays (2 and 3) and those who were excluded because of having a delay of more than a year
(4). (B) includes a censored patient because of death (1), patients with varying delays (2 and 3) and a patient with a delay of more than 1 year, included in the
analysis but not displayed in the Kaplan–Meier curves. CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics
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date. On the other hand, all the lists of 100 and 150
codes were for different conditions, with different
event dates. We interpreted this as highly suggestive
of a mass transfer and therefore selected 100 as the
threshold. This reduced cases by 2.3%, 1.5%, 2.4%
and 1.5% for GBS, BP, ON and FS, respectively.
After excluding records deemed to be mass transfers,
we assessed delays in stand-alone CPRD for 53 414
patients (GBS: n = 905; BP: n = 13 234; ON:
n = 1837; and FS: n = 37 625).
Recording delays in stand-alone Clinical Practice
Research Datalink
We further excluded records with delays>1 year (% of
exclusions: GBS, 8.3%; BP, 4.8%; ON, 6.4%; and FS,
3.7%). Our ﬁnal analysis included 51 220 patients
(GBS: n = 830; BP: n = 12 602; ON: n = 1720; and
FS: n = 36 236). Table 1 summarizes gender, age and
year of event date for these patients.
Table 2 and Figure 3 present the cumulative
distribution of data accrual lags by condition in
CPRD, deﬁned as the time from event date to sys-
tem date. Most diagnoses were recorded within a
month (73.6% (GBS); 93.4% (BP)). BP had the
highest percentage of records with identical system
and event dates (72.0%), while ON had the lowest
(27.8%). BP and FS records accrue more quickly
than GBS and ON. These differences occur mainly
(but not entirely) until 10 weeks after the event
date, after which data accrual seemed to stabilize.
Using a more speciﬁc code list yielded similar
patterns (Appendix B). These patterns were con-
stant over time (Appendix C).
Comparison of Hospital Episode Statistics–Clinical
Practice Research Datalink
We included 13 482 patients (GBS: n = 678; BP:
n = 4060; ON: n = 485; FS: n = 8321) with a ﬁrst out-
come recorded in HES. Table 3 shows the characteris-
tics of included patients and completeness of recording
in CPRD. Age and sex distributions for GBS and FS
were similar to those observed for the stand-alone data.
BP and ON patients in HES were older (mean age: BP:
HES—57.4, CPRD—48.2; ON: HES—49.9, CPRD—
42.9). BP and ON had the lowest completeness of
recording and FS and GBS the highest. Most records
accrued within a year. When we added patients with a
ﬁrst record in CPRD, the increase in total completeness
was less than 10% (Appendix D).
Figure 4 illustrates data accrual patterns. BP and FS
accrued more quickly at initial stages and plateaued
sooner than the other outcomes. GBS showed a
steadier accrual pattern, plateauing at around 20 weeks
after HES recording. Sensitivity analyses using spe-
ciﬁc code lists showed similar patterns (Appendix E).
DISCUSSION
We have conducted a comprehensive analysis of
recording delays and completeness for four outcomes,
to inform NRTVSS. Our results showed that data
accrual patterns and completeness depend on the con-
ditions studied. Selecting conditions with different
characteristics (in clinical presentation, place of diag-
nosis and management) enabled us to capture these
different patterns. BP showed the quickest data accrual
and highest agreement between system and event date,
consistent with a condition often diagnosed and
Table 1. Gender, age and year of event date of included patients by condition
GBS (n = 830) BP (n = 12 602) ON (n = 1720) FS (n = 36 236)
Gender, n (%)
Male 465 (56.0) 6218 (49.3) 569 (33.1) 19 029 (52.5)
Female 365 (44.0) 6384 (50.7) 1151 (66.9) 17 207 (47.5)
Mean age (SD) 53.5 (20.1) 48.2 (20.2) 42.9 (17.8) 35.4 (29.0)
Year of event date, n (%)
2005 70 (8.4) 1317 (10.5) 187 (10.9) 3605 (9.9)
2006 98 (11.8) 1240 (9.8) 181 (10.5) 3774 (10.4)
2007 76 (9.2) 1275 (10.1) 191 (11.1) 3808 (10.5)
2008 100 (12.0) 1430 (11.3) 162 (9.4) 3989 (11.0)
2009 94 (11.3) 1407 (11.2) 175 (10.2) 3983 (11.0)
2010 84 (10.1) 1376 (10.9) 182 (10.6) 3853 (10.6)
2011 90 (10.8) 1390 (11.0) 196 (11.4) 3844 (10.6)
2012 96 (11.6) 1320 (10.5) 195 (11.3) 3923 (10.8)
2013 83 (10.0) 1251 (9.9) 166 (9.7) 3778 (10.4)
2014 39 (4.7) 596 (4.7) 85 (4.9) 1679 (4.6)
BP, Bell’s palsy; FS, febrile seizures; GBS, Guillain–Barré syndrome; ON, optic neuritis; SD, standard deviation.
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managed by GPs. GBS and ON showed the slowest
data accrual. GBS is an acute condition usually requir-
ing admission, while ON is typically diagnosed and
managed in outpatient settings. We considered FS as
an acute condition diagnosed at any level of care, but
in most cases not requiring prolonged admission. This
is consistent with an intermediate agreement between
system and event date (38.1%) and more rapid data
accrual than GBS and ON. Overall, our ﬁndings indi-
cate that conditions diagnosed by GPs or during
short-term hospital admissions tend to accrue more
quickly than conditions diagnosed in hospital with
longer admission or diagnosed in outpatients. In gen-
eral, data captured in CPRD accrued within the ﬁrst
month of the diagnosis, making NRTVSS possible
using this data source.
Our assessment of completeness showed that a low
proportion of diagnoses ﬁrst recorded in HES subse-
quently accrued in CPRD. It seems particularly
unlikely that GPs are aware of <50% of cases of
serious conditions such as GBS. A recent UK study
that contacted GPs about patients with a coded GBS di-
agnosed in HES found that 68.2% (95% conﬁdence
interval: 60.7–74.9%) were aware of a GBS diagnosis
made in hospital that has been conﬁrmed (Julia Stowe,
personal communication). Incomplete diagnostic cod-
ing in general practice may occur because GPs instead
scan in hospital letters or record diagnoses in free text,
neither of which is now available to researchers using
CPRD because of changes in the information gover-
nance environment in the UK. This might have
decreased the ability to assess fully the validity of
CPRD data for research purposes. The inclusion of
therapy codes might help to capture some incompletely
coded diagnoses for conditions requiring treatment, but
the conditions we examined do not have unique treat-
ments. On the other hand, HES is itself an imperfect
source to capture conditions of interest as it might in-
clude unconﬁrmed cases. If that is the case, our analy-
sis would have underestimated completeness in CPRD.
For NRTVSS, if completeness is constant over time,
this should not bias the results, but it decreases power.
Knowing whether there is enough power is a key as-
pect when considering a new data source to implement
NRTVSS. This goes beyond the scope of our study but
should be assessed by future work looking at trial
Table 2. Cumulative distribution of delays by condition (n (%))
Delay* GBS (n = 830) BP (n = 12 602) ON (n = 1720) FS (n = 36 236)
Same day 275 (33.1) 9076 (72.0) 478 (27.8) 14 254 (39.3)
First week 371 (44.7) 10 459 (83.0) 699 (40.6) 22 181 (61.2)
First month 611 (73.6) 11 776 (93.4) 1310 (76.2) 31 031 (85.6)
6 months 790 (95.2) 12 431 (98.6) 1672 (97.2) 35 575 (98.2)
1 year 830 (100.0) 12 602 (100.0) 1720 (100.0) 36 236 (100.0)
BP, Bell’s palsy; FS, febrile seizures; GBS, Guillain–Barré syndrome; ON, optic neuritis.
*Deﬁned as the difference between the system and the event date.
Figure 3. Weekly data accrual in CPRD across 52 weeks considering data accrued during the ﬁrst year and diagnosis made up to June 2014. BP, Bell’s palsy;
CPRD, Clinical Practice Research Datalink; FS, febrile seizures; GBS, Guillain–Barré syndrome; ON, optic neuritis
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implementation of NRTVSS using CPRD. Results
from that work will allow further conclusions on the
possibility of implementing NRTVSS using CPRD. A
further consideration is that, for conditions which
may not always require hospital admission, hospital-
ized patients may be a particular subset of all cases,
for example, those with more severe disease (as
highlighted in studies of upper gastrointestinal bleed-
ing and venous thromboembolism14,20) or speciﬁc pa-
tient characteristics (as in our study, which showed
that patients with BP and ON captured in HES were
older). This will matter if the adverse event is more
likely among these speciﬁc subgroups.
Previous adjustments for accrual delays when
conducting NRTVSS with administrative claims data
have focused on delays in processing information for
ﬁling and approval.12 Primary care-based data have
different sources of delay, and our work focused on
delays in practices documenting feedback from
secondary care. Our work thus differs from Greene
et al.12 in the reasons for the delays we have
considered. In addition, we looked at four outcomes
(GBS, BP, ON and FS), while Greene et al.12 have
only considered GBS. Other sources of delay include
time before data are made available; CPRD data are re-
leased to researchers monthly and practices upload
Table 3. Characteristics of included patients, time of follow-up and completeness of records in Clinical Practice Research Datalink per condition of interest
GBS (n = 678) BP (n = 4060) ON (n = 485) FS (n = 8321)
Gender, n (%)
Male 363 (53.5) 1844 (45.4) 155 (32.0) 4662 (56.0)
Female 315 (46.5) 2216 (54.6) 330 (68.0) 3659 (44.0)
Mean age (SD) 55.8 (21.0) 57.4 (24.1) 49.9 (25.2) 34.8 (31.2)
Year of diagnosis,* n (%)
2005 61 (9.0) 424 (10.4) 56 (11.5) 1264 (15.2)
2006 73 (10.8) 460 (11.3) 45 (9.3) 1108 (13.3)
2007 79 (11.7) 400 (9.9) 47 (9.7) 1103 (13.3)
2008 85 (12.5) 417 (10.3) 47 (9.7) 1055 (12.7)
2009 79 (11.7) 515 (12.7) 56 (11.5) 912 (11.0)
2010 69 (10.2) 545 (13.4) 68 (14.0) 793 (9.5)
2011 76 (11.2) 471 (11.6) 48 (9.9) 702 (8.4)
2012 71 (10.5) 404 (10.0) 56 (11.5) 715 (8.6)
2013 69 (10.2) 358 (8.8) 54 (11.1) 531 (6.4)
2014 16 (2.4) 66 (1.6) 8 (1.6) 138 (1.7)
Median follow-up time (years) 0.9 1.9 2.1 1.4
Completeness, % (95% conﬁdence interval)†
Maximum 45.9 (41.5–50.5) 26.8 (25.0–28.7) 28.5 (22.9–35.0) 46.0 (44.8–47.2)
At 1 year 41.3 (37.6–45.3) 22.1 (20.8–23.5) 22.4 (18.9–26.5) 41.8 (40.7–42.9)
BP, Bell’s palsy; FS, febrile seizures; GBS, Guillain–Barré syndrome; ON, optic neuritis; SD, standard deviation.
*Considering the start of episode date in Hospital Episode Statistics database.
†Kaplan–Meier estimates of individuals with a record in Clinical Practice Research Datalink.
Figure 4. Kaplan–Meier recording estimates considering a ﬁrst record in HES and a subsequent record in CPRD, truncated at 1 year. BP, Bell’s palsy; CPRD,
Clinical Practice Research Datalink; FS, febrile seizures; GBS, Guillain–Barré syndrome; HES, Hospital Episode Statistics; ON, optic neuritis
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data some time before each release. These delays
could be examined by looking at the time between last
collection date and date of release, and adjustments
made depending on the patterns of such delays. Delays
in making diagnoses could involve identifying early
symptom codes, with the extent of delay varying by
condition. The results of our study indicate that
adjustments for data accrual delays should be tailored
for individual conditions and that future studies should
consider including setting-speciﬁc adjustments, that is,
generating delay distributions for diagnoses made in
primary care, in-patient and outpatient settings. More
broadly, we recommend that researchers reﬂect on
the source of delays in their data and whether these
delays are likely to be dependent on the outcomes
of interest, to help decide whether to establish
condition-speciﬁc data accrual patterns.
To the best of our knowledge, this is the ﬁrst in-depth
analysis of recording delays in CPRD. Sammon and
Petersen13 recently examined the number of records
lost as a function of last collection date, to inform inci-
dence or prevalence studies. Our study complements
and extends this work by quantifying delays for
selected conditions and investigating how their charac-
teristics affect delays. Our study is novel in showing
the limitations of using system dates, and we have
proposed a simple approach to minimize the effects
of these limitations that are relevant to those planning
surveillance using CPRD. We also provide the ﬁrst
analyses of both completeness and timeliness of
recording of these four speciﬁc conditions in CPRD.
This study is subject to some limitations. Firstly,
measurement error in delays in stand-alone CPRD
may have resulted from errors in system and event
dates. We addressed misclassiﬁcation of system dates
by excluding dates that were likely to have been part
of mass transfers. As we did not take an unduly low
threshold, we may have included some transferred sys-
tem dates and thus overestimated delays. However,
our exclusion of delays >1 year should have mini-
mized this issue. Furthermore, if the same criteria are
applied to a future NRTVSS, inclusion of these re-
cords should not bias results. The event date is also
an imperfect measure of the date of diagnosis. When
entering diagnoses made elsewhere, GPs might insert
the diagnosis date, but alternatively, the date of hospi-
tal admission or discharge, the date the hospital letter
was received or the date of data entry. For the latter
three scenarios, our delays (the difference between
system and event dates) would be underestimated.
However, if this coding behaviour is constant over
time, any adjustments made in the future considering
our results would be valid. Furthermore, the choice
of code lists affects the validity of cases. We did not
validate the code lists directly, but assessed the poten-
tial effects of imperfect validity by using code lists
with different levels of sensitivity. The use of a more
speciﬁc code list did not substantially affect our re-
sults. When implementing a new system, this should
be further assessed; previous analyses suggest that a
more sensitive code list might produce more timely re-
sults.18 Finally, we did not quantify the uncertainty
around the data accrual estimates in CPRD. However,
our sensitivity analysis describing yearly patterns
showed stable results, suggesting it is appropriate to
use our distributions for future adjustments.
In conclusion, this work shows that most diagnoses
recorded in stand-alone CPRD accrued within the
ﬁrst month, making NRTVSS possible. The distribu-
tion of delays was condition-speciﬁc, and the weekly
delay distribution could be used to adjust for delays
in the NRTVSS analysis. CPRD can be a viable data
source to use in this kind of analysis; next steps will
include trial implementation of the system using
these data.
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KEY POINTS
• Near real-time vaccine safety surveillance using
electronic health records is one of the methods
available to detect vaccine safety signals. It
requires timely data.
• The Clinical Practice Research Datalink (CPRD)
is a potential data source for this surveillance.
• Delays in recording of events in CPRD will limit
its utility, and delays were found to vary by
condition. For Bell’s palsy and febrile seizures,
events were recorded sooner than for Guillain–
Barré syndrome and optic neuritis. For all these
conditions, most events documented by practices
were recorded within the ﬁrst month of the
presumed diagnosis date.
• Records of Guillain–Barré syndrome, Bell’s
palsy, optic neuritis and febrile seizures
diagnosed in hospital have low completeness of
recording in CPRD, with less than 50% recorded
within a year of the hospital admission date.
• The CPRD is a feasible data source to implement
near real-time surveillance, although sensitivity
of recording of events ﬁrst seen at hospital may
be low.
a. leite et al.444
© 2017 The Authors. Pharmacoepidemiology & Drug Safety
Published by John Wiley & Sons Ltd.
Pharmacoepidemiology and Drug Safety, 2017; 26: 437–445
DOI: 10.1002/pds
ETHICS STATEMENT
All data were anonymized prior to receipt by the
authors. Ethics approval for the study was given by
the Independent Scientiﬁc and Advisory Committee
(of CPRD) and the London School of Hygiene and
Tropical Medicine Ethics Committee.
ACKNOWLEDGEMENTS
The research was funded by the National Institute for
Health Research Health Protection Research Unit
(NIHR HPRU) in Immunisation at the London School
of Hygiene and Tropical Medicine in partnership with
Public Health England. The views expressed are those
of the author(s) and not necessarily those of the NHS,
the NIHR, the Department of Health or Public Health
England. The funders had no role in the study design,
data collection, analysis or interpretation.
REFERENCES
1. Herrett E, Gallagher AM, et al. Data resource proﬁle: Clinical Practice Research
Datalink (CPRD). Int J Epidemiol 2015; 44: 827–836.
2. Alexandropoulou K, van Vlymen J, Reid F, Poullis A, Kang JY. Temporal trends
of Barrett’s oesophagus and gastro-oesophageal reﬂux and related oesophageal
cancer over a 10-year period in England and Wales and associated proton pump
inhibitor and H2RA prescriptions: a GPRD study. Eur J Gastroenterol Hepatol
2013; 25: 15–21.
3. Millett ER, Quint JK, Smeeth L, Daniel RM, Thomas SL. Incidence of
community-acquired lower respiratory tract infections and pneumonia among
older adults in the United Kingdom: a population-based study. PLoS One
2013; 8: e75131.
4. West J, Fleming KM, Tata LJ, Card TR, Crooks CJ. Incidence and prevalence of
celiac disease and dermatitis herpetiformis in the UK over two decades:
population-based study. Am J Gastroenterol 2014; 109: 757–768.
5. Clarke AT, Johnson PC, Hall GC, Ford I, Mills PR. High dose atorvastatin
associated with increased risk of signiﬁcant hepatotoxicity in comparison to
simvastatin in UK GPRD cohort. PLoS One 2016; 11: e0148349.
6. Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk
of Guillain Barré syndrome following inﬂuenza A (H1N1) 2009 monovalent
vaccines. Vaccine 2013; 31: 4448–4458.
7. Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive
developmental disorders: a case–control study. Lancet 2004; 364: 963–969.
8. Stowe J, Andrews N, Bryan P, Seabroke S, Miller E. Risk of convulsions in
children after monovalent H1N1 (2009) and trivalent inﬂuenza vaccines: a
database study. Vaccine 2011; 29: 9467–9472.
9. Johansson S, Wallander MA, de Abajo FJ, García Rodríguez LA. Prospective
drug safety monitoring using the UK Primary-Care General Practice Research
Database. Drug Saf 2010; 33: 223–232.
10. Leite A, Andrews NJ, Thomas SL. Near real-time vaccine safety surveillance
using electronic health records—a systematic review of the application of statis-
tical methods. Pharmacoepidemiol Drug Saf 2016; 25: 225–237.
11. Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bi-
valent human papillomavirus vaccine and the risk of fatigue syndromes in girls in
the UK. Vaccine 2013; 31: 4961–4967.
12. Greene SK, Kulldorff M, Yin R, et al. Near real-time vaccine safety surveillance
with partially accrued data. Pharmacoepidemiol Drug Saf 2011; 20: 583–590.
13. Sammon CJ, Petersen I. Backdating of events in electronic primary health care
data: should one censor at the date of last data collection. Pharmacoepidemiol
Drug Saf 2016; 25: 378–384.
14. Crooks CJ, Card TR, West J. Deﬁning upper gastrointestinal bleeding from
linked primary and secondary care data and the effect on occurrence and
28 day mortality. BMC Health Serv Res 2012; 12: 1–9.
15. Herrett E, Shah AD, Boggon R, et al. Completeness and diagnostic validity of
recording acute myocardial infarction events in primary care, hospital care,
disease registry, and national mortality records: cohort study. BMJ 2013;
346: f2350.
16. Millett ERC, Quint JK, De Stavola BL, Smeeth L, Thomas SL. Improved inci-
dence estimates from linked vs. stand-alone electronic health records. J Clin
Epidemiol 2016; 75: 66–69.
17. Health and Social Care Information Centre. Hospital Episode Statistics. 2015.
http://www.hscic.gov.uk/hes (accessed 25 July 2016).
18. Maro JC, Brown JS, Dal Pan GJ, Kulldorff M. Minimizing signal detection time
in postmarket sequential analysis: balancing positive predictive value and sensi-
tivity. Pharmacoepidemiol Drug Saf 2014; 23: 839–848.
19. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time
since registration and measured incidence rates in the General Practice Research
Database. Pharmacoepidemiol Drug Saf 2005; 14: 443–451.
20. Gallagher AM, Williams T, Leufkens HG, de Vries F. The impact of the choice
of data source in record linkage studies estimating mortality in venous thrombo-
embolism. PLoS One 2016; 11: e0148349.
SUPPORTING INFORMATION
Additional supporting information may be found in
the online version of this article at the publisher’s
web site.
recording delays in CPRD 445
© 2017 The Authors. Pharmacoepidemiology & Drug Safety
Published by John Wiley & Sons Ltd.
Pharmacoepidemiology and Drug Safety, 2017; 26: 437–445
DOI: 10.1002/pds
 125 
 
5.4 Code-lists used for the in-depth delays assessment 
The code-lists used for the analysis reported in Paper 2 (presented in Section 5.3) are 
available below. This corresponds to Appendix A of the supporting information of the paper. 
As explained in the paper, the main analysis used a less specific Read codes list, followed by 
a sensitivity analysis using a more specific set of Read codes. The lists used in the main 
analysis are presented and the codes considered for the sensitivity analysis are highlighted 
in each list. The methods used to obtain these lists are detailed in Section 3.2. Results from 
the sensitivity analysis are presented in Section 5.5. 
5.4.1 Guillain-Barré syndrome  
5.4.1.1 CPRD 
Read code Read term 
F370000 Guillain-Barre syndrome 
F370200 Miller-Fisher syndrome 
F370.00 Acute infective polyneuritis 
F37X.00 Inflammatory polyneuropathy, unspecified 
F37y.00 Other toxic or inflammatory neuropathy 
F37z.00 Toxic or inflammatory neuropathy NOS 
F370z00 Acute infective polyneuritis NOS 
F370100 Postinfectious polyneuritis 
F37..00 Inflammatory and toxic neuropathy 
Fyu7100 [X]Other inflammatory polyneuropathies 
Fyu7B00 [X]Inflammatory polyneuropathy, unspecified 
F21X.00 Acute disseminated demyelination, unspecified 
Fyu4200 [X]Acute disseminated demyelination, unspecified 
Fyu4000 [X]Other specified acute disseminated demyelination 
5.4.1.2 HES 
ICD-10 Description 
G61.0 Guillain-Barré syndrome 
 
5.4.2 Bell’s palsy 
5.4.2.1 CPRD 
Read code Read term  
1476 H/O: Bell's palsy*  
F310.00 Bell's (facial) palsy  
F31z.00 Facial nerve disorder NOS  
F31..00 Facial nerve disorders  
2BR6.00 O/E -cranial nerve 7-palsy-LMN  
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Read code Read term  
2BR7.00 O/E -cranial 7 -paralysis -LMN  
*Patients with a first diagnosis of history of Bell’s palsy were excluded to avoid retrospective recording  
5.4.2.2 HES 
ICD-10 Description 
G51.0 Bell's palsy 
 
5.4.3 Optic Neuritis 
5.4.3.1 CPRD 
Read code Read term 
F210.00 Neuromyelitis optica 
F4H3z00 Optic neuritis NOS 
F4Hz.00 Disorder of optic nerve or visual pathway NOS 
F4H3.00 Optic neuritis 
F4H5z00 Optic chiasm disorder NOS 
F4H..00 Disorders of optic nerve and visual pathways 
F4H4z00 Other optic nerve disorder NOS 
F4H4.00 Other optic nerve disorders 
F210.11 Devic's disease 
F4H5.00 Optic chiasm disorders 
F4H3000 Unspecified optic neuritis 
F4H6z00 Other visual pathway disorder NOS 
FyuJ.00 [X]Disorders of optic nerve and visual pathway 
F4H3200 Acute retrobulbar neuritis 
5.4.3.2 HES 
ICD-10 Description 
H46 Optic neuritis 
 
5.4.4 Seizures 
5.4.4.1 CPRD 
Read code Read term 
R003400 [D]Nocturnal seizure 
F25H.00 Generalised seizure 
1B27.00 Seizures in response to acute event 
1B63.00 Had a fit 
1B63.11 Fit - had one, symptom 
1B64.00 Had a convulsion 
1B64.11 Convulsion - symptom 
1B6B.00 Febrile convulsion 
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Read code Read term 
282..00 O/E - fit/convulsion 
282..11 O/E - a convulsion 
282..12 O/E - a fit 
282..13 O/E - a seizure 
2822 O/E - grand mal fit 
2823 O/E - petit mal fit 
2824 O/E - focal (Jacksonian) fit 
2824.11 O/E - Jacksonian fit 
2824.12 O/E - focal fit 
2825 O/E - psychomotor fit 
2827 O/E - febrile convulsion 
2828 Absence seizure 
282Z.00 O/E - fit/convulsion NOS 
F132z12 Myoclonic seizure 
F250011 Epileptic absences 
F250200 Epileptic seizures - atonic 
F250300 Epileptic seizures - akinetic 
F251200 Epileptic seizures - clonic 
F251300 Epileptic seizures - myoclonic 
F251400 Epileptic seizures - tonic 
F251600 Grand mal seizure 
F251y00 Other specified generalised convulsive epilepsy 
F252.00 Petit mal status 
F253.00 Grand mal status 
F253.11 Status epilepticus 
F254500 Complex partial epileptic seizure 
F255600 Simple partial epileptic seizure 
F256.00 Infantile spasms 
F256.11 Lightning spasms 
F256z00 Infantile spasms NOS 
F25X.00 Status epilepticus, unspecified 
F25y300 Complex partial status epilepticus 
F25z.11 Fit (in known epileptic) NOS 
Fyu5900 [X]Status epilepticus, unspecified 
Fyu5200 [X]Other status epilepticus 
Q480.00 Convulsions in newborn 
Q480.11 Fits in newborn 
Q480.12 Seizures in newborn 
R003.00 [D]Convulsions 
R003000 [D]Convulsions, febrile 
R003011 [D]Pyrexial convulsion 
R003100 [D]Convulsions, infantile 
R003200 [D]Fit 
R003211 [D]Fit (in non epileptic) NOS 
R003y00 [D]Other specified convulsion 
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Read code Read term 
R003z00 [D]Convulsion NOS 
R003z11 [D]Seizure NOS 
Ryu7100 [X]Other and unspecified convulsions 
Eu44511 [x]pseudoseizures 
5.4.4.2 HES 
ICD-10 Description 
R56.0 Febrile convulsions 
5.5 In-depth delays assessment: sensitivity analyses  
The in-depth delays analysis, presented in Section 5.3, included several sensitivity analyses, 
published as supporting information, and assessing three aspects of the analyses conducted. 
The first sensitivity analysis attempted to assess the effect of imperfect validity of the code-
lists used for outcome ascertainment. For this analysis, a more specific code-list was used 
and the results are presented in Section 5.5.1. The second sensitivity analysis assessed trends 
in recording delays over time (both for the main and secondary analysis) and is presented in 
Section 5.5.2. The third and final analysis assessed how completeness changed if patients 
with a prior record in CPRD were included in the cohort (see Section 5.5.3).  
5.5.1 Specific code-lists 
The code-lists used in this thesis have not been validated. However, it has been previously 
suggested that using an initial code-list in the main analysis, followed by a sensitivity analysis 
using another code-list with a different level of specificity, might be used as an indication of 
the quality of recording.85 This strategy was used for the Read-code lists; in the main analysis, 
a broader code-list was used, followed by a sensitivity analysis with a more restricted set of 
codes. For the secondary analysis (using linked CPRD-HES data) to identify outcomes in CPRD, 
the strategy described above was followed (a broader code-list in the main analysis and a 
more specific one in the sensitivity analysis). In contrast, each outcome in HES data was 
identified using a single ICD-10 code-list that was designed to include only more specific 
codes. The approach of selecting more specific codes in HES data was deemed to result in a 
higher positive predictive value (compared to a less specific code-list), allowing capture of 
less false positive diagnoses (which would not require a subsequent record in CPRD). 
Figure 5.2 shows the results of the sensitivity analysis of the data accrual process in CPRD 
using a more specific set of Read-codes for all the outcomes studied and corresponds to 
Appendix B of the supporting information. Overall, the patterns were similar to the ones 
observed in the main analysis using a broader code-list (see Figure 3 in Section 5.3), with a 
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few noticeable differences for febrile seizures and Guillain-Barré syndrome. For febrile 
seizures, using a more specific code-list resulted in a more delayed data accrual pattern, with 
less than 20% of the records being recorded on the same day of the event (compared to 
around 40% in the main analysis). Nevertheless, this difference seems to be mainly in the 
first few days after the event and after the second week after the event date the patterns 
became very similar. For Guillain-Barré syndrome, the use of a more specific code-list led to 
a more delayed data accrual throughout the analysis period but the extent of the additional 
delay was minimal. For both outcomes, the differences observed are unlikely to affect the 
implementation of a near-real time system.  
 
 
Figure 5.2. Weekly data accrual in CPRD across 52 weeks considering diagnosis made until June 2014 and using a 
specific set of read-codes. BP – Bell’s palsy, FS – Febrile seizures, GBS – Guillain-Barré syndrome, ON – Optic 
neuritis. 
 
The results of the sensitivity analysis using a more specific set of Read-codes for the 
completeness analysis using linked CPRD-HES data (Figure 5.3, originally published as 
Appendix E of the paper’s supporting information) are also very consistent with those of the 
analysis presented in the paper (see Figure 4 in Section 5.3). The overall accrual pattern 
overlaps with the one observed and completeness at one year is similar. The results of this 
sensitivity analysis indicate that the use of less specific codes does not affect completeness 
of recording.  
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Figure 5.3. Kaplan-Meier recording estimates considering a first record in HES and a subsequent record in CPRD, 
using a specific set of read-codes. BP – Bell’s palsy, FS – Febrile seizures, GBS – Guillain-Barré syndrome, ON – 
Optic neuritis.  
 
5.5.2 Data accrual per calendar year  
The analyses presented in Section 5.3 used ten years of data and assumed that there were 
no differences in data accrual over time. However, recording behaviours might not be 
constant throughout time, thus limiting the utilisation of these results in a future system. To 
assess this issue, I compared data accrual patterns by year. The results for the stand-alone 
CPRD data are displayed in Figure 5.4 and results for the linked CPRD-HES data are presented 
in Table 5.2 (results presented in Appendix C of the paper’s supporting information). Figure 
5.4 shows extremely consistent patterns in each year for Bell’s palsy and febrile seizures. 
Results for Guillain-Barré syndrome and optic neuritis have a good overlap but present more 
variability. This is likely to be related to the smaller number of records for these two 
outcomes, particularly for Guillain-Barré syndrome, which showed higher variability. Similar 
results were observed using linked CPRD-HES data (Table 5.2). These results are reassuring 
when considering use of the overall data accrual distribution to adjust for delays in the 
implementation study (see Sections 5.3 and 6.3).  
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Figure 5.4. Comparison of the data accrual in CPRD per year of diagnosis considering the records made within one 
year, by condition of interest. BP – Bell’s palsy, FS – Febrile seizures, GBS – Guillain-Barré syndrome, ON – Optic 
neuritis. 
 
Table 5.2. Median (Q1-Q3) number of days of data accrual for the conditions studied and years included.  
Year GBS  Bell's Palsy Optic Neuritis  FS 
2005 8 (0 - 45) 0 (0 - 0) 12 (0 - 28) 3 (0 - 14) 
2006 6 (0 - 34) 0 (0 - 1) 12 (0 - 25) 4 (0 - 16) 
2007 9 (0 - 28) 0 (0 - 1) 14 (0 - 31) 4 (0 - 16) 
2008 12 (0 - 37) 0 (0 - 1) 10 (0 - 21) 4 (0 - 16) 
2009 14 (0 - 37) 0 (0 - 2) 12 (0 - 28) 4 (0 - 15) 
2010 13 (0 - 41) 0 (0 - 4) 13 (0 - 32) 4 (0 - 15) 
2011 12 (0 - 30) 0 (0 - 3) 12 (0 - 30) 5 (0 - 16) 
2012 11 (0 - 25) 0 (0 - 3) 10 (0 - 26) 4 (0 - 15) 
2013 12 (0 - 31) 0 (0 - 3) 13 (2 - 38) 4 (0 - 14) 
2014 9 (0 - 31) 0 (0 - 5) 14 (4 - 36) 4 (0 - 14) 
*Considering the start of episode date in the hospital data. FS – Febrile seizures, GBS - Guillain-Barré 
syndrome. 
 
5.5.3 Inclusion of patients with a previous diagnostic record in CPRD  
The last sensitivity analysis assessed the effect of having conducted the completeness 
analysis only on patients with no previous recording of the outcome of interest in CPRD. The 
results of this analysis that considered all patients are presented in Figure 5.5 (originally 
published as Appendix D of the paper’s supporting information), with no appreciable 
differences from Figure 4 of the Section 5.3. When all patients were considered, 
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completeness at one year decreased for febrile seizures and Guillain-Barré syndrome and 
increased for Bell’s palsy and optic neuritis. For all outcomes, absolute differences were 
lower than 4%, showing the results are not sensitive to changes in the cohort.  
 
Figure 5.5. Kaplan-Meier recording estimates considering an event as having a record in CPRD at any time. 
Patients with a record in CPRD prior to HES were considered to have a follow-up of one day. Completeness at one 
year (%, 95% confidence interval) was: BP - 30.7 (29.4-32.1); FS - 43.9 (42.9-45.0); GBS - 43.3 (39.6-47.1); ON - 
30.3 (26.6-34.5). BP – Bell’s palsy, FS – Febrile seizures, GBS – Guillain-Barré syndrome, ON – Optic neuritis.  
 
Overall, the three sensitivity analyses indicate that the results from the study assessing 
delays in recording outcomes in CPRD are robust and can be used when implementing a near 
real-time system and adjusting for delays. An in-depth explanation of the impact of delays 
and possible adjustment for delays is presented in the next Chapter.  
5.6 Overall discussion and conclusions 
The initial feasibility assessment showed CPRD meets some of the conditions necessary to 
implement near real-time vaccine safety surveillance: it is population-based, has good 
validity (based on the existing data) and data are timely enough to allow a real-time activity. 
To proceed with the detailed feasibility assessment, it was necessary to select the 
vaccine/outcome pairs. Due to the need to prepare all the data and explore the issues arising 
from the system implementation, only two pairs were selected (seasonal influenza 
vaccine/Guillain-Barré syndrome and MMR/febrile seizures). The selection was based on 
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consideration of the outcome characteristics (as explained above in the in-depth delays 
assessment) but also the existing vaccines and the frequency of the outcome. Having two 
outcomes with different characteristics allowed the implementation of a system within the 
time frame available and, at the same time, ensured the implementation study captured a 
wider diversity of issues. For example, having both a rarer and a more frequent outcome 
allowed the use of PMaxSPRT and BMaxSPRT (see 4.1 and 7.1).   
When selecting the outcomes, only the outcomes included in the in-depth delays assessment 
were considered. This was to ensure that the delay distribution was known as the system 
included an adjustment for delays, based on the delay distribution (see Section 6.3). Rare 
outcomes were also given preference as a way to understand the power available to detect 
a signal with a small number of events.  
For the vaccines, CPRD has been used in several hypothesis-confirmation vaccine safety 
studies and vaccination records are considered to be complete for vaccines such as MMR160 
(for which general practices are financially incentivised87) but it is not anticipated to 
constitute a good source for vaccines administered outside general practice such as HPV. 
Thus, only vaccines administered in general practice were included.  
After consideration, the pairs selected were seasonal influenza vaccine/Guillain-Barré 
syndrome and MMR/febrile seizures. Guillain-Barré syndrome was deemed to exemplify a 
rare outcome, which is often assessed following seasonal influenza vaccine. This vaccine was 
also considered to be of particular relevance, owing to the specific characteristics of its 
schedule. As seasonal influenza vaccines change on a yearly basis and administration occurs 
within a short period of time there is limited time to detect a signal and implement measures 
should one be identified. For the analysis of this pair, only individuals aged 65 years and 
above were included as this is the group of adults for which the vaccine is universally 
recommended and administered in practices. Regarding MMR/febrile seizures, the decision 
was mainly driven by the known increase in febrile seizures following MMR.75 This pair thus 
served as a positive control. It also met other requirements for its selection: MMR is one of 
the childhood vaccines administered in practices and febrile seizures is a more frequent 
outcome in the age group of interest than Guillain-Barré syndrome. By selecting these pairs 
diversity was achieved – a rare outcome following an adult vaccine and a more frequent one 
following a childhood vaccine, which simultaneously served as a positive control.  
The work conducted to trial the implementation of a near real-time system is presented in 
Chapter 7. Before this, in the next Chapter, data-related aspects of implementing a system 
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are explained and their implications discussed. These aspects include issues with the data 
available to conduct the implementation study using previously collected data and 
implications of delays for the implementation.      
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6 PRACTICAL ASPECTS FOR IMPLEMENTING A NEAR REAL-TIME 
SYSTEM USING CPRD DATA 
6.1 Introduction 
Following the selection of seasonal influenza vaccine/GBS and MMR/febrile seizures as 
vaccine/outcome pairs to assess, and before performing the actual implementation of 
NRTVSS in CPRD, it was necessary to reflect on the data available and how that could affect 
the implementation. This included aspects related to the data that could be used for analysis 
(i.e. the data stored in-house at LSHTM and/or data potentially extracted online, see 3.1.1.3) 
and delays in recording and receiving data (explained in Section 5.3). This Chapter starts by 
expanding on the data availability described in Section 3.1.1.3 and explains how this 
influenced the implementation study, presented in Chapter 7. Following that, it builds on the 
delays paper presented in Section 5.3 and discusses the influence of these delays on the 
implementation of the system, as well as possible adjustments. Overall, this Chapter 
provides a rationale for the data used in the implementation study.  
6.2 Issues with data extraction for the implementation study 
The implementation study presented in Chapter 7 used a monthly sequential time-step, as 
this is the frequency of CPRD data releases. Ideally, it would be possible to extract data 
monthly, however, at the moment, this is limited by the online search tool used to extract 
data, which does not allow searches of special immunisation codes in the immunisation file 
that are required to identify vaccinated individuals (see Sections 3.1.1.3 and 3.2). An 
alternative to get around this issue would be to extract data online for all individuals targeted 
by the vaccine of interest (for example, all those aged 65 years older and above) and then 
apply the algorithms developed to identify vaccinated individuals to this dataset. This option 
would result in the extraction of large amounts of data and would therefore demand more 
computational power. It would also require special ethics permission (special permission is 
required when the number of individuals in a CPRD study is greater than one million).  
To overcome these issues the solution was to use the LSHTM in-house version of the data. 
These data allow for searches of Read codes, therapy codes and specific vaccination 
information contained in the immunisation file, thus allowing extraction of information on a 
limited number of individuals (only those potentially vaccinated). However, LSHTM only 
receives new CPRD data every six months, therefore using these data required the 
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identification of when each record accrued, i.e. in which monthly version of the data it would 
be available for the first time. For example, if data released in July 2016 (one of the data 
releases used, see Section 7.1) are used for analysis it is necessary to identify which data 
were available in the June 2016 release, in the May 2016 release, and so on (see Figure 6.1). 
This can be done by using the last collection date for each practice in each monthly version 
of the data and the dates of each monthly release. Events with a system date and last 
collection date before the date of each monthly release would be included in a given monthly 
release of the data. To conduct the implementation study, practice files from each monthly 
release were thus requested from CPRD to identify the last collection dates. This solution 
minimised the amount of data to extract and the amount of data requested from CPRD and 
was considered the most appropriate for the purposes of mimicking a near real-time system 
in the implementation study. Implications for the use of this system in practice and 
alternative approaches are presented in the discussion (Section 8.4).   
Figure 6.1. Reconstruction of the data accrual process. Arrows in grey represent the data releases not available to 
LSHTM. Based on the data available (July 2016) it was necessary to identify which data were available in the 
previous releases  
6.3 Options to adjust for delays in CPRD  
As previously explained, near real-time vaccine safety surveillance requires timely and 
readily available data but availability of diagnostic data in CPRD is subject to a variety of 
different delays: (i) delays in physicians making a diagnosis after an initial consultation; (ii) 
recording delays; (iii) delays in data being uploaded to data providers; (iv) delays in uploaded 
data being made available to researchers. These delays might make it difficult or impossible 
to implement a system, particularly for vaccines requiring a very timely detection of adverse 
events, such as seasonal influenza. To the best of my knowledge there is no work analysing 
delays in diagnosing a condition in the context of near real-time vaccine safety surveillance. 
Such investigation is beyond the scope of a near real-time system but this type of delay is 
likely to result in random misclassification of the outcome in and outside the risk-window 
(conditions which started before the risk-window are recorded during the risk-window and 
vice-versa) thus biasing the analysis towards the null. The systematic review presented in 
Section 4.1 showed delays in existing systems due to other reasons were dealt with in two 
July 2016
June 2016
May 2016
...
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main ways: (a) delaying the analysis for some weeks; (b) adjusting for delays based on a 
historical delay distribution. The adjustments considered by the systems identified in the 
review focused on delays due to data being unavailable to researchers and were based on 
historical data.113 Site-specific distributions of data accrual were generated and used to 
adjust the number of expected events when using PMaxSPRT, by applying the proportion of 
data estimated to be received by a certain time. For example if, based on historical data, the 
number of expected cases during the first week was ten but only 50% of the data were 
available after the first week, then the adjusted number of expected cases was five. If no 
adjustment were implemented, we would consider ten expected cases, thus overestimating 
the number of expected cases, which in turn would bias the analysis towards no signal. This 
simple approach is only possible if we assume that an underlying distribution of delays exists 
and is constant over time.  
CPRD data structure differs from the data sources used previously to perform near real-time 
vaccine safety surveillance. Practices upload data at different times, and information of the 
time of uploading is available in the data (last collection date) but all data are released to 
researchers simultaneously. As some of the outcomes of interest are diagnoses made mainly 
in secondary care (for example Guillain-Barré syndrome) it is also important to consider 
delays due to recording feedback from other levels of care. The effect of these delays on the 
implementation of the system depends on the test used. As PMaxSPRT and BMaxSPRT were 
the tests selected to implement a system (see Section 7.1) an explanation on the effects on 
delays is provided for these two tests. 
6.3.1 PMaxSPRT 
The work presented in Section 5.3 described delays in recording selected conditions of 
interest for near real-time vaccine safety surveillance. The knowledge generated from these 
analyses can also be used to adjust for these types of delays. It is thus important to consider 
different ways to carry out these adjustments and how to best implement them in light of 
the CPRD structure.  
Delays in obtaining data available for analysis are important, due to biases related to 
differences in the accrual of case and comparator data. In the case of PMaxSPRT the 
comparison is an observed vs. expected number of cases. Therefore, delays need to be taken 
into account if there is differential data accrual in the observed and expected cases. As 
explained in Section 7.1, PMaxSPRT is implemented by applying a historical rate to a follow-
up period. As this follow-up period uses the last collection date when calculating rates there 
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is no differential data accrual due to delays in practices uploading data. Nevertheless, as 
explored in Section 7.4, this source of delay might lead to a decrease in power.  
On the other hand, delays in recording outcomes will lead to biased results if unaccounted 
for. This happens because the rates calculated to generate the number of expected events 
are based on historical (stable) data where delays do not affect the rates, whilst the observed 
number of cases is subject to recording delays because they are obtained closer to the time 
of the last collection date from the practice and therefore there is less time for data to 
accrue. Overall, the bias would be towards the null, resulting in loss of power to identify a 
signal. The issue is represented in Figure 6.2 where four patients with an outcome of interest 
and different recording patterns are depicted.  
Figure 6.2. Potential patterns of recording for four patients experiencing the outcome of interest within the risk 
window. A. represents what would be observed using stable data and B. what would be observed in recent data. 
lcd - last collection date 
 
For the purposes of this explanation, it is assumed the system date represents the date the 
event was entered in the patient’s record. Figure 6.2 A shows that the outcome might be 
Data release 
Vaccination 
Risk window 
P1 
P2 
P3 
P4 
A. 
4 events: 
P1 – Outcome only gets recorded after lcd 
P2 – Outcome only happens after lcd 
P3 – Outcome happens and is recorded within the risk window and before lcd 
P4 – Outcome is recorded after the risk window but before lcd.  
X 
X 
X 
X 
Event date 
System date 
X  lcd 
Data release 
Vaccination 
Risk-window 
P1 
P2 
P3 
P4 
B. 
Only 2 events will appear in the most recent version of the data as P1 and P2 were only 
recorded after the last collection date.  
X 
X 
X 
X 
Event date 
System date 
X  lcd 
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recorded at different times: outside the risk-window and after data have been uploaded for 
the next data release (P1); during the risk-window but after data have been uploaded for the 
next release (P2); during the risk-window and before data have been uploaded (P3); or 
outside the risk-window, before the data are uploaded for the next data release (P4). Figure 
6.2 B represents what would be observed in the most recent version of the data: only two of 
the four events would be captured, given that the remaining two events were recorded after 
the data were uploaded. The missing events would only be observed in later versions of the 
data.  
From the other two sources of delays (recording outcomes and receiving data) and when 
using PMaxSPRT, delays in recording are the delays that require adjustment. Below, possible 
ways to implement this adjustment are presented and discussed. 
1. Apply a single recording delay distribution at the patient level – Data accrual 
depends on the outcome of interest as seen in Section 5.3, but also on the time 
available for data to accrue (the longer the available time, the more data will accrue). 
When considering observed events in a post-vaccination risk-window the latter will 
vary from patient to patient depending on the time between the date of vaccination 
and last collection date. To allow for the delays, the observed number of events 
could be increased according to the delay distribution, but increasing the number of 
observed events would artificially inflate power to detect a signal. A better solution 
is to keep the observed number, but reduce each individual’s follow-up time based 
on the previously generated delay distribution (see Section 5.3). The adjusted follow-
up time is then summed and the historical outcome rate is applied to the total 
adjusted follow-up. This adjustment helps to ensure the comparison of observed vs. 
expected is unbiased.  
The adjustment using the delay distribution can be done with different levels of 
complexity. A detailed adjustment would consider, for each individual, the interval 
between each day of the vaccine risk-window and the end of follow-up time. For 
each of these intervals, the proportion of records accrued within that number of days 
(from the delay distribution) is used. These proportions are then summed resulting 
in a patient-level adjusted follow-up time. For example, consider an outcome with a 
risk-window of two days and an individual with 60 days between the first day of the 
risk-window and the end of follow-up time. If the proportion of records accrued 
within 60 days is 0.80 and the corresponding proportion for 59 days is 0.78, then the 
adjusted follow-up time for that same patient would be 1.58 days (0.80+0.78) 
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instead of two. This correction is easy to apply to short risk-windows as illustrated in 
the example, but would require a huge analytical effort for long risk-windows such 
as the window considered for Guillain-Barré syndrome (42 days, see Section 7.1). A 
simpler way to implement the correction is to consider the risk-window mid-point 
and apply the correction based on the interval between this point and the end of 
follow-up time. The implementation is then similar to the one explained above but 
using a single interval and thus a single proportion of records accrued. This is a 
simplification of the data accrual process because it assumes the event would occur 
at the risk-window mid-point but does not require successive adjustments for each 
day. Figure 6.3 provides a representation of this adjustment using the same four 
hypothetical patients presented in Figure 6.2 and assuming a risk-window of 42 days. 
The first individual has an initial follow-up time of 42 days (corresponding to the risk-
window) and an interval of 30 days between the risk-window mid-point and end of 
follow-up. If 75% of the records are expected to accrue within 30 days then the 
adjusted follow-up is 22.5 days. This process is repeated for all patients and each 
adjusted follow-up is summed yielding the total adjusted follow-up time. The 
outcome rate is then applied to this follow-up time to obtain the adjusted number 
of expected events.  
A correction based on the mid-point is simple to implement, and relies on the delay 
distribution generated for the work previously conducted and presented in Section 
5.3. For these reasons, this was the adjustment used in the implementation study, 
reported in Section 7.1. Other options considered are presented below.  
Figure 6.3. Representation of data considered for adjustment of delays at the patient level. 
 
Data release 
Total follow-up time – 132 days 
Total adjusted follow-up time – 98.7 days 
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P3 X 
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30 
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60 days (r
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 = 80.0%) 
Vaccination 
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Event date 
System date 
r
d
   expected recording 
d days after the event 
X    lcd 
FU  Follow-up time 
FU = 42 days 
FU = 42 days 
FU = 5 days 
FU = 42 days 
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2. Consider the system date – Instead of using the event date and adjusting for delays 
it is possible to generate the outcome rate based on the system date, thus 
considering a recorded outcome rate instead of an outcome rate. Using the system 
date for outcomes can be done in different ways: 
a. Calculate the outcome rate by considering the events recorded within the 
historical period. This rate would be applied to the risk-window selected 
after vaccination, which would give the expected number of recorded cases 
within the risk-window. The observed and expected number of cases would 
be equivalent. However, this would capture events occurring before the 
vaccination but recorded in the risk-window, and would not include some 
events occurring in the risk period but recorded outside it. This random 
misclassification would thus give a biased estimate.  This option is depicted 
in Figure 6.4 using the same example from previous Figures. A fifth individual 
was included to capture the possibility of including events occurring before 
vaccination.   
Figure 6.4. Outcomes considered when the adjustment is based on the use of the system date.  
 
b. To avoid random misclassification it is necessary to consider both the system 
and event dates. In this case, only outcomes happening during the risk-
window and recorded during a season should be included. These are the 
events considered to calculate the observed number. To generate an 
equivalent historical rate representing this situation, it is necessary to 
consider vaccinated individuals in the historical data and then only include 
those who have had the event date within the risk-window and had an 
outcome recorded within the season and by the date of the monthly 
analysis. Additionally, and as explained in Section 6.2, it is important to know 
at which data release the record first appeared in the data. Figure 6.5 
Data release 
Vaccination 
Risk window 
P1 
P2 
P3 
P4 
Two events are considered but one occurred outside the risk window. Analysis is biased.  
X 
X 
X 
X 
Event date 
System date 
X  lcd P5 
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represents the events considered to calculate the historical rate and the 
observed number of events if the intention is to include events both 
occurring within the risk-window and being captured in a specific data 
release. This assessment is based on the last collection date for each data 
release. It thus assumes that practices upload their data at approximately 
the same time before each new release. Implementing this adjustment, 
would require assessment of the vaccination status for the entire historical 
period as well as information on the last collection date for each monthly 
release, for both the historical and study period.  
 
Figure 6.5. Events considered based on the system date before the next data release 
 
Option 2a was biased, hence not suitable for implementation. Options 1 and 2b are valid but 
present disadvantages as well as advantages. Option 1 was simple to implement and did not 
require additional data extraction and analysis as it used data generated for the analysis 
presented in Section 5.3. Option 2b would require information on vaccinated individuals for 
the historical period, as well as monthly information on the last collection date for this 
period. Additionally, it would result in a loss in power as the historical rate would be 
generated using less data.  Hence, Option 1 was selected and used in the implementation 
study (see Section 7.1). 
6.3.2 BMaxSPRT 
When implementing a near real-time system the issue of data availability goes beyond delays 
in recording and receiving data; it is necessary to consider periods (risk or comparison) that 
are to be included in the analysis but have not yet accrued. When applying PMaxSPRT to 
CPRD data, the latter issue is not relevant given that follow-up time is considered and 
therefore partially accrued risk-windows are implicitly accounted for. For BMaxSPRT that is 
Data release 
Vaccination 
Risk window 
P1 
P2 
P3 
P4 
Two events are considered in both observed and expected but requires more calculation of 
rates for vaccinated in historical seasons and lcd for each release of historical data  
X 
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Event date 
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X  lcd 
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not the case and so partially accrued periods need attention. Furthermore, delays in data 
accrual should also be taken into consideration. Below, the issues of partially accrued periods 
and delays in data availability are presented in the context of BMaxSPRT.  
6.3.2.1 Partially accrued periods 
BMaxSPRT using a self-controlled approach involves comparing the number of events 
occurring during the risk period with those occurring during the comparison period. The 
comparison period might be pre- or post-vaccination. For the former, if the risk-window is 
long and has not yet accrued, comparing events during the comparison and risk period might 
result in a biased estimate (underestimating the risk). The partially accrued period might 
result from an actual time constraint (with the period of interest in the future) or from a 
delay in receiving data from a practice. Despite being an issue with data delays, the latter is 
considered in this Section as the mechanism of bias is similar to that resulting from an actual 
partially accrued period. This is illustrated in Figure 6.6 considering CPRD’s data structure, 
for a vaccinated individual and a specific practice. If the data were uploaded on 28th March 
and the release occurred on 6th April and this period is within the comparison period, there 
would be no information regarding that interval.  
Figure 6.6. Schematic representation of data available for analysis for the risk and comparison periods, for a 
release and a specific patient. lcd – last collection date 
 
The issue of partially accrued periods in this context might be addressed in several ways, 
including: (i) shortening the comparison or risk period, (ii) including a pre-vaccination 
comparison period, and (iii) restricting the comparison to the period that has accrued in the 
risk/comparison window (e.g. for a pre-vaccination comparison window and a risk-window 
of 42 days, if only 14 days of the risk-window have elapsed then only the first 14 days of the 
comparison period are used).113 Options (i) and (ii) depend on the specific outcome to be 
studied, as its characteristics determine the period length. For Option (iii), in CPRD, 
individuals will have different time periods accrued due to practices uploading data at 
different time points. To take this structure into account and apply Option (iii) it is possible 
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to calculate the average number of days of the risk/comparison period that have accrued 
and consider only that time period for the equivalent period (comparison or risk, depending 
on which one comes first). Alternatively, it is possible to count the number of days accrued 
in each period for each patient, sum them and calculate the ratio of the comparison period 
to the risk period. This ratio can be used as a matching ratio in the BMaxSPRT (see Section 
3.3.2). As explained in 7.1, BMaxSPRT was used to assess febrile seizures following MMR and 
the latter adjustment option was preferred as it makes use of all the data available 
(compared to the use of an average accrued period). Additionally, the comparison period 
was split into pre- and post risk-window periods. This further minimised the issue of partially 
accrued periods. Figure 6.7 presents this adjustment together with the adjustment 
considered for delays in recording outcomes (see Section 6.3.2.2), for a specific individual.  
 
Data  
Observed Adjusted 
Period Period duration (days) 
Control 1 (c1) 5 4 
Risk 15 11 
Control 2 (c2) 7 4  
Ratio (control/risk) 
Control/Risk 5+7
15
≈ 0.8 4+4
11
≈ 0.7 
 
Figure 6.7. Adjustments for delays when using a binomial-based maximized sequential probability ratio test 
(BMaxSPRT). The number of days in each period is adjusted by the expected recording (r) and the ratio of adjusted 
days in the control and risk period is calculated for each patient. The patient-level ratios are then averaged and 
used as a matching ratio in the BMaxSPRT.  
 
6.3.2.2 Data accrual delays  
As explained for PMaxSPRT, delays can bias the analysis if the data being compared differ 
due to these delays. In the case of the previous test this can happen due to potential 
differences between the expected and observed number of events. In the case of BMaxSPRT 
the comparison is between periods that are adjacent or close together and involves data 
which accrued recently. Delays will matter if there are differences in the data accrual for the 
periods being compared. In the case of febrile seizures, the data accrual curve (see Section 
Vaccination 
Risk window 
rd   expected recording d 
days after the event 
X     last collection date 
Control period 
X 
Risk - 10 days (r10 = 75.0%) 
c1 - 15 days (r15 = 80.0%) 
c2 - 5 days (r5 = 60.0%) 
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5.3) indicates a rapid change in the accrual rate for the first five weeks, which includes the 
risk and comparison periods used in the implementation study (see Section 7.1). Therefore, 
the adjustment used for PMaxSPRT was also applied in this context, for each period 
considered. In this case, the proportion of data accrued (based on the interval between each 
period mid-point and last collection date) was applied to the number of days of that period, 
generating an adjusted number of days. This adjusted number of days was then summed 
across all individuals for each period (risk and comparison) and the ratio of the two adjusted 
periods was used to incorporate partially accrued periods as explained above. Figure 6.7 
summarizes the overall adjustment (for delays and partially accrued risk windows).  
 
In the next Chapter, the implementation of a near real-time system using CPRD is presented, 
using the LSHTM version of the data and the adjustments for delays both for PMaxSPRT and 
BMaxSPRT, as explained above.  
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7 IMPLEMENTING A NEAR REAL-TIME SYSTEM USING CPRD DATA 
Following selection of the vaccine/outcome pairs to include in the trial implementation 
(seasonal influenza vaccine/GBS and MMR/febrile seizures) and definition of adjustment for 
delays, I proceeded to perform the abovementioned implementation of a near real-time 
system using CPRD data. The current Chapter presents the issues related to this 
implementation. This encompasses assessment of both how to best implement a system and 
how to improve existing limitations. The Chapter starts by detailing how the trial 
implementation was performed; in particular, it contains information on the selection of the 
most appropriate statistical test to identify a signal, adjustment for delays, and calculation 
of power to detect a signal. This work has been written as a paper (Paper 3), included here. 
In addition to the work presented in the paper, I provide further information on the use of 
variable matching ratios when applying BMaxSPRT. 
As part of the work performed to trial the implementation of a system, I identified that there 
was limited power to recognise an increased risk of GBS following seasonal influenza. Existing 
delays in recording and receiving data for analysis can limit the data available to perform 
NRTVSS, thus decreasing power to detect a signal in a timely way. Therefore, I re-assessed 
power in the absence of delays. This work has also been written as a paper (Paper 4), which 
is included in this Chapter, after the explanation of variable matching ratios. The Chapter 
finishes with the main conclusions of the work conducted to implement a near real-time 
system and improve its performance.  
7.1 Trial implementation (Paper 3) 
This paper was published in Vaccine in October 2017. It reports the design and results of the 
trial implementation of a near real-time system using CPRD data.  
As outlined in Section 5.6, I selected two vaccine/outcome pairs to trial the implementation 
of a system: seasonal influenza vaccine/GBS as an example of a rare outcome and MMR 
vaccine/febrile seizures as a positive control and an example of a more frequent outcome. 
In this paper, I detail how implementation was performed (including the choice of the most 
appropriate statistical test to identify a safety signal and adjustment for delays). The final 
step to assess the feasibility of implementing a system (assessment of power, see Section 
5.1), was also performed at this stage by calculating the power to detect a signal. 
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For seasonal influenza/GBS I implemented a system for the 2013/2014 and 2014/2015 
influenza seasons; for MMR/seizures the surveillance period was July 2014-June 2015. I used 
the continuous PMaxSPRT for both pairs and the continuous BMaxSPRT for MMR/febrile 
seizures; power calculations were performed for detecting increases in relative risk (RR) from 
1.5-10. The results showed no signal for influenza/GBS in either season. Power to detect a 
signal was above 80% for detecting 4-fold increases in the risk of GBS following seasonal 
influenza vaccine. For MMR/seizures, there was a signal with PMaxSPRT but not with 
BMaxSPRT. Power was ≥80% for detecting 2.5-fold increases in the risk of febrile seizures, 
for both tests. These results show that CPRD can be used to implement NRTVSS to exclude 
large increases in the risk of rare outcomes after seasonal influenza and lower increases in 
risk for more frequent outcomes. 
This paper is supported by additional information, including code-lists to identify the 
outcomes studied, algorithms developed to identify vaccinated individuals, determination of 
follow-up time, adjustment for delays, and handling of repeated febrile seizure episodes 
(Appendix A to E in the paper, respectively). These appendices are presented in the thesis in 
a number of places: Appendix A was previously presented in Section 5.4, as these same code-
lists were used for the assessment of delays in recording GBS and febrile seizures (Chapter 
5). Appendix D (adjustment for delays) includes the graphical representation of the 
adjustment for delays considered for PMaxSPRT and BMaxSPRT; it was presented in Chapter 
6, in which the issue of delays was explained in detail (Figure 6.3 and Figure 6.7, respectively). 
The remaining appendices (B. Vaccinated individuals, C. Follow-up time, and E. Repeated 
febrile seizures episodes) are presented in order after Paper 3, in Section 7.2, below. 
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Introduction: Near real-time vaccine safety surveillance (NRTVSS) using electronic health records is
increasingly used to rapidly detect vaccine safety signals. NRTVSS has not been fully implemented in
the UK. We assessed the feasibility of implementing this surveillance using the UK Clinical Practice
Research Datalink (CPRD).
Methods: We selected seasonal influenza vaccine/Guillain-Barré Syndrome (GBS) as an example of a rare
outcome and measles-mumps-rubella (MMR) vaccine/febrile seizures as a positive control. For influenza/
GBS we implemented a system for the 2013/2014 and 2014/2015 influenza seasons; for MMR/seizures
the surveillance period was July 2014–June 2015. We used the continuous Poisson-based maximized
sequential probability ratio test (PMaxSPRT), comparing observed-to-expected events, for both pairs.
We calculated an age-sex-adjusted rate using 5 years of historic data and used this rate to calculate
the expected number of events in pre-specified post-vaccination risk-window (GBS: 0–42 days, seizures:
6–21 days). For MMR/seizures we also implemented the system using the Binominal-based maximized
sequential probability ratio test (BMaxSPRT). For this, we compared seizures in the risk-window
(6–21 days) to a control window (0–5 and 22–32 days). Delays in recording outcomes influence the data
available, so we adjusted the expected number of events using a historical distribution of delays in
recording GBS/febrile seizures. Analyses were run using data up to each CPRD monthly release. We also
performed power calculations for detecting increases in relative risk (RR) from 1.5 to 10.
Results: For influenza/GBS we implemented a system in both seasons with no signal. Power to detect a
signal was >80% for RR  4. For MMR/seizures we were able to identify a signal with PMaxSPRT but
not with BMaxSPRT. Power  80% for RR  2.5 for both tests.
Conclusion: CPRD is a potential data source to implement NRTVSS to exclude large increases in the risk of
rare outcomes after seasonal influenza and lower increases in risk for more frequent outcomes.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Near real-time vaccine safety surveillance (NRTVSS) using elec-
tronic health records is amongst the tools available to perform
post-licensure vaccine safety surveillance. NRTVSS is usually
started shortly after a new vaccine is introduced and data is anal-
ysed at repeated points in time. Near real-time surveillance was
introduced in the USA in 2005 first using the sequential probability
ratio test and later its maximized version. It is now used routinely
in this country [1]. It has allowed the identification of several
safety signals [2].
In the UK, there are electronic health records available such as
the Clinical Practice Research Datalink (CPRD). NRTVSS has been
implemented in the UK using spontaneous reports to obtain the
observed number of events and CPRD to calculate the expected
number of events. This implementation inherits spontaneous
reports limitations, including underreporting [3]. A NRTVSS fully
relying on electronic health records has not been implemented to
date.
When envisaging a new data source to implement NRTVSS
timeliness is a key consideration. In CPRD, delays can happen
due to: (i) delays in making a diagnosis after an initial consulta-
tion; (ii) delays in recording diagnosis made in other levels of care
(e.g. hospital); (iii) delays in receiving data for analysis. To the best
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of our knowledge, there has been no work to explore systemati-
cally the influence of (i) on recording patterns using CPRD data.
For (ii), a previous analysis of CPRD data looking at conditions of
interest for vaccine safety has shown that recording delays exist,
but the majority of records accrue within a month after the date
of the event [4]. Researchers receive CPRD data on a monthly basis
(delay (iii)). Thus, from the evidence to date CPRD is a potential
source of data to implement NRTVSS.
In addition to delays, several questions regarding the actual
implementation of a system using CPRD data remain unaddressed,
such as which statistical method to use, how to account for delays,
and whether there is enough power to identify safety signals. To
address these we sought to trial the implementation of NRTVSS
using previously collected CPRD data.
2. Methods
2.1. Data source
We used data from CPRD, a primary health care database with
anonymised health records from a broadly representative sample
(6.9%) of the UK population. CPRD includes information on demo-
graphics, coded diagnosis, therapies, vaccines, health-related beha-
viours, and referrals to secondary care [5]. Diagnoses recorded in
CPRD include diagnoses made both in primary care and in hospital.
Hospital diagnoses are fed back to GPs via letter, which are later
coded in the system. Diagnoses are coded using Read-codes, a hier-
archical thesaurus of clinical terms used in the UK since 1985 [6].
CPRD contains several relevant dates. For each patient there is
information on the patient’s current registration with the practice
(crd) and the patient left the practice (tod). Each record contains
the date when the record was entered into the system (system
date) and the date deemed to represent when the event registered
took place (event date). At the practice-level, CPRD includes the
date when the practice met certain recording quality criteria (up-
to-standard date, uts) and the date when data were last collected
from the practice before each monthly release (last collection date,
lcd) [5].
2.2. Vaccine/outcome pairs
We selected two pairs: seasonal influenza vaccine/Guillain-
Barré syndrome (GBS) and Measles-Mumps-Rubella (MMR) vac-
cine/febrile seizures. NRTVSS is of particular relevance to assess
seasonal influenza vaccine due to the short time available for
action, and GBS is a rare outcome of interest following influenza
vaccine. Influenza vaccine/GBS was thus chosen to assess the
potential of CPRD as a data source to implement NRTVSS for rare
events. Febrile seizures are a known adverse reaction seen after
MMR vaccine, so we selected this pair to represent a positive con-
trol and as an example of a somewhat less rare event with a child-
hood vaccine [7]. Appendix A presents code-lists used to identify
GBS/seizures and Appendix B the algorithms used to identify vac-
cinated individuals.
3. Analysis
3.1. Statistical tests
Choice of the statistical test to use should be guided by the test
characteristics (e.g. power and underlying assumptions), frequency
of data updates and frequency of the outcome under study. One
approach is to select first the general group of tests (continuous
or group sequential) and then choose a specific version of the test
[2]. For continuous tests, data are looked at as often as desired, and
ideally when a new event is observed, while for group sequential
tests data are interrogated at discrete points in time [2]. Previous
work has shown that continuous sequential tests perform better
than group sequential [8] and aggregate data (weekly or monthly)
can be used in a continuous way [9]. As CPRD is updated monthly,
we considered continuous sequential tests more appropriate.
Poisson-based Maximized Sequential Probability Ratio Test
(PMaxSPRT), the Binomial-based Maximized Sequential Probability
Ratio Test (BMaxSPRT), and the Conditional Maximized Sequential
Probability Ratio Test (CMaxSPRT) are the continuous sequential
tests available. PMaxSPRT involves a comparison observed-to-
expected and its use has been proposed when less than 50 events
are expected, as it is a more powerful test [2]. Disadvantages
include limited ability to adjust for confounders and potential bias
by secular or coding trends, as it relies on historical data. It also
does not allow for uncertainty in the expected count (it is taken
as a fixed expected number). BMaxSPRT compares the number of
events in exposed-to-unexposed individuals or in periods within
individuals. This allows further adjustment for potential con-
founders but lessens power. Unlike PMaxSPRT, CMaxSPRT was
designed to account for uncertainty in the historical data. The com-
parison is made in terms of the cumulative person-time it took to
observe a certain number of adverse events in the historical and
surveillance data. It assumes event rates are constant in both ver-
sions of the data.
Given the rarity of GBS we selected PMaxSPRT for influenza vac-
cine/GBS. For seizures/MMR the number of expected events was
still lower than 50 (see below), suggesting the use of PMaxSPRT.
However, previous works have also considered the simultaneous
use of PMaxSPRT and BMaxSPRT owing to their complementary
strengths [9]. We preferred this approach as it allowed us to fur-
ther identify challenges/potential solutions when using CPRD to
perform NRTVSS. It has been previously suggested that PMaxSPRT
gives biased results when a small sample is used to estimate the
number of expected events [10]. To avoid this, we used a long his-
torical period (5 years) to obtain more stable estimates and thus
reduce uncertainty to negligible levels relative to uncertainty in
the observed data. It has also been suggested as an ad hoc guideline
that an alternative test (CMaxSPRT) should be used when the num-
ber of observed events in the historical data is less than five times
the number of expected events in the surveillance data. We thus
assessed whether this ad hoc rule held in our data.
Below we detail how we obtained the observed and expected
numbers of events to implement PMaxSPRT for each pair. We
start with an explanation for seasonal influenza/GBS followed by
MMR/seizures. For the latter we emphasize aspects that differ from
the first pair. For BMaxSPRT we used a case-only design and
compared the number of cases during the exposed-to-unexposed
periods, also detailed below. Analyses were performed using R
package Sequential 2.3.1 [11].
3.2. Influenza/GBS
We studied the 2013/14 and 2014/15 seasons (1st September–
31st March), using data released in July 2015 and 2016, respec-
tively. Using these data releases allowed at least a year from the
event date for them to be recorded. In all analyses we did not con-
sider the small proportion of events that are recorded with a delay
>1 year [4].
3.2.1. Historical rates, expected and observed number of events
(PMaxSPRT)
For the historical comparison, we used the general background
rate of GBS among individuals aged 65 years as this is the age in
which seasonal influenza vaccine is routinely recommended and
given in GP practices. For each study season, we calculated GBS
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historical rates stratified by age (65–74, 75–84, 85 years old) and
gender for the 5 previous seasons (2008/09–2012/13 and 2009/10–
2013/14, respectively). Numerators were first-ever GBS cases for
active patients. We have previously demonstrated that when GP
systems are updated the system date (the date a record is added
to a patient’s file, assigned automatically by the general practice
software) of some records can be altered to a later date [4]. For
those records, it is not possible to estimate accurately the delay
in recording the outcome. Hence, these records were identified
using the approach proposed in [4] and were excluded. Active
patients were defined as contributing follow-up time during each
season. Start of follow-up was the latest of uts, crd (plus 1 year
to exclude retrospective recording of previous diagnoses when reg-
istering with a new practice [12]), or 1st September 2008–13. End
of follow-up was the earliest of date of tod, lcd, or 31st March
2009–14. We averaged seasonal GBS rates over the five historical
seasons and applied this rate to the vaccine-exposed follow-up
time in the study seasons, to obtain an expected number of events
(adjusted by age and gender). For the study seasons end of follow-
up was the earliest of tod, lcd or 42 days after vaccination
(Appendix C) [13]. The observed number of events was the total
number recorded in the vaccine risk-window at the time of each
analysis.
3.2.2. Delays
For each patient we calculated the time between the risk-
window midpoint and lcd (time = d) and then used the previously
generated delay distribution [4] to calculate the probability (rd)
that an event that did occur within a year would be recorded by
delay d. This was used to adjust the follow-up to obtain an adjusted
follow-up. For example, if a patient had 30 days between the risk-
window mid-point and lcd and rd = 75%, then only 75% of this
patient follow-up time was considered (Fig. 2 in Appendix D).
We assumed no delays in vaccination data.
3.3. MMR/Seizures
The system was implemented for one year (July 2014–June
2015) using data released in July 2016.
3.3.1. Historical rates, expected and observed number of events
(PMaxSPRT)
We calculated febrile seizures rates during the second year of
life (12–23 months, timing of MMR 1st dose [13]), stratified by
age (two weeks periods) and gender, for the five years previous
to the study period (July 2009–June 2014). We first identified all
febrile seizures events for eligible patients and excluded records
likely to be duplicated (Appendix E).
We calculated follow-up time and the expected and observed
number of events as described above (Appendix C) for the histori-
cal period July 2009–June 2014 and the study period July 2014–
June 2015. A previous study looking at the risk of febrile seizures
following MMR and using hospital data identified a risk-window
of 6–11 days [7]. In this work, we used primary care data, which
are likely to capture febrile seizures with some delay. This can hap-
pen if parents seek care outside primary care (e.g. emergency ser-
vices) and GPs only receive and register the information regarding
the seizure a few days after it has occurred. We thus allowed extra
time, by using a risk window of 6–21 days to capture such events.
3.3.2. BMaxSPRT
To apply BMaxSPRT we used the same risk-window of 6–
21 days post-vaccination and used a control period of 1–5 (c1)
and 22–32 (c2) days post-vaccination, selected to be a period of
the same length and close to the risk period.
3.3.3. Delays (BMaxSPRT)
For BMaxSPRT it was necessary to adjust for delays for each of
the post-vaccination periods (the risk period and c1, c2). This was
done by calculating an adjusted follow-up period for each of these
intervals as shown in Fig. 3 in Appendix D. For each individual we
then calculated a ratio of the corrected follow-up for control period
compared to the risk period (see Appendix D for an example) and
then obtained an average ratio across individuals. This average
ratio was included in the calculations for the BMaxSPRT method
as the matching ratio [9]. This final adjustment simultaneously
accounted for delays in practices uploading data and partially
accrued period.
3.4. Implementation
To mimic a NRTVSS using pre-existing data we first recreated
how data accrued. To determine whether a record of interest
would have been in each data release we used: release date; lcd
(practice-level); event date of the record; and system date of the
record. CPRD is released on a monthly basis, on the first Monday
of each month. For a particular release we considered the outcome
would be captured if the event date, system date, and last
collection date all happened before the date of release. For exam-
ple, an event taking place (event date) on 9/10/2014, with a system
date of 10/11/2014, and lcd 28/10/2014 for the November release
would not appear in the November. If lcd for the December release
was 25/11/2014 then the event would appear in December.
As no signal was expected for influenza/GBS we further tested
NRTVSS implementation by adding cases to generate an increase
in risk of approximately 4 and 5-fold, which power calculations
suggested should be detectable.
Implementation was done graphically by calculating the log-
likelihood ratio test at the time of each data release. For PMaxSPRT
the log-likelihood is based on the number of observed and
expected events while for BMaxSPRT it considers the number of
observed events occurring in the control and risk periods. The
results from the log-likelihood ratio test were compared with the
critical limit. For each vaccine/outcome pair and study period we
calculated critical limits considering a minimum number of
observed events to reject the null hypothesis of 1, 2, and 4.
3.5. Power and expected time to signal
Post-licensure vaccine safety surveillance aims at detecting sig-
nals that might have been missed before vaccine approval, due to
the lack of power in the analyses conducted. When considering
NRTVSS we thus need to assess power. The R package Sequential
includes system performance tools, allowing calculating of power
and expected time to signal [11].
Power is affected by several factors: incidence of the outcome
(both background incidence and incidence following vaccination),
vaccine uptake, vaccine risk-window length, length of the study
period, delays in receiving the data, relative risk (RR) to be
detected, events in the first look at the data, minimum number
of events before rejecting the null, and level of significance. Calcu-
lations were performed for a plausible range of RR (1.5–10), con-
sidered no events in the first look at the data, and a level of
significance of 5% (a = 0.05). For PMaxSPRT we also required 1, 2
or 4 events before rejecting the null [14] and the remaining factors
were integrated through the expected number of events at the end
of the surveillance period. For BMaxSPRT we considered the total
number of events at the end of the surveillance period (both from
risk-window and control periods).
Expected time to signal is conditional on having identified a sig-
nal and is obtained in the units of expected number of events. As
CPRD data do not accrue at a constant rate, to know at which
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release we would expect a signal we evaluated at which release the
number of expected events would have been achieved.
4. Results
Table 1 presents the number of doses identified and the main
characteristics of individuals receiving the vaccine of interest.
4.1. Seasonal influenza/GBS
We identified 1.89 and 1.66 expected events for season 2013–
14 and 2014–15, respectively. The historical rates used were based
on 33 observed events for each season. Hence, the use of
CMaxSPRT was not deemed necessary. Fig. 1 presents system
implementation. No signal was identified for both seasons. When
we added cases to generate an increase in risk of 4- and 5-fold
we found, for an increase in risk of 4, the signal would be identified
at the beginning of January and February for the season 2013/14
and 2014/15, respectively, if a minimum of 4 events was stipu-
lated. For an increase of 5 times the risk the signals would be
detected a month before (Fig. 2).
Table 2 presents power and expected time to signal for sea-
sonal influenza/GBS and both seasons. In general, there was
power  80% to detect RR  4. If there was a signal this would
be detected at the beginning of December for large increases
in risk (6–8 times) and at the beginning of January for lower
increases (4–5 times).
Table 1
Main characteristics of individuals receiving the vaccine of interest for the pairs included.
Characteristic Vaccine/outcome pair
Influenza/GBS season 2013–14 Influenza/GBS season 2014–15 MMR/Febrile seizures
Number of doses (n) 533,110 477,454 28,249
Sex – n (%)
Male 240,884 (45.2) 216,224 (45.3) 14,474 (51.2)
Female 292,226 (54.8) 261,230 (54.7) 13,775 (48.8)
Age (years) – n (%)
65–74 270,690 (50.8) 242,168 (50.7) –a
75–84 188,423 (35.3) 168,160 (35.2) –a
85 73,997 (13.9) 67,126 (14.1) –a
Age (months) – n (%)
12 –a –a 11,460 (40.6)
13 –a –a 10,049 (35.6)
14 –a –a 3320 (11.8)
15 –a –a 3420 (12.1)
GBS – Guillain-Barre syndrome.
MMR – Measles-mumps-rubella.
a Age (at time of vaccination) is expressed in years for seasonal influenza/GBS and months for MMR/febrile seizures.
Fig. 1. Implementation of a system for influenza vaccine/GBS for season 2013–14 (A) and season 2014–15 (B). No signal is detected in any of the seasons.
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4.2. MMR/seizures
After investigation of duplicated records of febrile seizures we
decided to exclude those occurring with three days of one another
(Appendix E). We identified 11.3 expected episodes in the study
period and the historical rates were based on 2693 observed
events. Fig. 3 presents NRTVSS implementation. We identified a
signal using PMaxSPRT. For BMaxSPRT the signal was just missed.
Table 3 presents power and expected time to signal for febrile
seizures/MMR based on a one-year surveillance period. We
observed power  80% to detect RR  2.5. If there was a signal this
would be detected at the beginning of September (2 months after
beginning of surveillance) using PMaxSPRT for RR of 5, and in
subsequent months for lower increases in risk. Power for
BMaxSPRT was lower but would still allow detection of an RR of
2.5.
5. Discussion
We systematically assessed the feasibility of implementing a
NRTVSS using data from CPRD. Our study shows that it is feasible
to use CPRD and it would enable detection of medium/large
increases in risk of GBS following seasonal influenza vaccine
among individuals aged 65 years, and smaller increases in the
risk of febrile seizures following first dose of MMR.
For influenza/GBS, CPRD would only enable detection of large
increases in risk. In addition, the signal would only be detected
around mid-season (beginning of January) which might be late,
as the vaccine is recommended early in the season [15]. Despite
limited power to detect an increased risk, our finding of no
increased risk of GBS following seasonal influenza vaccine seems
consistent with the existing literature. For example, a recent work
assessing GBS following influenza vaccine in the USA between
2010/11 and 2013/14 found no signal for the season 2013/14, the
season we also assessed as part of our work [16]. Overall, we
believe the system now proposed addresses some of the limita-
tions of the existing system, which is based on spontaneous reports
and thus is limited by underreporting [3].
We were able to replicate a known signal for febrile seizures fol-
lowing MMR based a one-year surveillance period. This signal was
identified only with PMaxSPRT (after 3 months of surveillance, if a
minimum events of 2 events was stipulated). Although BMaxSPRT
did not quite signal as it is a less powerful test, it has the advantage
Fig. 2. Implementation of a system for influenza vaccine/GBS for season 2013–14 (A) and season 2014–15 (B), assuming an increase in risk of 4 and 5 times. A signal is
detected at different points in time depending on critical limits considered.
Table 2
Power and expected time to signal for seasonal influenza/GBS (seasons 2013–14 and 2014–15) using Poisson-based Maximized Sequential Probability Ratio.
Minimum events Season Data available at Power (time to signal in months from beginning of surveillance)a
Relative risk
1.5 2 2.5 3 4 5 6 8 10
1 2013–14 07–04-2014 13 25 40 55 (4) 78 (4) 91 (3) 97 (3) 100 (3) 100 (3)
2014–15 06–04-2015 12 23 37 51 (4) 74 (4) 88 (4) 95 (4) 99 (3) 100 (3)
2 2013–14 07–04-2014 14 28 44 60 (4) 82 (4) 93 (3) 98 (3) 100 (3) 100 (3)
2014–15 06–04-2015 14 26 41 55 (4) 77 (4) 90 (4) 96 (4) 100 (3) 100 (3)
4 2013–14 07–04-2014 16 33 50 65 (4) 86 (4) 95 (4) 98 (4) 100 (3) 100 (3)
2014–15 06–04-2015 16 31 47 62 (4) 83 (4) 93 (4) 98 (4) 100 (4) 100 (4)
Cells in bold refer to power 80%.
PMaxSPRT - Poisson-based Maximized Sequential Probability Ratio.
a Time to signal is only displayed for cells where equivalent power50%.
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of having a much more relevant comparator period that should be
less prone to bias and would likely have signalled with an extended
surveillance period. We would therefore suggest that despite the
low number of expected events (11) it is still worthwhile using this
method in addition to PMaxSPRT to make the signal more robust.
Others have suggested a minimum number of expected events of
50 [2].
A further aspect is the minimum number of events required to
reject the null hypothesis. As previous work has suggested, reject-
ing the null hypothesis only after a certain number of events
increases power [14]. Given we have limited power for seasonal
influenza/GBS we would recommend implementing a system with
a requirement of 4 events before rejecting the null.
Vaccine safety studies require careful specification of risk-
windows and, if applicable, comparator windows. This includes
not only knowledge of the characteristics of the vaccine/outcome
pair under study but also the data available for analysis. In the case
of MMR/seizures we decided to use a longer risk-window than pre-
viously suggested (6–21 days instead of 6–11 days) to account for
delayed recording of seizures in the primary care data. If our choice
resulted in an unduly long risk-window the result would be an
underestimation of the risk and thus a reduction in the power to
detect a signal. In practice, a way to address uncertainty in the
specification of risk-windows is to conduct a sensitivity analysis
using an alternative risk/comparator window. Alternatively, this
uncertainty can be addressed at the confirmatory stage by looking
at the distribution of cases within the risk-window.
Data quality should also be considered. Our previous assess-
ment of completeness of records first diagnosed in hospital showed
that CPRD had low sensitivity to capture GBS. However, if this sub-
optimal sensitivity is constant over time, for the purposes of the
current system the effect would be a decrease in power to detect
an event [2]. We know of no studies assessing the positive predic-
tive value of the outcomes included. As for the vaccination data,
the vaccines we selected are administered in general practices
and GPs are financially incentivised to achieve certain thresholds
of vaccine uptake. It is thus expected that individuals classified
as vaccinated are indeed so.
Our study presents several limitations. The use of PMaxSPRT is
susceptible to uncertainty in historical rates and a conditional test
Table 3
Power and expected time to signal for MMR/febrile seizures after, using Poisson and Binomial-based Maximized Sequential Probability Ratio.
Minimum events Test Data available at Power (time to signal in months from beginning of surveillance)a
Relative risk
1.5 2 2.5 3 4 5 6 8 10
1 PMaxSPRT 06–07-2015 30 73 (5) 95 (4) 99 (3) 100 (2) 100 (1) 100 (1) 100 (1) 100 (1)
BMaxSPRT 06–07-2015 28 63 (6) 85 (6) 95 (5) 99 (5) 100 (4) 100 (3) 100 (3) 100 (3)
2 PMaxSPRT 06–07-2015 33 76 (5) 96 (4) 100 (3) 100 (2) 100 (1) 100 (1) 100 (1) 100 (1)
4 PMaxSPRT 06–07-2015 36 79 (5) 96 (4) 100 (3) 100 (2) 100 (1) 100 (1) 100 (1) 100 (1)
Cells in bold refer to power80%.
BMaxSPRT - Binomial-based Maximized Sequential Probability Ratio.
PMaxSPRT - Poisson-based Maximized Sequential Probability Ratio Test.
a Time to signal is only displayed for cells where equivalent power50%.
Fig. 3. Implementation of a system for MMR/febrile seizures using PMaxSPRT (right) and BMaxSPRT (left). Only for PMaxSPRT a signal is detected.
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was proposed to address this issue. We tried to minimize this by
using data from the 5 previous seasons/years to estimate historical
rates. Given the amount of observed events in the historical data is
substantial larger (more than five times) than the number of
expected events in the study period we considered that the use
of a conditional test was not necessary. Secondly, for our study per-
iod we considered only vaccinated individuals while for historical
rates we included both vaccinated and non-vaccinated. Including
vaccinated individuals in historical periods could have led to a
slight overestimate of the background rate and underestimate of
the RR and thus miss a signal. However, even if there were
increases in risk in the historical periods due to the vaccine, the
increase in the attributable risk would be small, thus minimizing
this issue. Nevertheless, we were able to detect a signal for sei-
zures/MMR, which is reassuring. Finally, our study is limited by
assumptions of the method used, including homogenous distribu-
tion of a potential risk during the risk-window and throughout the
study period and that if there is an increase in risk these additional
cases would be also recorded in CPRD.
We proposed a new adjustment for delays but it might still not
fully capture existing delays [17]. We only considered a mid-point
for adjustment, which simplifies the data accrual process. Further-
more, we considered a delay distribution based on historical data
and recording patterns might have changed, although previous
work looking at ten years’ worth of data shows consistent record-
ing patterns [4]. Overall, we believe our adjustment reduces bias
due to data availability and enables an earlier start of surveillance.
As previously pointed out there are few strategies available to
deal with potential confounding factors [2]. For influenza/GBS we
were able to account for gender and partially for age. If there is a
signal, further adjustment for confounders is one of the initial steps
[1], potentially including more detailed adjustment for age (we
only considered 10-year age groups) and for other potential con-
founders. Influenza incidence may be one of these potential con-
founders, as GBS is known to be associated with influenza-like
illness [18]. Rapid yearly estimates are provided for influenza inci-
dence and could potentially be used in this context. For seizures/
MMR, we were able to account for age and gender in the PMaxSPRT
analysis but we did not explicitly account for age in the BMaxSPRT.
Febrile seizure rates are known to change rapidly with age [19] but
the use of a control period before and after the risk period should
have helped to limit potential confounding due to age.
Our study made use of previously collected data to mimic a new
system. However, CPRD is expanding, to include practices using
different softwares [20]. While this can be seen as an opportunity
to increase power to detect lower increases in risk for rare out-
comes, there might be differences in coding systems and behaviour
that could limit the applicability of the results of our previous stud-
ies. Alternatively, these new practices could be used for signal con-
firmation should a signal be identified. This strategy would be a
way to avoid using the same data for signal identification and
confirmation.
As we have further knowledge on NRTVSS and its application
using CPRD next steps include application to new vaccines. In addi-
tion, there is the need to define which steps to undertake if a signal
is detected. Yih et al. [1] proposed a series of steps in case a signal
is found, broadly including: to check data and code, to examine
descriptive statistics for patterns in time between the exposure
and outcome, to adjust for additional confounders, to conduct a
non-sequential analysis with a different comparator, to conduct a
review of records, to compare the results with similar outcomes
or other existing data, to analyse new data or to design a new
study. All steps can be conducted using CPRD data. However, there
is limited ability to perform a timely confirmation of the patient’s
recorded diagnoses. Currently, when GPs are asked to validate
diagnoses identified from coded information this process may take
several months. Future discussions with data providers and
medicines regulatory authorities may help to facilitate the process
of data validation. An in-depth presentation of the steps required
following a signal is beyond the scope of this work.
In conclusion, our results suggest the implementation of
NRTVSS using CPRD as a way to complement existing methods,
by allowing timely identification of signals for more frequent out-
comes and by excluding large increases in risk for less frequent
outcomes.
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7.2 Supporting information 
As stated in Section 7.1, some of the supporting information of Paper 3 was previously 
presented in this thesis: for code-lists used to identify GBS and febrile seizures (Appendix A) 
see Section 5.4  and for the graphical representation of the adjustment for delays considered 
for PMaxSPRT and BMaxSPRT (Appendix D) see Chapter 6 (Figure 6.3 and Figure 6.7). The 
remaining appendices (B. Vaccinated individuals, C. Follow-up time, and E. Repeated febrile 
seizures episodes) are presented below. 
7.2.1 Identification of vaccinated individuals (Appendix B) 
As outlined in Sections 3.1.1.1 and 3.2, information regarding the vaccination of a patient is 
provided in different files within their electronic health records and it is not always 
consistent. It is thus necessary to create algorithms to identify vaccinated individuals. Section 
3.2 presented the methods followed to develop these algorithms for seasonal influenza and 
for MMR vaccines. In this Section, I provide information on the resulting algorithm. For each 
vaccine, this included use of the relevant code-lists and how these were combined to 
ascertain vaccination status. The relevant code-lists included: (i) a list of Read codes 
indicating that influenza vaccine had been administered (designated as Read codes indicating 
vaccination); (ii) a list of codes indicating that the vaccine had not been administered 
(designated as Read codes indicating the vaccine has not been given), and (iii) a list of therapy 
codes indicating a prescription for the vaccine of interest (entitled Therapy codes). Lists (i) 
and (ii) were used to identify records in the clinical, referral, test, and immunisation files. List 
(iii) was used to search the therapy file. The immunisation file contains additional coded 
information on vaccines, comprising ‘immunisation type’ codes (indicating the type of 
vaccine) and ‘immunisation status’ codes (indicating vaccination status). I thus selected 
codes indicating that the record was related to the vaccine of interest (seasonal influenza or 
MMR, see Codes in the immunisation file), and the status codes that indicated that the 
vaccine was administered; the remaining immunisation status codes (advised or refused) did 
not provide evidence of vaccine administration. 
7.2.1.1 Seasonal influenza vaccine  
The lists drawn up for seasonal influenza vaccine are presented below, followed by the 
algorithm developed to identify individuals vaccinated against seasonal influenza.  
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7.2.1.1.1 Read codes indicating vaccination 
Read code Read term 
65ED100 Administration of first intranasal seasonal influenza vacc 
65EE.00 Administration of intranasal influenza vaccination 
65ED000 Seasonal influenza vaccination given by pharmacist 
ZV04800 [V]Influenza vaccination 
65EE000 Administration of first intranasal influenza vaccination 
65ED200 Seasonal influenza vaccination given while hospital inpt 
65ED300 Administration of second intranasal seasonal influenza vacc 
65EE100 Administration of second intranasal influenza vaccination 
65ED.00 Seasonal influenza vaccination 
65E2.00 Influenza vaccination given by other healthcare provider 
65E..00 Influenza vaccination 
ZV04811 [V]Flu - influenza vaccination 
65E2000 Seasonal influenza vaccin given by other healthcare provider 
65E2100 First intranasal seasonal flu vacc gvn by othr hlthcare prov 
65E2200 Secnd intranasal seasonal flu vacc gvn by othr hlthcare prov 
  
 
7.2.1.1.2 Read codes indicating the vaccine has not been given 
Read code Read term 
9N4q100 DNA first intranasal seasonal influenza vaccination 
8I2F000 Seasonal influenza vaccination contraindicated 
14LJ.00 H/O: influenza vaccine allergy 
9OX5600 Second intranasal seasonal influenza vaccination declined 
9OX5400 First intranasal seasonal influenza vaccination declined 
8I6D000 Seasonal influenza vaccination not indicated 
9OX5.00 Influenza vaccination declined 
9OX5300 Second intranasal influenza vaccination declined 
9OX5200 First intranasal influenza vaccination declined 
8I2F.00 Influenza vaccination contraindicated 
68NE000 No consent for seasonal influenza vaccination 
9OX5100 Seasonal influenza vaccination declined 
ZV14F00 [V]Personal history of influenza vaccine allergy 
8I6D.00 Influenza vaccination not indicated 
9N4q.00 Did not attend flu vaccination appointment 
 
7.2.1.1.3 Therapy codes 
Product code Product name 
11824 Enzira vaccine suspension for injection 0.5ml pre-filled syringes (Pfizer Ltd) 
1329 
Fluvirin vaccine suspension for injection 0.5ml pre-filled syringes (Novartis 
Vaccines and Diagnostics Ltd) 
7951 FLUVIRIN AQUEOUS ML VAC 
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Product code Product name 
23251 FLUVIRIN PRE-FILLED SYRINGE 
9710 
Agrippal vaccine suspension for injection 0.5ml pre-filled syringes (Novartis 
Vaccines and Diagnostics Ltd) 
27407 
Imuvac vaccine suspension for injection 0.5ml pre-filled syringes (Abbott 
Healthcare Products Ltd) 
2552 
Influvac Sub-unit vaccine suspension for injection 0.5ml pre-filled syringes (Abbott 
Healthcare Products Ltd) 
57401 
Influvac Desu vaccine suspension for injection 0.5ml pre-filled syringes (Abbott 
Healthcare Products Ltd) 
51087 
Optaflu vaccine suspension for injection 0.5ml pre-filled syringes (Novartis 
Vaccines and Diagnostics Ltd) 
2139 
Fluarix vaccine suspension for injection 0.5ml pre-filled syringes (GlaxoSmithKline 
UK Ltd) 
57917 
Fluarix Tetra vaccine suspension for injection 0.5ml pre-filled syringes 
(GlaxoSmithKline UK Ltd) 
43827 
Intanza 9microgram strain vaccine suspension for injection 0.1ml pre-filled 
syringes (sanofi pasteur MSD Ltd) 
43825 
Intanza 15microgram strain vaccine suspension for injection 0.1ml pre-filled 
syringes (sanofi pasteur MSD Ltd) 
47932 Fluenz vaccine nasal suspension 0.2ml unit dose (AstraZeneca UK Ltd) 
57678 Fluenz vaccine nasal suspension 0.2ml unit dose (AstraZeneca UK Ltd) 
398 Influenza inactivated split virion Vaccination (Aventis Pasteur MSD) 
38421 Influenza inactivated split virion Vaccination (Evans Vaccines Ltd) 
44759 INFLUENZA PRE-FILLED SYRINGE 
40876 
Influenza vaccine (split virion, inactivated) 9microgram strain suspension for 
injection 0.1ml pre-filled syringes 
61580 
Influenza vaccine (split virion, inactivated) suspension for injection 0.25ml pre-
filled syringes 
24779 Influenza inactivated split virion Paediatric vaccination 
639 
Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled 
syringes 
61898 
Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled 
syringes (A A H Pharmaceuticals Ltd) 
45661 
Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled 
syringes (Pfizer Ltd) 
922 Influenza inactivated surface antigen Vaccination 
48658 
Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled 
syringes (sanofi pasteur MSD Ltd) 
48740 
Influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-
filled syringes 
51289 Influenza vaccine (live attenuated) nasal suspension 0.2ml unit dose 
32391 
Influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-
filled syringes (Novartis Vaccines and Diagnostics Ltd) 
30198 Influenza inactivated split virion Vaccination (sanofi pasteur MSD Ltd) 
61792 Fluenz Tetra vaccine nasal suspension 0.2ml unit dose (AstraZeneca UK Ltd) 
48085 Influenza inactivated split virion Vaccination (Chiron UK Ltd) 
57140 Influenza vaccine (live attenuated) nasal suspension 0.2ml unit dose 
40760 
Influenza vaccine (split virion, inactivated) 15microgram strain suspension for 
injection 0.1ml pre-filled syringes 
49716 
Influenza vaccine (surface antigen, inactivated, virosome) suspension for injection 
0.5ml pre-filled syringes 
2601 Mfv-ject Vaccination (Aventis Pasteur MSD) 
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Product code Product name 
13595 Fluzone Vaccination (Aventis Pasteur MSD) 
16585 
Viroflu vaccine suspension for injection 0.5ml pre-filled syringes (Janssen-Cilag 
Ltd) 
10030 
Inflexal V vaccine suspension for injection 0.5ml pre-filled syringes (Janssen-Cilag 
Ltd) 
834 
Begrivac vaccine suspension for injection 0.5ml pre-filled syringes (Novartis 
Vaccines and Diagnostics Ltd) 
18612 Mastaflu vaccine suspension for injection 0.5ml pre-filled syringes (Masta Ltd) 
30156 
Invivac vaccine suspension for injection 0.5ml pre-filled syringes (Abbott 
Healthcare Products Ltd) 
54677 
Preflucel vaccine suspension for injection 0.5ml pre-filled syringes (Baxter 
Healthcare Ltd) 
63690 
Inflexal V suspension for injection 0.5ml pre-filled syringes (sanofi pasteur MSD 
Ltd) 
65205 
FluMist Quadrivalent vaccine nasal suspension 0.2ml unit dose (AstraZeneca UK 
Ltd) 
 
7.2.1.1.4 Codes in the immunisation file 
Immunisation type 
Code Description 
4 FLU 
84 FLUSOHP 
85 FLUSPHARMA 
89 FLUSIN 
97 FLUSINOHP 
100 FLUSIMOHP 
 
Immunisation status 
Code Immunisation Status 
1 Given 
4 Refusal to start or complete course 
9 Advised 
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7.2.1.1.5 Algorithm 
Based on the lists above, I developed the algorithm presented in Figure 7.1. Priority was given 
to information on the immunisation file as this contains specific information on vaccines, 
followed by information from the therapy file, as the latter indicates a prescription was 
issued.   
Figure 7.1. Algorithm utilised to identify individuals vaccinated against influenza vaccine.  
 
Influenza immunisation type code 
and immunization status ‘given’ 
Yes 
Vaccinated on the event 
date of the (first) 
immunisation record 
No 
Therapy code indicating 
prescription of an 
influenza vaccine 
Yes 
Refused code on 
the same day of 
the prescription 
Yes 
Not vaccinated 
No 
Vaccinated on 
the date of the 
prescription 
No 
Read code indicating 
vaccination         
(clinical file) 
Yes 
Code indicating 
the vaccine has 
not been given 
Yes 
Read code indicating 
vaccination was given 
outside the practice 
Yes 
Vaccinated on the 
date of the code 
indicating 
vaccination 
No 
Not vaccinated 
No 
Vaccinated on the 
event date of the code 
No 
Not vaccinated 
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7.2.1.2 Measles-Mumps-Rubella vaccine 
MMR is a combined vaccine and thus for an individual to be considered vaccinated I required 
evidence that s(he) had received all the components of the vaccine. To assess this, each 
vaccine code included in the list that was developed was assigned as having one of more 
components of the vaccine. The components each specific code corresponds to are denoted 
in the list below as ‘1’ in the respective column of the lists. When assessing specific 
information from the immunisation file, the component assessment was carried out by 
considering an additional variable in this file which indicates which compound of the vaccine 
had been administered. The code-lists and respective components are presented below, 
followed by the algorithm that was developed.  
7.2.1.2.1 Read codes indicating vaccination  
Read 
code Readterm MMR measles mumps rubella 
ZV04200 [V]Measles vaccination  1   
ZV06400 
[V]Measles-mumps-rubella (MMR) 
vaccination 1    
ZV04600 [V]Mumps vaccination   1  
ZV04300 [V]Rubella vaccination    1 
U60K014 [X] Adverse reaction to measles vaccine  1   
U60K016 [X] Adverse reaction to mumps vaccine   1  
U60K017 [X] Adverse reaction to rubella vaccine    1 
TJK4.00 Adverse reaction to measles vaccine  1   
TJK6000 Adverse reaction to mumps vaccine   1  
TJK6100 Adverse reaction to rubella vaccine    1 
65B..11 German measles vaccination    1 
65MA.00 
Measles mumps and rubella booster 
vaccination 1    
9ki1.11 Measles mumps rubella catch-up vaccination 1    
65A2.00 Measles vaccin.+immunoglobulin  1   
65A..00 Measles vaccination  1   
65A1.00 Measles vaccination  1   
SLK4.00 Measles vaccine poisoning  1   
65M1.00 Measles/mumps/rubella vaccn. 1    
65M2.00 Measles/rubella vaccination  1  1 
65MB.00 MMR pre-school booster vaccination 1    
65MC.00 MMR vaccination - 2nd dose 1    
65M2.11 MR - Measles/rubella vaccination  1  1 
65F5.00 Mumps vaccination   1  
SLK6000 Mumps vaccine poisoning   1  
F034C00 Post measles vaccination encephalitis  1   
F034E00 Post mumps vaccination encephalitis   1  
F034F00 Post rubella vaccination encephalitis    1 
65B..00 Rubella vaccination    1 
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7.2.1.2.2 Therapy codes 
Product 
code productname MMR measles mumps rubella 
18912 Immravax Vaccination (Aventis Pasteur MSD) 1    
12711 Measles live Vaccination  1   
18172 
Measles, Mumps and Rubella vaccine (live) 
powder and solvent for solution for injection 
0.5ml vials 1    
20845 
Measles, Mumps and Rubella vaccine (live) 
powder and solvent for suspension for 
injection 0.5ml pre-filled syringes 1    
4189 MEASLES SCHWARZ STRAIN VAC  1   
9089 MEASLES EDMONSTON STRAIN VAC  1   
25157 
Mumpsvax Vaccination (Aventis Pasteur 
MSD)   1  
4190 Mumps Vaccination   1  
11016 MUMPSVAX ML VAC   1  
2244 Rubella Vaccine    1 
49697 
Rubella vaccine powder and solvent for 
solution for injection 0.5ml vials    1 
10348 
Almevax rubella Vaccination (Celltech 
Pharma Europe Ltd)    1 
12005 
Attenuvax Vaccination (MSD Thomas Morson 
Pharmaceuticals)  1   
11714 
Priorix vaccine powder and solvent for 
solution for injection 0.5ml vials 
(GlaxoSmithKline UK Ltd) 1    
15473 
Mevillin-l Vaccination (Manufacturer 
unknown)  1   
38476 
M-M-RVAXPRO vaccine powder and solvent 
for suspension for injection 0.5ml pre-filled 
syringes (sanofi pasteur MSD Ltd) 1    
10333 
Pluserix Vaccination (GlaxoSmithKline 
Consumer Healthcare) 1    
3906 
M-M-R II vaccine powder and solvent for 
solution for injection 0.5ml vials (sanofi 
pasteur MSD Ltd) 1    
30506 
Meruvax ii Vaccination (MSD Thomas Morson 
Pharmaceuticals)    1 
10335 Rubavax Vaccination (Aventis Pasteur MSD)    1 
3468 
Ervevax vaccine powder and solvent for 
solution for injection 0.5ml vials 
(GlaxoSmithKline UK Ltd)    1 
 
7.2.1.2.3 Read Codes indicating the vaccine has not been given 
Read code Read term 
9ki0.11 Did not attend for MMR catch-up vaccination 
9N4z000 Did not attend measles mumps and rubella vaccination 
9N4z400 Did not attend second measles mumps and rubella vaccination 
9N4c.00 DNA - DTaP, polio and MMR booster 
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Read code Read term 
9ki0.00 DNA MMR catch-up vaccination - ESA 
9ki2.00 MMR catch-up vacc declind - enhanced services administration 
68NT.00 MMR not given 
8I3x.00 MMR vaccination declined 
68NI.11 MMR vaccine contra-indicated. 
68NB.00 No consent - measles imm. 
68NC.00 No consent - rubella imm. 
68NM.00 No consent for MMR 
68Na.00 No consent for MMR1 
68Nb.00 No consent for MMR2 
68NY.00 No consent for MR - Measles/rubella vaccine 
 
7.2.1.2.4 Codes in the immunisation file 
Code Immunisation Type MMR measles mumps rubella 
7 MEASLES  1   
8 RUBELLA    1 
9 MUMPS   1  
50 MR  1  1 
51 MMR 1    
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7.2.1.2.5 Algorithm 
Based on the lists above, I developed the algorithm presented in Figure 7.2.  
 
Figure 7.2. Algorithm used to identify children vaccinated with measles-mumps-rubella vaccine (MMR). 
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7.2.2 Follow-up time (Appendix C) 
Figure 7.3 summaries the follow-up time included to calculate the historical GBS rate (the 
background rate) and the follow-up time during the study period. When calculating the GBS 
rate for each of the historical seasons, all active patients aged 65 years or older were 
included. Their follow-up time started at the latest of the practice’s up-to-standard date, the 
patient’s current registration date plus one year and 1st September of each season. The 
follow-up ended at the earliest of the last collection date from the practice, the date the 
patient transferred out of the practice or died, and 31st March of each season. For the 
seasons under study (2013/14 and 2014/15), only individuals aged 65 years or older who had 
received an influenza vaccine were included. For these individuals, follow-up began at the 
latest of the practice up-to-standard date, the patient’s current registration date plus one 
year, 1st September of each season and the date of vaccination. Follow-up terminated at the 
earliest of the last collection date from the practice, the date the patient transferred out of 
the practice or died, 31st March of each season, and the end of the risk-window (42 days in 
the case of GBS).  
Figure 7.3. Included follow-up time for hypothetical patients for historical influenza vaccination seasons, used to 
calculate background rates (top) and for the surveillance period (bottom). Dashed lines indicate time not 
considered for the current analysis, the solid line indicate the follow-up time considered. uts – Date at which 
practice reached research-level  quality, crd – current registration date of the patient with the practice, tod – date 
the patient transferred out of the practice, lcd – last data collection date (for the practice).   
 
1 September 
Historical season ­ Hypothetical patient 
uts tod lcd crd(+1y) 
31 March 
uts vaccine tod lcd 
31 March 1 September 
Surveillance period ­ Hypothetical patient 
crd(+1y) 
42 days 
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7.2.3 Repeated consultations for febrile seizures (Appendix E) 
7.2.3.1 Methods 
After an initial febrile seizure episode, GPs may ask parents to come back in a few days to 
reassess the child and the GP may then code the second consultation as a febrile seizure. 
Counting all the seizure-coded consultations would thus overestimate the incidence of 
seizures. To avoid this, I first investigated which records were likely to refer to the same 
episode, so that non-incident consultations could be excluded. I looked at the cumulative 
distribution of the time difference between subsequent records. For this initial step, an extra 
month at the beginning and end of the historical period was included to ensure inclusion of 
consultations starting before and finishing after the first and final eligible consultations. 
7.2.3.2 Results 
During the historical period studied for this analysis (June 2009 - July 2014) I identified 3,263 
children with at least one seizure recorded, with a total of 4,084 seizure records. Among 
those children, 2,309 had a single seizure recorded and 954 had two or more seizures 
recorded within the study period; the maximum number of seizure records per child was 14. 
The difference between two adjacent seizure records had a median of 13 days (Q1-Q3:1-68 
days) and the cumulative distribution is depicted in Figure 7.4. A steep gradient was observed 
in the few days following an initial seizure-coded consultation, after which the steepness 
decreased and was constant until approximately 100 days after the initial consultation. 
Looking at consultations occurring only 30 days after a previous record (Figure 7.5) we can 
see that the steep line occurs within three days of a previous record. This indicates that 
records registered within three days of a previous record refer to the same seizure rather 
than to a different occurrence of seizures. I thus decided to exclude any record within three 
days of a previous one, which resulted in the exclusion of 447 seizure-coded consultations. 
After exclusion, differences between remaining records were recalculated and no remaining 
records had a difference of three or less days.  
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Figure 7.4. Cumulative distribution of the time difference for two subsequent records of seizures within the same 
patient.  
 
Figure 7.5. Cumulative distribution of the time difference for two subsequent records of seizures within the same 
patient considering differences of 30 days or less 
7.3 Variable matching ratios 
As outlined in Section 7.1, I investigated the use of BMaxSPRT to assess febrile seizures 
following MMR vaccine. In this particular example, I used matching ratios as a way to account 
for delays in recording outcomes and receiving data, as well as partially accrued periods. In 
this Section I provide further information on the matching ratios obtained as part of the 
analyses, together with information on the use of variable (as opposed to fixed) matching 
ratios.  
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The calculation of matching ratios was presented in Figure 6.7 and explained in detail in 
Section 6.3.2. In brief, these ratios were calculated as the quotient of the number of days in 
the control period to the number of days in the risk period. The number of days considered 
in the ratio was adjusted for delays in recording outcomes, using the delay distribution 
presented in Section 5.3. This was calculated for all the children included at each data 
release. Table 7.1 provides the matching ratios obtained and used to generate the test 
statistics provided in Figure 3 from Section 7.1. Overall, the matching ratios are lower at the 
beginning and get closer to one as surveillance progresses. This can be explained by the fact 
that as time passes, data have had more time to accrue and therefore we have data from 
both the control and risk periods for the individuals identified in the early releases. Hence, 
this adjustment is more relevant early in the surveillance period. 
Table 7.1. Matching ratios used to adjust for delays and partially accrued periods in the binomial-based maximized 
probability ratio test 
Release number  Ratio unexposed to exposed 
1 0.84 
2 0.81 
3 0.91 
4 0.94 
5 0.95 
6 0.96 
7 0.98 
8 0.97 
9 0.98 
10 0.98 
11 0.98 
12 0.98 
 
The matching ratios obtained by this approach are variable which meant that the log-
likelihood ratio (𝐿𝐿𝑅𝑛), as presented in Section 3.3.2 and reproduced below, could not be 
used. As a reminder, the observed number of events at a given moment is denoted as 𝑛 
(exposed plus unexposed), 𝑐𝑛 denotes the number of events among the exposed at a given 
point and 𝑧 the matching ratio. 
𝐿𝐿𝑅𝑛 = ln(𝐿𝑅𝑛)
= 𝑐𝑛𝑙𝑛 (
𝑐𝑛
𝑛
) + (𝑛 − 𝑐𝑛) ln (
𝑛 − 𝑐𝑛
𝑛
) − 𝑐𝑛 ln (
1
𝑧 + 1
) − (𝑛 − 𝑐𝑛) ln (
𝑧
𝑧 + 1
) 
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The use of this formula assuming several different matching ratios (𝑧𝑛) would result in the 
estimation of different RR. In the package Sequential.99 Kulldorff and Silva addressed this 
issue by using an alternative formula to estimate the log-likelihood (Ivair Silva, personal 
communication). For 𝑛 tests, all with different matching ratios, the log-likelihood to estimate 
RR would be: 
𝐿𝐿𝑅(𝑅𝑅) ∝  𝑐1𝑙𝑛
𝑅𝑅
𝑅𝑅+𝑧1
− (𝑛1 − 𝑐1)𝑙 𝑛(𝑅𝑅 + 𝑧1) + … + 𝑐𝑛𝑙𝑛
𝑅𝑅
𝑅𝑅+𝑧𝑛
− (𝑛𝑛 − 𝑥𝑛)𝑙 𝑛(𝑅𝑅 +
𝑧𝑛)  
This formula incorporates the assumption of a single RR thus allowing the use of variable 
matching ratios. This is the log-likelihood implemented in the function used to implement 
the system (Analyze.Binomial, see Section 3.4). Work by Silva showed that violating the 
assumption of constant ratios still gives accurate results.161 Nevertheless, the extent of 
variability in the matching ratios that can be assumed as constant remains unknown. As a 
general message, I would recommend researchers to reflect on the need to using matching 
ratios (variable or fixed) and then decide on the most appropriate method to estimate the 
log-likelihood. In any case, the use of both approaches is straightforward as they can be 
implemented easily using the functions in R.  
7.4 Influence of delays in the performance of a system (Paper 4) 
This paper was accepted for publication in Pharmacoepidemiology and Drug Safety in 
October 2017. It reports the work conducted to assess the influence of delays in the 
performance of a near real-time system.  
When I implemented a system using CPRD data the results showed that implementation is 
feasible but there was limited power to detect an increased risk of GBS following seasonal 
influenza vaccine (power ≥ 80% to detect a RR of four or more). Given that existing delays in 
receiving data and recording outcomes can affect the amount of data available, thus 
reducing power, I assessed how these sources of delays influence power and the expected 
time to signal. I utilised the same data and study period used to implement a system for 
seasonal influenza vaccine/Guillain-Barre Syndrome (GBS) (2013-2014/2014-2015 seasons, 
see Section 7.1). I used PMaxSPRT and calculated power and time to detect a signal, under 
different combinations of the presence/absence of delays in recording outcomes and in 
receiving data. For each combination, calculations were performed for a range of RRs (1.5-
10).  
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The results showed there was power of 80% or more to detect a four-fold increase in risk of 
GBS. Removing delays did not substantially improved power (a maximum increase of 4% in 
the absence of delays) or timeliness. Therefore, removing delays in CPRD will not significantly 
improve the performance of a near real-time system; expansion of the data is required. 
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Abstract
Purpose: Near real‐time vaccine safety surveillance (NRTVSS) using electronic health records
has been used to detect timely vaccine safety signals. Trial implementation of NRTVSS using the
Clinical Practice Research Datalink (CPRD) has shown that there is limited power to detect safety
signals for rare events. Delays in recording outcomes and receiving data influence the power and
timeliness to identify a signal. Our work aimed to compare how different sources of delays influ-
ence power and expected time to signal to implement NRTVSS using CPRD.
Methods: We studied seasonal influenza vaccine/Guillain‐Barré syndrome and performed
power and expected time to signal calculations for the 2013‐2014/2014‐2015 seasons. We used
the Poisson‐based maximised sequential probability ratio test, which compares observed‐to‐
expected events. For each study season, we obtained an average Guillain‐Barré syndrome/sei-
zures age‐sex–adjusted rate from the 5 previous seasons and then used this rate to calculate
the expected number of events, assuming a 42‐day risk‐window. Calculations were performed
for detecting rate ratios of 1.5 to 10. We compared power and timeliness considering combina-
tions of the presence/absence of delays in recording outcomes and in receiving data. The R‐pack-
age Sequential was used.
Results: In general, there was ≥80% power to detect increases in risk of ≥4 at the end of the
season. Assuming absence of delays slightly improved power (a maximum increase of 4%) but did
not noticeably reduce time to detect a signal.
Conclusion: Removing delays in data availability is insufficient to significantly improve the
performance of a NRTVSS system using CPRD. Expansion of CPRD data is required.
KEYWORDS
delay, electronic health records, pharmacoepidemiology, power, safety, surveillance, vaccines
1 | INTRODUCTION
Near real‐time vaccine safety surveillance (NRTVSS) is an option in the
post‐licensure vaccine safety toolkit. Near real‐time vaccine safety
surveillance is usually initiated soon after a new vaccine is introduced,
and data from electronic heath records are examined at regular points
in time. This helps with timely detection of safety signals.1
Near real‐time vaccine safety surveillance has not been fully
implemented in the UK, but our recent study trialling NRTVSS imple-
mentation using data from the Clinical Practice Research Datalink
(CPRD) showed it is possible to implement a system.2 Nevertheless,
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system performance (including power and expected time to signal) to
identify a rare outcome (Guillain‐Barré syndrome, GBS) following sea-
sonal influenza was not optimal. In particular, using the most powerful
test (Poisson‐based maximised probability ratio test, PMaxSPRT), there
was power of ≥80% to identify a fourfold increase in risk, and a signal
would be detected 3 months after the start of surveillance. It is thus
important to understand what factors affect power and expected time
to signal and what changes to currently available data might improve
the ability to identify signals rapidly using CPRD.
If PMaxSPRT is used, the expected number of events at the end of
the surveillance period dictates power and expected time to signal. The
expected number of events is a function of the data available, depend-
ing on both the number of individuals contributing data (the volume of
data) and on delays in data availability. Clinical Practice Research
Datalink is a primary care database, and the volume of data is deter-
mined by the number of practices and patients contributing data.
Delays can occur in (i) identifying a condition after the initial consulta-
tion, (ii) recording a condition diagnosed outside the practice (e.g. in
hospital), (iii) practices uploading their data to CPRD, and (iv)
researchers receiving data for analysis. Previous work assessing delays
due to (ii) showed that, for selected conditions of interest regarding
vaccine safety, records accrue within a month of the deemed date of
diagnosis.3 Regarding (iii) and (iv), CPRD data are made available to
researchers monthly and practices upload data prior to this, with the
last collection date from each practice recorded in CPRD.
Clinical Practice Research Datalink is a dynamic database, and new
practices may start contributing data. Additionally, changes to the
mode of data collection from practices and frequency of data releases
could reduce delays. Both expansion and reduction of delays could
improve NRTVSS system performance. We sought to assess how
delays influenced power and expected time to signal, to inform data
providers on how decreasing delays could improve performance of a
NRTVSS system. As a secondary objective, we further assessed the
performance of a system based on data available around the middle
of the surveillance period for a short vaccine programme of fixed
length, to understand what could be detected at a time when it would
still be possible to implement measures to minimise risks.
2 | METHODS
We used data from our previous study that evaluated the feasibility of
implementing a NRTVSS system. Here, we provide a brief summary of
the methods used to obtain those data (for further information see
Leite et al2). Additionally, we explain how we assessed the influence
of delays on power and expected time to signal, the main focus of this
report.
2.1 | Data source
We used CPRD, a UK database containing anonymised primary care
records from individuals registered with participating practices (6.9%
of the population). Information is Read‐coded, including demographics,
diagnoses, therapies, vaccinations, health‐related behaviours, and
referrals to and feedback from hospital.4 Clinical Practice Research
Datalink also contains information of when a patient joined and left a
practice (current registration date and transfer out date, respectively),
when a practice met certain requirements necessary for it to be con-
sidered of research quality (up‐to‐standard) and when information
was last collected from each practice (last collection date, available in
each monthly update).4
2.2 | Vaccine/outcome pairs and study period
Our original study evaluated seasonal influenza vaccine/GBS and
mumps‐measles‐rubella vaccine/seizures. As there was sufficient
power to detect a twofold increase in risk for mumps‐measles‐rubella
vaccine/seizures, we considered the performance of the system for
this pair was satisfactory. We thus only assessed the influence of
delays for seasonal influenza/GBS. We included individuals aged
≥65 years and studied seasons 2013/2014 and 2014/2015, using data
released in July 2015 and 2016, respectively.
2.3 | Analysis
We used continuous PMaxSPRT as it is the most powerful test, and
CPRD provides data in a near‐continuous fashion (monthly).5 The number
of expected events was obtained based on the average GBS age‐sex–
specific rate from the 5 seasons prior to the study seasons (2008‐2013
and 2009‐2014), considering a 42‐day post‐vaccination risk‐window.
We applied the historical rates to the follow‐up time in the study
periods to obtain the expected number of events. Start of follow‐up
time was the latest of the up‐to‐standard date, current registration
date (plus 1 year to exclude retrospective recording of events when
registering with a new practice6), the beginning of the study period,
and the start of the risk‐window. End of follow‐up was the earliest of
the patient's transfer out date, the practice's last collection date, end
of the study period, or end of the risk‐window.
The number of expected events was calculated in slightly different
ways, to consider different delay scenarios (see below). Based on
these numbers, we calculated power and expected time to signal (per-
formance measures), assuming a range of plausible rate ratios (1.5‐10),
KEY POINTS
• The Clinical Practice Research Datalink (CPRD) can be
used to implement near real‐time vaccine safety
surveillance, but there is limited power to detect
signals for rare outcomes.
• Delays in recording outcomes and in receiving data
might limit power and timeliness of a system. We
assessed the influence of these sources of delays to
inform data providers of the steps required to improve
a system using CPRD data.
• Removing delays in recording outcomes and receiving
data is unlikely to significantly improve the
performance of a system using CPRD data. Expansion
of the data available is needed.
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a level of significance of 5%, and stipulating a minimum of 1, 2, or 4
events before raising a signal. Calculations were performed using the
R package Sequential.7
We assessed the influence of delays on system performance by cal-
culating follow‐up time (hence, the expected number of events) assuming
the system had different combinations of presence/absence of delays in
recording outcomes and in receiving data. Additionally, we looked at
performance measures assuming analyses ended at the mid‐season
(December release). Ending surveillance earlier might increase power as
less sequential tests are performed, but the number of expected events
is likely to be lower (due to less data available), thus reducing power.
The delay scenarios assessed are presented in Table 1. The scenario
considering both sources of delays was used as a reference, as this
corresponded to what we did for the test implementation.2
For delays in recording outcomes, we considered the follow‐up
time for the patients as explained above (absence of delays) and then
adjusted this follow‐up time to account for delays, by reducing the
expected number of events based on the historical delays' distribution
(presence of delays).
For delays in receiving data, we included all data available for the
study period regardless of when these data were received (absence
of delays) and then included only data received by the end of the sur-
veillance period (presence of delays). We identified data received by
the end of surveillance by using the last collection date in that data
release. For the reference scenario, we considered the last collection
dates available in the April 2014 and April 2015 releases for season
2013/2014 and 2014/2015, respectively. Similarly, we used the last
collection dates available in the December releases (2013 and 2014
for season 2013/2014 and 2014/2015, respectively) when assessing
performance at the mid‐season (scenario 3).
3 | RESULTS
Table 2 presents the results of our calculations. In general, there was
≥80% power to detect increases in risk of ≥4 at the end of the season.
Removing sources of delays improved power by 1% to 4% and would
allow detection of a signal at the same release of the implementation
scenario. Stopping surveillance around mid‐season (scenario 3)
resulted in substantial reductions in power, particularly to detect
medium (3‐6 fold) increases in risk. For this scenario, there was ≥80%
power to detect an increase in risk of 8 to 10. If there was a signal, this
would be detected by early December.
4 | DISCUSSION
We analysed the impact of delays in data availability on NRTVSS
implementation using CPRD as a way to inform data providers about
measures that could improve performance of a NRTVSS system. Our
results showed that delays affect power, but only slightly. There
were almost no differences observed in the expected time to signal,
even when there were improvements in power. Removing delays
would thus be insufficient to improve the performance of a system
using CPRD data, as the main limiting factor is the volume of data
available.
The small differences between each scenario are probably related
to the performance measures being calculated on the basis of
expected events at the end of the surveillance period. Most individuals
are vaccinated at the beginning of the season, and by its end, data have
had enough time to accrue. This applies to both sources of delays.
Assessment of the performance at mid‐season revealed that we
would be able to detect only very large increases in risk at the begin-
ning of December. This raises the issue of timeliness, as by then most
individuals would have been vaccinated and any intervention might
have limited reach.
Clinical Practice Research Datalink currently collects data from
practices using VISION software, but it is expanding to include prac-
tices using EMIS software.8 Presently, there are data from 4.4 million
active patients. Initial analysis of EMIS practices indicates an additional
2.6 million active patients (Rachel Williams, personal communication).
Assuming this would translate to a similar number of expected events,
the new data would amount to approximately 3 expected events,
which would be sufficient to detect increases of threefold or more in
the risk of GBS following seasonal influenza vaccination. This might
not be enough to detect small increases in risk, particularly for rare
events. Furthermore, including data from practices using a different
software may pose new challenges. For example, the adjustment for
delays we proposed is based on the delay distribution observed using
data from VISION practices, and it might not be applicable for EMIS
practices.3 Including EMIS practices in a NRTVSS will thus require
additional exploration of these data.
In our work, we considered a power of ≥80% as a satisfactory per-
formance. However, GBS can be a severe condition, and when
implementing a system, it may be necessary to require higher power
level to detect more serious conditions (such as 90%). For existing
CPRD data, requirement of 90% power would mean that we could only
accurately identify increases in risk ≥5.
TABLE 1 Combination of delays assessed under each scenario
Scenario—Source of
Delays
Delays
End of Surveillance CommentsRecording Receiving
Recording/receiving (reference) + + April data release
(end of season)
Corresponds to the way NRTVSS was implemented using CPRD data.
Reference scenario
1. None − − April data release
(end of season)
Ideal scenario; events are recorded as they happen and data are
available immediately
2. Recording + − April data release
(end of study period)
Mimics a situation where CPRD receives data on a daily basis and
makes it available straight away
3. Recording/receiving + + December data release Corresponds to the reference scenario but considering data available
until December
Abbreviations: CPRD, Clinical Practice Research Datalink; NRTVSS, near real‐time vaccine safety surveillance.
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TABLE 2 Expected number of events, power, and expected time to signal under different combination of delays
Minimum
events RR
Delay Scenario
Reference Scenario 1 Scenario 2 Scenario 3
Season 2013‐2014
Expected number of events
— — 1.89 2.09 1.94 0.62
Power (expected time to signal in terms of data release)
1 1.5 13 13 13 10
2 25 26 25 16
2.5 40 42 40 22
3 55 (J) 58 (J) 55 (J) 30
4 78 (J) 81 (J) 79 (J) 44
5 91 (D) 93 (J) 92 (D) 58 (D)
6 97 (D) 98 (D) 97 (D) 69 (D)
8 100 (D) 100 (D) 100 (D) 85 (D)
10 100 (D) 100 (D) 100 (D) 93 (D)
2 1.5 14 15 15 11
2 28 30 29 18
2.5 44 46 45 27
3 60 (J) 62 (J) 61 (J) 35
4 82 (J) 84 (J) 83 (J) 52 (D)
5 93 (D) 95 (D) 94 (D) 65 (D)
6 98 (D) 98 (D) 98 (D) 76 (D)
8 100 (D) 100 (D) 100 (D) 89 (D)
10 100 (D) 100 (D) 100 (D) 96 (D)
4 1.5 16 17 16
2 33 34 33
2.5 50 (J) 52 (J) 50 (J)
3 65 (J) 68 (J) 66 (J)
4 86 (J) 88 (J) 86 (J) a
5 95 (J) 96 (J) 95 (J)
6 98 (J) 99 (J) 99 (J)
8 100 (D) 100 (D) 100 (D)
10 100 (D) 100 (D) 100 (D)
Season 2014‐2015
Expected number of events
— — 1.66 1.84 1.69 0.38
Power (expected time to signal in terms of data release)
1 1.5 12 13 12 9
2 23 25 24 13
2.5 37 40 37 18
3 51 (J) 55 (J) 52 (J) 23
4 74 (J) 78 (J) 75 (J) 34
5 88 (J) 91 (J) 89 (J) 44
6 95 (J) 97 (J) 96 (J) 54 (D)
8 99 (D) 100 (D) 100 (D) 70 (D)
10 100 (D) 100 (D) 100 (D) 81 (D)
2 1.5 14 14 14 10
2 26 28 26 16
2.5 41 43 41 22
3 55 (J) 59 (J) 56 (J) 29
4 77 (J) 81 (J) 78 (J) 42
5 90 (J) 93 (J) 91 (J) 53 (D)
6 96 (J) 98 (J) 96 (J) 63 (D)
8 100 (D) 100 (D) 100 (D) 78 (D)
10 100 (D) 100 (D) 100 (D) 87 (D)
4 1.5 16 16 16
2 31 33 31
2.5 47 50 (J) 48
3 62 (J) 65 (J) 63 (J)
4 83 (J) 86 (J) 84 (J) a
5 93 (J) 95 (J) 94 (J)
6 98 (J) 98 (J) 98 (J)
8 100 (J) 100 (J) 100 (J)
10 100 (J) 100 (J) 100 (J)
Abbreviations: D, December; J, January; RR, rate ratio.
aNumber of expected events is too small to calculate performance measures.
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Ourwork is subject to some limitations. Our adjustment for record-
ing delays was based on a simplification of the data accrual process and
on a historical distribution of delays. Nevertheless, previous work has
shown constant recording delay patterns during a 10‐year period,
which is reassuring.3 Furthermore, while absence of delays in recording
and receiving data is the ideal scenario, it is unlikely that delays in
recording can be changed as result of direct action by data providers.
Finally, this work is based on a single vaccine/outcome pair. Neverthe-
less, results for other vaccine/outcome pairs are likely to be similar to
the ones observed for seasonal influenza/GBS. The reason for this is
twofold: first and as explained above, the lack of improvement in the
system's performance is probably related to the fact that the perfor-
mance is assessed at the end of the surveillance period (when most of
the data have already accrued); second, delays in receiving data are
fixed and similar for all outcomes. Regarding delays in recording out-
comes, GBS is likely to have longer delays than other conditions due
to prolonged hospitalisation. Therefore, removing delays in recording
these other outcomeswould result in even less improvement on power.
In conclusion, minimising delays in data availability are unlikely to
substantially improve the performance of a system using CPRD data.
Expansion of the data is required.
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7.5 Conclusions 
This Chapter reports the main work conducted to achieve the overarching aim of this thesis: 
assessing the feasibility of implementing a near real-time system using CPRD data. Together 
with the results presented in the remaining Chapters, the trial implementation showed that 
CPRD can be used to implement such a system but with limited power to identify small 
increases in the risk of GBS following seasonal influenza. Therefore, I complemented the 
implementation work by assessing how limitations in power to detect a signal could be 
addressed. This latter work showed that to improve the performance of the system 
expansion of the data is needed. The information contained in this Chapter can thus be used 
by those wishing to implement a system as well as by data providers as a means to guide 
their policy regarding data availability and expansion.  
The next Chapter presents an overall discussion of the work conducted as part of this thesis, 
together with its main conclusions.  
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8 DISCUSSION 
In this thesis I have sought to assess the feasibility of implementing near real-time vaccine 
safety surveillance using CPRD data through four main objectives (2.4.2): to review the 
methods currently used to perform NRTVSS using electronic health records (Chapter 4); to 
examine recording delays in CPRD for selected conditions, due to practices receiving and 
recording diagnosis made at secondary care (Chapter 5); to trial the implementation of 
NRTVSS using previously collected CPRD data (Chapter 7); and to assess how delays in 
recording outcomes and receiving data influence the power and time to detect a safety signal 
(Chapter 7). This chapter provides a review of the main findings, discusses the main strengths 
and limitations of the overall project, and points out implications for both research and 
practice. 
8.1 Summary of the main findings 
8.1.1 Methods currently under use to perform NRTVSS 
8.1.1.1 What was known 
In 2005, the Vaccine Safety Datalink in the USA proposed the use of a sequential test, SPRT, 
as a way to generate quickly vaccine safety signals.7 It was later shown that the use of SPRT 
was challenging because it requires the probability/RR of the adverse event to be selected in 
advance: if the RR/probability specified is too high, the test may not lead to rejection of the 
null hypothesis (even if there is an increased risk); conversely, the selection of an unduly low 
RR/probability may result in a delayed signal.96 A maximized version of the test was then 
proposed (MaxSPRT), with a composite alternative hypothesis; it is available based on two 
distributions for events, Poisson (PMaxSPRT) and binomial (BMaxSPRT).96 Further tests have 
been developed to address other limitations identified while using MaxSPRT. For example, 
PMaxSPRT requires a reliable estimate of the expected number of events using sufficient 
past data whereas the conditional version (CMaxSPRT) was developed for use when these 
estimates are based on few data.162 Group sequential tests were also applied in this 
context.163 Near-real time vaccine safety surveillance is conducted routinely in the USA9 but 
there was limited information on its use elsewhere. Previous publications reviewed the use 
of these methods but focused on the statistical aspects of existing tests8,164 and on the work 
conducted by VSD.9  
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8.1.1.2 What this study adds 
This study identified several methods to perform NRTVSS using electronic health records and 
the way these have been applied. It identified 31 systems in 2015 when it was first conducted 
and 2 additional studies in 2017 at the time of its update. The review showed that NRTVSS 
has been increasingly used in the USA but also in a few other places, such as the UK, Taiwan 
and New Zealand. The main vaccine that had been assessed is influenza vaccine (both 
seasonal and pandemic). The systems identified used three main groups of statistical tests: 
continuous sequential tests, which allow testing as often as desired; group sequential tests, 
where testing is conducted at discrete points in time; and statistical process control, which 
uses a graphical representation to compare the number of observed events to an expected 
mean plus a number of standard deviations. The most common tests were the Poisson-based 
maximized sequential probability ratio test (PMaxSPRT, used by 44% of the systems 
identified) and its binomial version (BMaxSPRT, used by 24%). The test selected for use in 
the studies depended on the frequency of data updates and the adverse event of interest. 
Only 75% of studies addressed confounding, mainly by adjusting the expected rate (carried 
out by 51% of studies that adjusted). Delays in data availability were considered in some 
studies, either by delaying the analysis or adjusting for delays and partially accrued periods. 
Overall, this review provided a broad overview of existing studies (including both VSD and 
non-VSD studies) and from a more applied perspective than the previously published 
literature on the topic. It summarised the main characteristics of systems performing 
NRTVSS. Therefore, it can be used to inform those wishing to implement similar systems.   
8.1.2 Recording delays 
8.1.2.1 What was known 
When considering a new data source to implement a near real-time vaccine safety 
surveillance system it is necessary to know what type of delays these data are subject to. In 
the case of CPRD data, delays occur for a variety of reasons: (i) delays in physicians making a 
diagnosis following an initial consultation; (ii) delays in recording outcomes diagnosed in 
other levels of care (e.g. hospital); (iii) delays in practices uploading data to CPRD; and (iv) 
delays in researchers receiving uploaded data for analysis (from CPRD). Previous studies 
using NRTVSS considered delays either by postponing the analysis or by adjusting the number 
of expected events. This adjustment only considered delays in receiving data for analysis 
(corresponding to reasons (iii) and (iv)) and was based on a historical distribution of delays.113 
CPRD data are made available on a monthly basis and there is information (the last collection 
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date) on when practices last uploaded their data. A previous study using THIN, a related 
primary care data source, examined the number of records lost as function of the last 
collection date (delays due to reason (iii)), to inform incidence/prevalence studies. This study 
showed that not accounting for delays in uploading data results in underestimation of 
incidence/prevalence.88 There was no known work assessing delays due to other reasons 
(reasons (i) and (ii)). Furthermore, there was no known work using the system date (the date 
when a record is entered in the GP system) to assess delays. 
Several outcomes of interest for vaccine safety are diagnosed mainly in secondary care (e.g. 
GBS) and may not be fully captured in CPRD. This can happen if GPs only scan the hospital 
letters without adding a diagnostic code to the patient’s record. Previous studies have shown 
that the use of CPRD linked data improves the sensitivity of diagnosis86,165 but existing 
linkages with hospital data are updated too infrequently to allow the use of these data in a 
NRTVSS. I was not aware of previous studies evaluating the completeness of recording 
diagnoses of interest for vaccine safety and made mainly in secondary care (e.g. GBS). This 
information is relevant to understand the extent to which diagnoses are not captured in 
CPRD.   
8.1.2.2 What this study adds 
This study included a comprehensive analysis of recording delays in CPRD for selected 
conditions of interest for vaccine safety surveillance (GBS, Bell's palsy, optic neuritis, and 
febrile seizures), both using stand-alone CPRD data and CPRD-hospitalisation linked data.  
The assessment of delays in stand-alone data was done by calculating the difference 
between the event date (the purported date of diagnosis of the condition) and the system 
date (as outlined in Section 8.1.2.1, the date the record was added to the patient’s medical 
file).  As a preparatory step, I also investigated how system dates can be altered, due to data 
updates by general practices. The analysis showed that mass transfers of data do indeed 
occur in general practice, and these transfers need to be identified before system dates can 
be used to assess recording delays. The study highlights this hitherto unrecognised problem, 
and suggests one methodological approach for addressing this. Following removal of 
updated system dates, the main analysis of stand-alone CPRD data showed that data accrual 
in CPRD varies with the condition of interest and in general, over 70% of all records in CPRD 
data accrue within the first month. 
While the analysis of stand-alone CPRD data showed that records of selected conditions 
accrue with an acceptable delay, it does not provide any information on how completely 
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these conditions are recorded in CPRD. Hence, I analysed linked CPRD-hospitalisation data, 
which demonstrated that CPRD has low sensitivity to capture coded diagnoses for selected 
conditions first recorded in hospital. However, for the diagnoses that were subsequently 
captured in CPRD, data accrual occurred within the ten weeks of their hospitalisation for 
GBS, and within the first month for the remaining conditions.  
Overall, this study shows that recording delays in CPRD are compatible with the 
implementation of a near real-time vaccine safety surveillance and the delay distribution can 
be used to adjust for delays when implementing a near real-time system.  
8.1.3 Implementation of a near real-time system using CPRD data 
8.1.3.1 What was known 
In the UK, two near real-time systems using electronic health records had been previously 
implemented.10,139 One was UK-wide and used sequential tests; it relied on spontaneous 
reports to obtain the observed number of events and CPRD to obtain the expected number 
of events.10 The second system was implemented in Scotland, used hospital data and applied 
statistical process control to identify new signals.139 Statistical process control does not 
formally control for multiple testing and has been considered more appropriate to identify 
issues with vaccine quality rather than identify new adverse events.96 There was no known 
implementation relying fully on electronic health records and using sequential tests. CPRD is 
a population-based data source used extensively for research purposes. It is released 
monthly and practices upload their data some time before that. My work conducted to 
examine recording delays in CPRD showed that records are indeed registered with some 
delay but these delays are compatible with NRTVSS. From this regard, CPRD data could 
potentially be used to implement a NRTVSS. However, additional questions remained 
unaddressed, such as what is the most appropriate statistical test to use, how to account for 
delays and whether there is enough power to detect a signal.  
8.1.3.2 What this study adds 
This study showed that it is possible to implement a NRTVSS using CPRD, for at least two 
selected vaccine/outcome pairs: seasonal influenza vaccine/GBS and MMR/febrile seizures. 
For seasonal influenza vaccine/GBS, PMaxSPRT was deemed as the most appropriate test 
while for MMR/febrile seizures both the PMaxSPRT and the BMaxSPRT could be used. For 
MMR/febrile seizures, I was able to replicate a known safety signal, and showed that there 
was sufficient power to detect a signal of an increased risk of 2.5 times or more. For seasonal 
influenza/GBS there was more limited power to identify a safety signal; at its current size, 
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use of CPRD would enable exclusion of large increases in risk (over four times) of this rare 
outcome following seasonal influenza. This work proposes an adjustment for delays adapted 
to CPRD’s data structure and based on the delays analysis reported in Section 5.3.  
This work will inform any future decision-making by UK regulatory authorities about how 
best to implement this type of surveillance, including awareness of both the strengths and 
limitations of using CPRD data in this context. Additionally, these results are useful to 
researchers or practitioners who are developing near real-time surveillance activities using 
related electronic health record data.  
8.1.4 Power to detect a signal and delays 
8.1.4.1 What was known 
The work conducted as part of the third objective of this thesis (Section 7.1) showed it is 
possible to implement a near real-time vaccine safety surveillance system using data from 
CPRD but there is limited power to identify a rare outcome (GBS) following seasonal influenza 
vaccine (power was ≥80% to identify a 4-fold increase in risk). For MMR/febrile seizures there 
was sufficient power to detect a 2.5-fold increase in risk. When using PMaxSPRT the number 
of expected events at the end of the surveillance determines power. This number is a 
function of the data available, depending on both the number of individuals contributing 
data (the volume of data) and on delays in data availability (both in practice staff recording 
outcomes and CPRD receiving data from participating practices). CPRD is a dynamic database 
and the number of individuals can increase (by including data from new practices and/or 
existing practices increasing in size) and delays can be reduced (by changing the way data 
are collected from practices and the regularity of data releases). The performance of a near 
real-time system could therefore improve by expanding the database and/or reducing 
delays. 
8.1.4.2 What this study adds 
This study explored the effect of delays in recording outcomes and receiving data on the 
performance (the power to detect a signal and the expected time to signal) of a system 
assessing GBS following seasonal influenza vaccine. Additionally, it assessed the system 
performance based on data available around the middle of the surveillance period, to 
understand what could be detected at a time when it would still be possible to implement 
some measures.  
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The results showed that absence of delays produced only limited improvements in power 
(with a maximum improvement of 4%). Timeliness in the absence of delays was similar to 
that observed when assuming delays. Assessment of power at mid-influenza season (early 
December) showed a substantial reduction in power (compared to end of the season), and 
would only allow detection of very large increases in risk (relative risks of more than eight). 
Removing delays would thus not be sufficient to improve the performance of a near real-
time vaccine safety surveillance system for rare outcomes; expansion of CPRD is required. 
The results of this study can be used to inform any future decision-making by data providers 
about how best to improve the data available to support near real-time surveillance. More 
widely, the study provides a framework on how to consider delays and their effect on near 
real-time surveillance activities when using electronic health record data.  
8.2 Strengths  
The strengths of each study were discussed in the Chapters in which they are reported. Here, 
I provide an overview of the strengths of the project as a whole. These include the use of 
large, population-based electronic health records, careful consideration of data-related 
aspects and the implementation of a new vaccine safety surveillance system.  
8.2.1 Use of large, population-based data 
This work used CPRD, a large, population-based database, used extensively for epidemiologic 
research. Post-licensure vaccine safety studies require large databases as the main concern 
is the detection of rare adverse events. The use of CPRD in this context enables the detection 
of signals for rare events (at least for large increases in the relative risk, see Section 7.1). In 
general, collecting primary data to identify such rare events would be costly, time-consuming 
and would not generate timely results. Additionally, a population-based data resource is 
important to ensure that the results obtained are indeed representative of what is happening 
in the population. In practice, if the system is applied and no signals are detected, the results 
will be important to reassure the population that the vaccine under study is safe; on the 
other hand, if a signal is identified and then confirmed the results will help deciding which 
measures should be taken.    
8.2.2 Careful consideration of data-related aspects 
Throughout this project, I have carefully considered data-related aspects that could 
potentially affect the work conducted. First, I used rigorous methods to develop code-lists, 
and used wider and narrower definitions when evaluating delays in recording outcomes to 
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assess the effect of imperfect validity of diagnostic code-lists. I then assessed delays in stand-
alone CPRD by using the system date, the date a record has been entered into the patient’s 
file. As part of this work, I also investigated how system dates can be changed due to 
software and patient record updates, and proposed a method to investigate and exclude 
these. To the best of my knowledge the system date had not been previously used in this 
context and the mass transfer of records had not been investigated up to now. Finally, I 
proposed adjustments to account for delays in recording outcomes (for PMaxSPRT and 
BMaxSPRT) and receiving data (for BMaxSPRT), as well as partially accrued periods (for 
BMaxSPRT). These adjustments were based on previous work113 but I adapted them to the 
structure of CPRD data. Overall, these aspects should be considered when envisaging the use 
of a data source to implement near real-time vaccine safety surveillance; my work can also 
be used by others looking at similar systems and related electronic health data.    
8.2.3 Implementation of a surveillance system 
The project reported in this thesis establishes the main features of a system that can be 
implemented in the UK. As such, I sought to provide results for vaccine/outcome pairs 
encompassing a range of characteristics, including a rare (GBS) and a more frequent outcome 
(febrile seizures), as well as an adult (influenza vaccine) and a childhood vaccine (MMR). I 
have also proposed an implementation for two tests (PMaxSPRT and BMaxSPRT) which 
further maximised the range of issues explored as part of my work. Time requirements to 
implement a system were not formally assessed but are discussed in Section 8.4. In addition 
to proposing the main aspects of a system relying solely on CPRD data, I assessed what needs 
to change to address existing limitations. In particular, I identified limited power to detect 
small increases in the risk of GBS following influenza vaccine (see Section 7.1) and, therefore 
I re-assessed power in the absence of delays for influenza vaccine/GBS. This particular work 
can be used to inform discussion with data providers about the way forward to improve data 
to be used in the context of a near real-time system. In summary, my work provides 
information not only on how a near real-time vaccine surveillance system can be 
implemented but also on how to address some of the existing limitations with currently 
available data.  
8.3 Potential limitations  
The specific limitations of each study were presented in Chapters 4, 5, and 7. In this section, 
I present the overarching limitations of the thesis in terms of my own work, limitations of 
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the data used and intrinsic limitations of the methods available. Issues related to the 
generalisability of the results are also presented here.  
8.3.1 Limitations of my work 
Due to the limited time in which to conduct this work, I selected two vaccine/outcome pairs 
to trial the implementation of a system using CPRD data. Systems run in routine practice 
generally assess five to ten pairs.8 The tests selected were deemed to be the most 
appropriate to assess the pairs included. However, the inclusion of new pairs might require 
the use of tests not selected for the purposes of this work. For example, if there are limited 
data to estimate the historical rate of the outcome of interest CMaxSPRT might be required. 
Nevertheless, I tried to capture a range of issues to provide a broad overview of the 
challenges faced when implementing a system using CPRD data (see Section 8.2.3). These 
should be regarded as an initial step towards the implementation of a system as routine 
practice.  
A key issue when using CPRD data is the validity of diagnostic codes used to ascertain 
outcomes and vaccines. Time constraints also prevented carrying out a full validation study 
of the code-lists used as part of this study. However, I assessed the effect of imperfect validity 
on delays by using a broader and more specific set of codes and the completeness of 
diagnostic codes in CPRD. The use of two lists with different levels of specificity yielded no 
significant effect on the delay distribution, which indicates that outcome misclassification 
does not impact the distribution generated. 
8.3.2 Limitations of the data used 
CPRD data have not been collected for research purposes. As such, researchers using these 
data should be aware of their limitations. As outlined in Section 8.3.1, I assessed the effect 
of imperfect validity of codes by using two lists with different levels of specificity with no 
appreciable effect in the delay distribution. On the other hand, my work assessing the 
completeness of diagnoses captured in CPRD (i.e. sensitivity, see Section 5.3) showed 
appreciable underreporting, even for serious conditions (e.g. GBS).  In the context of near 
real-time surveillance, if underreporting is constant over time it decreases power to detect 
a signal, but it may have wider implications for research in general. The need to use linked 
data to improve completeness of diagnostic records has been previously recognized.86,165 
However, present linkages with hospital data are not timely enough to be used in a near real-
time system. If this changes in the future the use of linked data would be an important 
improvement to a near real-time system. With regards to vaccination information, I am not 
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aware of a study that formally assesses the validity of vaccination information for the 
vaccines assessed as part of this study. However, both MMR for young children and seasonal 
influenza vaccine for individuals aged 65 years or more are administered in GP practices. 
Administration of these vaccines is part of the services practices should deliver166 and 
practices are paid based on the records entered into the system.167 It is thus expected that 
this information is well recorded. Moreover, the inclusion of only vaccinated individuals with 
careful development of algorithms to identify these individuals should have contributed to 
minimising further potential misclassification.  
Delays in recording outcomes and in receiving data for analysis can also limit the feasibility 
of a near real-time system. I extensively considered delays in the context of this project, both 
by characterizing them and by adjusting for delays during the trial implementation analyses. 
These efforts ensured the analyses conducted were feasible and unbiased (as far as delays 
are concerned) but they did not remove existing delays. Outcomes diagnosed in hospital are 
only recorded after GPs receive feedback from hospital-based physicians, therefore, as 
discussed above, using readily available linked CPRD-hospital data would likely minimise this 
source of delays. Uploading data from practices more frequently (e.g. daily, weekly) and 
make them available to researchers would also reduce delays further. CPRD is now trialling 
new data collection from practices using EMIS software (see below), with daily uploads. As 
this system progresses towards implementation, discussion with data providers will be 
important to anticipate these improvements and to decide how to best integrate them into 
the surveillance system.  Nevertheless, my work assessing the influence of power on delays 
for influenza vaccine/GBS showed that removing delays only results in limited improvements 
in power to detect a signal.  
I have also shown that there is limited power to detect a signal for a rare outcome (GBS) 
following seasonal influenza (see Section 7.1) and suggested that data expansion is required 
to improve power. Such improvement should be possible as CPRD is about to release data 
that are substantially larger due to the inclusion of practices using EMIS software. EMIS is 
one of the main software in the UK78 and this will be an important addition for future CPRD 
expansion. CPRD is now assessing data from EMIS practices and the current plan is to include 
data from these practices in the Spring of 2018 (with test usage for selected studies from the 
Autumn of 2017) (Dan Dedman, CPRD, personal communication). In the future, CPRD is also 
planning to include practices using TPP SystmOne software (Helen Booth, CPRD, personal 
communication). Only after data are released will it be possible to assess what improvement 
results from these additional data.  
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8.3.3 Limitations of the methods 
As pointed out in my systematic review of existing methods to perform near real-time 
vaccine safety surveillance (see Section 4.1), there were limited strategies to account for 
confounders and, in general, only a few confounding variables were considered. In 2015, 
Cook et al. proposed a group sequential test using generalized estimating equations to allow 
for more flexible control for confounding than previously existing methods.168 To the best of 
my knowledge, this new method has not been subsequently applied, and confounding has 
been addressed at the confirmation stage, after a signal is found. This might be related to 
the fact that near real-time surveillance is regarded as a simple and quick signal 
strengthening method, which requires a full confirmatory study afterwards when a signal is 
found. As such, it should not be over-complex, and more complete and robust approaches 
are left to the confirmatory stage.   
8.3.4 Generalisability 
This work aimed to assess the feasibility of using CPRD to implement a near real-time vaccine 
safety surveillance system. Therefore, the issue of generalisability is discussed from the 
perspective of applying the existing results to new CPRD data releases. This is particularly 
important as CPRD is undergoing substantial changes that may limit the use of the results 
generated as part of this project. The issues presented in this section should also be 
considered if implementation using other primary care databases is envisaged (e.g. 
ResearchOne, THIN, RCGP RSC).  
The main change, as highlighted in Section 8.3.2 above, is the addition of practices using 
EMIS software. The inclusion of EMIS practices brings additional challenges to the 
implementation of a system, including: (i) the use of system date; (ii) GPs’ recording 
behaviour; (iii) mode of data collection; and (iii) a different coding system. These aspects are 
reviewed. As explained in Section 5.3, in Vision practices’ data, the date when a record was 
added to a patient’s file (the system date) can be changed when the software version is 
updated. My work included investigation of which records have been included in such 
updates, followed by their exclusion. Currently, it is not known if this is also an issue for data 
from EMIS practices. Release of these data and conversations with data providers will be 
important to gain a deeper insight of the relevant issues for EMIS data. The need to exclude 
records due to mass transfers for EMIS data should thus be assessed in light of that 
information. Similarly, the delay distribution generated using Vision practices data may not 
be generalizable for EMIS practices data. Previous CPRD work looking at Huntington’s disease 
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suggested a slightly lower prevalence for the disease as estimated from EMIS practices in 
comparison to Vision practices (Dan Dedman, CPRD, personal communication). This may be 
due to the EMIS system not requiring GPs to enter a code when adding information to a 
patient’s file (Dan Dedman, CPRD, personal communication). Further differences between 
the two systems may lead to a different delay distribution. If EMIS data contain information 
on the date each record was entered (an equivalent to system date) both the issue of mass 
transfer of records and delays in recording outcomes can be assessed using the programme 
files I developed. The use of my files would reduce the workload required to conduct a new 
assessment, as only data extraction and minor adaptions of the files to the new data would 
be required.  
Data collection will also differ between EMIS and Vision practices. CPRD is likely to receive 
daily data extracts from EMIS data, which has potential to reduce delays in practices 
uploading their data. If CPRD data releases start to be provided more often than monthly, 
frequency of testing might be increased accordingly. Nevertheless, my work assessing the 
effect of reducing delays on power (Section 7.4) showed that removing delays will only 
slightly improve the performance of a system.  
All the work developed was based on Read codes version 2 lists while EMIS codes information 
using Read codes version 3. All GPs systems will be required to adopt SNOMED CT codes by 
April 2018.169 Therefore, in the future, implementation will require the mapping of existing 
lists to SNOMED CT codes.  
Future changes that can limit the application of the proposed implementation include 
changes in the way data are captured from hospital (for example, automatic capture of 
hospital-coded data by the GP system) and/or expansion of CPRD data to include other data 
sources (for example linkage of child health records from all settings). This would improve 
the validity of diagnostic codes (by improving the sensitivity) but would also lead to changes 
in the delay distribution (used for adjustment of delays), thus requiring data re-analysis. 
Overall, the effect of changes affecting the data used for implementation should be carefully 
considered and adaptions should be adopted as required.   
8.4 Implications for practice 
This work establishes the main aspects of a near real-time vaccine safety system using CPRD 
data. However, full implementation will require further considerations. To start with, a fully 
functioning system will require monitoring of more than one or two outcomes (generally five 
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to ten8). Additionally, the implementation of this system will require the establishment of 
further steps should a signal be identified. VSD has proposed several steps after a signal is 
identified, including: checking the data and code, examining descriptive statistics for patterns 
in time between the exposure and outcome, adjusting for additional confounders, 
conducting a non-sequential analysis with a different comparator, conducting a review of 
records, comparing the results with similar outcomes or other existing data, analysing new 
data or designing a new study.9 When using CPRD, it is no longer possible to access GPs’ free-
text, and it may not be feasible to obtain medical records of cases identified and validate 
them in a timely manner. However, the remaining steps can be applied. A debated issue is 
the use of the same dataset to identify and confirm a signal.34 Some authors claim this should 
be avoided due to possible biases. I am not aware of a formal study showing and quantifying 
these biases in the context of signal identification and confirmation. However, a related issue 
has been extensively discussed in the field of prognostic models,170 and it is recommended 
that a model is fitted and validated in separate datasets, preferably from different patient 
centres. If we consider the same approach in the context of signal identification and 
confirmation, there are further primary care datasets available in the UK such as THIN and 
RCGP. Within CPRD, in the future it would be possible to use Vision practices for system 
implementation and EMIS practices for signal confirmation. Nevertheless, this approach 
would remove the power gain of adding EMIS practices to the data used to implement a 
system. Furthermore, these concerns arose in the context of data mining studies.34 Unlike 
data mining, NRTVSS is hypothesis driven and there is a rationale for selection of the 
vaccine/outcome pairs to assess. In epidemiologic terms, particularly regarding confounding 
factors, NRTVSS also provides an initial analysis and (as highlighted above) there is room for 
more robust and rigorous analysis following a signal, even if the same data are used. Hence, 
I would propose the application of the steps previously mentioned (e.g. more detailed 
adjustment for confounders in a formal epidemiological study) using CPRD data. This is also 
the approach followed by VSD, in which the same data are used for NRTVSS and signal 
confirmation. Authors defending this approach claim that analyses at the confirmation stage 
should be ‘statistically independent’ or ‘orthogonal’ from the ones used at the identification 
stage, i.e. they should look at aspects of the data that are distinct from each other.171,172 
Nevertheless, further research on the use of the same data for identifying and confirming a 
signal would be useful.  
One of the challenges when implementing this system in practice is data availability. As 
explained in Section 6.2, for the purposes of this work it was not possible to use the monthly 
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release of the data to mimic a near real-time system. Instead, I used the 6-month releases 
available to LSHTM, which were deemed appropriate within the scope of this project. If the 
system is implemented in practice, monthly data releases should be used. The MHRA is one 
of the possible implementers of this system and they can access and extract data without 
the restrictions of the online extraction tool. As such, the issues relating to identifying 
individuals with immunisation codes would not be relevant. If others wish to proceed 
towards implementation of this type of system, one option is to discuss with data providers 
the possibility of searching for immunisation codes in the online extraction tool.  
The issue of timeliness regarding data has been discussed extensively. However, it is also 
necessary to consider the time required to perform the analysis. Having produced several 
programs to conduct these analyses I can make them available to those who wish to pursue 
this type of surveillance using CPRD data. That would greatly reduce the time required to 
conduct the analysis. It is difficult to give a precise estimate of the time required to set up 
and run a system as this depends greatly on the knowledge of the data and methods used, 
as well as on the number of events to study for each vaccine. Nevertheless, in Table 8.1, I 
provide a breakdown of the tasks required to implement a system, alongside an estimate of 
the time required to perform each task. The most time-consuming work can be done before 
the beginning of the surveillance period, preventing unnecessary delays at this stage. The R 
package Sequential also helps to reduce the time required for analysis; for example, 
Sequential stores the results from one analysis to the next, thus simplifying the analysis 
process.  Overall, I estimate that two full-days of work are required to perform the analysis 
of each data release for a specific vaccine/outcome pair. It is noteworthy that adding more 
outcomes will not increase the workload in a linear way, as several tasks will take 
approximately the same time for one or more outcomes. However, those implementing a 
system should consider the additional workload from implementing a system and whether 
it is necessary to have a dedicated person to perform the entire analysis. I would recommend 
that a specific person is assigned to perform the several stages of the analysis, with further 
support from a team with a wide set of skills. Having a dedicated person would diminish the 
time required to acquire the specific skills needed to implement the system (e.g. 
familiarisation with the package Sequential). However, I do not think a full-time dedicated 
person would be required. In the future, the work can be further automated by the 
development of dedicated programs, and the use of R Markdown to produce standard 
reports.173 R Markdown allows the development of dynamic documents with R, embedding 
R code and text in the same file. Such files are particularly useful when one wishes to run and 
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report similar analyses at repeated points in time such as in the case of sequential analyses. 
Developing an R Markdown file to generate a standard report for each sequential analysis 
would therefore reduce the workload required to report each new analysis. 
Table 8.1. Tasks required to implement a system and estimate of time commitment, for a specific vaccine/outcome 
pair 
Task Time (hours) 
Prior to surveillance  
Development of code-lists (per outcome) 1 to 2 
Development of algorithm to identify vaccinated individuals (per vaccine) 6 to 8 
Sub-total (prior to surveillance) 7 to 10 
PMaxSPRT - Before surveillance starts  
Definition of the comparator period 1 
Data extraction 2 to 3 
Data cleaning and management 3 to 4* 
Calculation of an appropriate historical rate 3 
Generation of delay distribution 3 
Calculation of expected number of events at end of surveillance based on historical 
data 
2 
Sub-total (PMaxSPRT - Before surveillance starts) 14 to 16 
BMaxSPRT - Before surveillance starts  
Calculation of the observed number of events at end of surveillance based on 
historical data 
2** 
After surveillance starts (task required at each data release) – similar for PMaxSPRT and BMaxSPRT 
Data extraction 2 to 3 
Data cleaning and management 3 to 4* 
Identification of vaccinated individuals and their follow-up time (includes 
refinement of algorithm to identify vaccinated individuals) 
4 to 6 
Calculation of the expected number of events (PMaxSPRT only) and identification 
of the observed number of events (PMaxSPRT and BMaxSPRT) 
2 
Calculation of the test statistics 1 
Sub-total (After surveillance starts) 12 to 16 
*Assuming adaption of pre-existing programme files. **Assuming use of the same historical data 
as PMaxSPRT 
 
8.5 Implications for future research 
As outlined above, a fully functioning system will require the assessment of more than two 
vaccine/outcome pairs. New outcomes might require the use of other tests that were not 
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studied as part of this project, such as the conditional maximized sequential probability ratio 
test. Furthermore, the assessment of vaccines other than seasonal influenza and MMR may 
require the use of further tests or their combination. For example, when assessing newly 
introduced vaccines, it may be necessary to allow some time for initial uptake. A possible 
strategy in this context is to initiate the sequential analysis only after a pre-determined 
number of doses have been given.163 The specific tests to apply to each vaccine/outcome 
pair should be decided on a case-by-case basis.  
Other areas of research include comparison of the system proposed in this thesis with other 
systems. For example, NRTVSS had been previously implemented using spontaneous reports 
to generate the observed number of events and CPRD to calculate the expected number of 
events, while I am now proposing to implement the system relying exclusively on CPRD data. 
The properties of both systems could be assessed as a way to understand how to best use 
them in practice (using one or both systems).  
As outlined in Section 2.3.1.3.4, it has been shown that it is possible to identify mild AE to 
vaccines (e.g. injection site pain, fever and malaise) using social media and other online 
reports but their place in pharmacovigilance is still unclear.57,58 In particular, it is not known 
if social media should be considered as a tool to support signal detection or if it can be used 
on its own. As with electronic health records, these data contain a vast amount of records 
and may seem appealing to identify rare adverse events, however, there are additional issues 
that need to be explored. For example, it may be difficult to capture conditions less familiar 
to the general public such as GBS and there might be issues regarding representativeness of 
the data. Addressing these questions could inform how to best use these two (near) real-
time systems in practice. Additionally, it would be important to know how the two systems 
(NRTVSS and social media) perform in terms of their timeliness.  
The work conducted also has implications for other researchers using these data sources. 
First, to the best of my knowledge, this is the first work to recognize objectively that general 
practice records are subject to mass transfers, which also update the date a record was 
entered in the patient’s file. More importantly, the work using linked data to assess 
completeness showed low sensitivity of coded records in CPRD for some diagnoses. For the 
implementation of a near real-time system, if recording is constant over time this would 
decrease the number of existing records, thus diminishing power to detect a signal. However, 
this has implications for researchers in general, who should be aware that even serious 
conditions such as GBS might not be coded by GPs. Overall, these issues highlight that 
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researchers need to have a deep understanding of existing data to be able to use them in an 
appropriate manner.  
8.6 Personal development 
The work developed as part of my PhD allowed me to acquire a range of skills. Firstly, I 
learned in detail the specific methods used to perform near real-time vaccine safety 
surveillance. Secondly, I made enormous progress in my understanding of the complex CPRD 
structure and how it can be use to perform epidemiological research. I learnt how to create 
and use code-lists and how to extract data. I have also developed my knowledge of the 
potential and limitations of using CPRD (and other electronic health records) to perform 
epidemiological research. Thirdly, I developed my command of both STATA and R. When I 
first started this project, my STATA knowledge was limited; I have thus greatly expanded it, 
not only by using new commands to perform data cleaning, management and analysis, but 
also by learning how to best use STATA to analyse very large datasets, trying to maximise the 
efficiency of my commands and thus reduce computational time. Being already fluent in R 
before the start of my PhD, I learnt how to use the specific functions required to implement 
a NRTVSS and to assess the performance of a system (Sequential package). Finally, I have 
greatly developed my writing skills. This is probably the area where I feel I benefitted the 
most from my PhD experience. Having received detailed feedback on my written documents 
has enabled me to improve my writing and the way I communicate my work. Overall, these 
skills will be vital in my future career as a researcher.  
In addition to the work around my PhD project, the time spent at LSHTM has given good 
opportunities to understand the daily functioning of an academic institution with a vibrant 
research environment. There is a wealth of research seminars given by a wide range of 
resident and invited speakers, and my regular attendance at these has enabled me to make 
contact with other researchers working on a variety of public health topics. Furthermore, I 
was able to develop my teaching skills. At LSTHM, I taught on several Masters-level modules 
(Statistics for Epidemiology and Population Health, Extended Epidemiology and Statistical 
Methods in Epidemiology), focusing on the application of statistical methods in epidemiology 
and development of epidemiological concepts. In these modules, I led practical sessions, 
supporting students with the use of STATA, and for some, I also assessed final assignments. 
The progress made was achieved with the invaluable support of my supervisors, bridging 
academic and public health practice. Throughout the course of my project I have also 
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collaborated with the MHRA, by sharing results and discussing the steps of my project. This 
collaboration has been beneficial for me as I was able to improve my project using MHRA 
experts' knowledge but also benefited the MHRA, as my work provided them with valuable 
information. Furthermore, I had the opportunity to present my work at several national and 
international conferences, where I received feedback from experts in the area of vaccine 
safety. For a full list of presentations see Appendix B of this thesis.  
8.7 Conclusions 
Near real-time vaccine safety surveillance using electronic health records is one of the 
methods available to assess vaccine safety after approval. It started to be used in 2005 in the 
USA and it has been increasingly used worldwide ever since. Several statistical approaches 
have been considered to conduct this type of surveillance, including continuous sequential 
tests, group sequential tests, and statistical process control. PMaxSPRT and BMaxSPRT were 
the tests most commonly used. There were limited strategies to account for confounding 
factors and it is possible to account for delays in receiving and recording data as part of the 
implementation of a system. In the UK, this type of surveillance had been implemented using 
spontaneous reports to obtain the number of observed events and CPRD to calculate the 
number of expected events. Research-level primary data sources are available in the country.  
For a data source to be considered for use in a near real-time vaccine safety surveillance 
system it should be population-based, have a good validity of both vaccination and outcome 
information, be available in a timely manner and have enough power to detect signals. CPRD 
data are known to be population-based and it is generally considered to have good validity 
for vaccines administered in general practices and outcomes of interest for vaccine safety. 
As part of this work, I have shown that outcomes of interest for vaccine safety are recorded 
with some delay but this is compatible with the implementation of a near real-time system.  
Trial implementation of a system using CPRD data was successfully carried out. PMaxSPRT 
was deemed as the most appropriate test to use for rare events while both PMaxSPRT and 
BMaxSPRT can be used for more frequent events. Adjustment for delays was possible and 
should be considered when implementing a system. There was good power to detect a signal 
for more frequent events such as febrile seizures following MMR vaccine but limited power 
to detect a signal for rare events. Further exploration of this issue showed that removing 
delays was not sufficient to improve power in this context and CPRD data expansion is 
therefore required.  
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Overall, it is possible to implement NRTVSS using CPRD data and further expansion of CPRD 
(both in terms of size and data available) might help addressing some of the currently existing 
limitations. The work reported here will support and strengthen pharmacovigilance 
activities.  
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APPENDIX A: OUTCOMES NOT INCLUDED IN THE FEASIBILITY 
ASSESSMENT 
Table S 1. Outcomes not included in the feasibility assessment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Outcome Number of times studied 
Acute flaccid paralysis 1 
All hospitalization 1 
Appendicitis 1 
Arthritis 1 
Asthma/wheezing 2 
Auto-immune disorders 1 
Cardiovascular events 1 
Cerebrovascular events 1 
Death 1 
Epilepsy 1 
Fatigue syndromes 1 
Fever 2 
Gram negative sepsis 1 
Haematochezia 1 
Invasive Haemophilus influenzae type b disease 1 
Juvenile onset of diabetes 1 
Kawasaki disease 3 
Myocarditis (±pericarditis) 2 
Narcolepsy 1 
Other neurologic outcomes 1 
Paralytic syndromes 2 
Respiratory events 2 
Serious local reactions 1 
Stevens-Johnson syndrome 1 
Stillbirth 1 
Stroke 2 
Sudden infant death 1 
Syncope 1 
Varicella zoster 1 
Venous Thromboembolism 1 
Herpes zoster 1 
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APPENDIX B: LIST OF PRESENTATIONS  
Below I provide a list of presentations (oral and posters) performed as part of my PhD project.  
1. Near-real time vaccine safety surveillance – a systematic review of statistical 
methods. Health Protection Research Unit in Immunisation Annual Scientific 
Meeting. London: 30 March 2015 (oral presentation); 
2. Near-real time vaccine safety surveillance using the Clinical Practice Research 
Datalink: a feasibility study – LSHTM Vaccine Centre Research Degree Students 
meeting. London: 21 July 2015 (oral presentation); 
3. Near-real time vaccine safety surveillance – a systematic review of statistical 
methods. 31st International Conference on Pharmacoepidemiology and Therapeutic 
Risk Management: Boston: 24 August 2016 (poster);  
4. Assessing recording delays in the Clinical Practice Research Datalink (CPRD) to inform 
near real-time vaccine safety surveillance. LSHTM Vaccine Centre Retreat. Windsor: 
11 February 2016 (oral presentation); 
5. Assessing recording delays in the Clinical Practice Research Datalink (CPRD) to inform 
near real-time vaccine safety surveillance. Public Health England Applied 
Epidemiology Scientific Conference. Warwick: 22 March 2016 (oral presentation); 
6. Assessing recording delays in the Clinical Practice Research Datalink (CPRD) to inform 
near real-time vaccine safety surveillance. International Population Data Linkage 
Conference. Swansea: 25 August 2016 (oral presentation);  
7. Near real-time vaccine safety surveillance using electronic health records. Uppsala 
Monitoring Centre. Uppsala Monitoring Centre Seminar. Uppsala: 26 October 2016. 
Available from: https://www.youtube.com/watch?v=dCq50ydl_FY  (accessed 2017-
07-07) (oral presentation); 
8. Implementing near-real time vaccine safety surveillance using the Clinical Practice 
Research Datalink  - Is there enough power? International Society for 
Pharmacoepidemiology Mid-Year Meeting. London: 3 April 2017 (poster); 
9. Vigilância de segurança de vacinas em tempo quase real [Near real-time vaccine 
safety surveillance]. II Encontro da Rede de Bioestatísticos Portugueses e da Secção 
de Biometria da Sociedade Portuguesa de Estatística [2nd meeting from the 
Portuguese Biostatisticians Network and Biometrics Section from the Portuguese 
Society of Statistics]. Lisbon: 6 January 2017. Available from: 
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https://www.youtube.com/watch?v=FoGgiR5mNrE (accessed 2017-07-07) 
[Portuguese] (oral presentation); 
10. Implementing near-real time vaccine safety surveillance using the Clinical Practice 
Research Datalink (CPRD). Public Health England Applied Epidemiology Scientific 
Conference. Warwick: 22 March 2017 (oral presentation); 
11. Implementing Near-Real Time Vaccine Safety Surveillance Using the Clinical Practice 
Research Datalink. 33rd International Conference on Pharmacoepidemiology and 
Therapeutic Risk Management: Montreal: 28 August 2017 (oral presentation). 
 
 
